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ABSTRACT 
After an initial phase of growth and development, bone undergoes a continuous cycle 
of repair, renewal and optimization, by a process termed remodelling. Bone 
remodelling is the coordinated processes of resorption by osteoclasts and formation 
by osteoblasts, where old bone is replaced by new bone. Disorder of bone 
remodelling cycle can result in metabolic bone diseases, such as postmenopausal 
osteoporosis, hypothyroidism and primary hyperparathyroidism. Due to the large 
number of bone cell types, stages of differentiation, and the numerous growth factors 
and cell to cell interactions involved, our current understanding of bone remodelling 
and the coupling between osteoblasts and osteoclasts is still fragmentary.  
In the first part of this research, a novel predator-prey based mathematical 
model is developed to simulate bone remodelling cycles in trabecular bone at the 
basic multicelluar unit level, through integrating bone removal by osteoclasts and 
formation by osteoblasts. The model is able to replicate the curves of bone 
remodelling cycles obtained from standard bone histomorphometric analysis. The 
application of the model is firstly demonstrated by using experimental data recorded 
for normal (healthy) bone remodelling, to simulate the temporal variation in the 
number of osteoblasts and osteoclasts, and resultant effect on bone thickness. The 
reconstructed histomorphometric data and remodelling cycle characteristics 
compared well with the specified input data. Two sample pathological conditions, 
hypothyroidism and primary hyperparathyroidism, were then examined to 
demonstrate how the model could be applied more broadly. The model was validated 
by comparing model predictions (maximum populations of osteoclasts and 
osteoblasts) in the normal condition with experimental data. Further data is required 
to fully validate the model’s predictive capability. 
A second mathematical model is then developed to simulate how the 
interaction between multiple myeloma (MM) cells and the bone microenvironment 
leads to a ‘vicious cycle’ between tumour development and bone destruction. The 
model includes the roles of inhibited osteoblast activity and stimulated osteoclast 
activity, and is able to mimic the temporal variation of bone cell concentrations and 
resultant bone volume after invasion and then removal of the tumour cells. The 
model explains why MM-induced bone lesions rarely heal even after the complete 
removal of MM cells. The model’s predictions agree with published experimental 
and clinical observations. The model is also used to simulate therapies for MM-
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induced bone disease, including bisphosphonates, bortezomib and the inhibition of 
TGF-β. The simulation confirms that treatments with bisphosphonates and 
bortezomib can reduce the tumour burden and bone destruction, which is consistent 
with clinical observations. However, the inhibition of TGF-β does not appear to 
suppress bone destruction, although it does decrease the MM cell concentration.  
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GLOSSARY 
 
Bisphosphonates They are also called diphosphonates, and are a 
class of drugs that prevent the loss of bone 
mass, used to treat osteoporosis and similar 
diseases. 
BMPs (Bone morphogenetic 
proteins) 
A group of growth factors also known as 
cytokines and as metabologens. 
BMSCs (Bone marrow 
stromal cells) 
Also known as mesenchymal stem cells. They 
are multipotent stem cells that can 
differentiate into a variety of cell types. 
BMU (Basic multicellular 
unit) 
A bone remodelling unit consisting of 
osteoclasts and osteoblasts. 
Bone lining cells Bone lining cells are derived from inactive 
osteoblasts and osteoblast precursors which 
cease activity or differentiated and flattened 
out on bone surfaces. 
Bortezomib  It is the first therapeutic proteasome inhibitor 
to be tested in humans. 
CAMs (Cell adhesion 
molecules) 
Cell adhesion molecules are proteins located 
on the cell surface involved with the binding 
with other cells or with the extracellular 
matrix (ECM) in the process called cell 
adhesion. 
Cancellous bone Type of porous bone that consists of a network 
of thin bars or plates of bone, in a lattice type 
configuration (also known as trabecular bone), 
found inside the ends of long bones, and in the 
vertebrae. 
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Cortical bone Dense bone that forms the surface of bones. 
Cytokines Any of the several cells that are released by 
the cells of the immune system and act as 
intercellular mediators in the generation of an 
immune response. 
Deposition  The laying down of new bone. 
Hill function A mathematical formulation is used to 
represent to intercellular between ligands and 
receptors. 
Histology Study of the microscopic structure and 
arrangement of tissue. 
Histomorphometry Classification of structure at microscopic 
level. 
Hypothyroidism Hypothyroidism is the disease state in humans 
and in animals caused by insufficient 
production of thyroid hormone by the thyroid 
gland. Cretinism is a form of hypothyroidism 
found in infants.  
IGF-1 (Insulin-like growth 
factor 1) 
Insulin-like growth factor 1 also called 
somatomedin C is a protein in humans 
encoded by the IGF1 gene. 
IL-6 (interleukin-6) Interleukin-6 is a protein that in humans is 
encoded by the IL6 gene. 
In silico In silico means experiments “performed on 
computer or via computer simulation”. 
In vivo In vivo means experiments performed in living 
organisms.  
In vitro In vitro means experiments performed outside 
of living organisms. 
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Marrow Soft fatty substance in the cavities of bones in 
which blood cells are produced. 
M-CSF (Macrophage colony 
stimulating factor) 
M-CSF is a secreted cytokine which 
influences hematopoietic stem cells to 
differentiate into macrophages or other related 
cell types. 
MIP-1α (Macrophage 
inflammatory protein-1)  
Macrophage inflammatory protein-1 
belonging to the family of chemotactic 
cytokines is crucial for immune responses 
towards infection and inflammation. 
Modelling  Theoretical representation simulating the 
behaviour or activity of systems (biological or 
otherwise). 
Multiple Myeloma A hematological malignancy that develops 
within the bone marrow microenvironment. 
Multiple Myeloma-induced 
bone disease 
Bone related disease resulting from multiple 
myeloma with symptoms of bone pain, bone 
fracture and bone destruction. These 
complications are devastating to patients.   
OPG (osteoprotegerin) OPG is a protein and belongs to tumor 
necrosis factor (TNF) receptor superfamily, 
acting as a cytokine receptor. 
Osteoblasts precursors Mesenchymal stem cells which commit to the 
osteoblastic lineage. 
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Osteoblasts Osteoblasts are derived from mesenchymal 
progenitors and are responsible for building 
new bone by synthesizing and secreting 
unmineralized bone matrix, and also 
participate in the bone calcification  
Osteoclast precursors Hematopoietic precursors, which are capable 
of differentiating into osteoclasts. 
Osteoclast Osteoclasts are multinucleated giant cells 
which range in diameter from 20 to over 
100µm, with one osteoclast containing from 1 
to more than 50 nuclei  
Osteoclasts are responsible for resorbing bone 
during the remodelling cycle.  
Osteocytes Osteocytes are defined by location, and they 
are the osteoblasts buried in the newly formed 
osteoid during bone formation. 
Osteoporosis A bone disease characterised by decreasing 
bone mass and connectivity. 
Parathyroid hormone A polypeptide with a molecular weight of 
9500, which is the most important hormone 
regulating calcium homeostasis and bone 
remodelling. 
Primary 
Hyperparathyroidism 
Primary hyperparathyroidism causes 
hypercalcemia (elevated blood calcium levels) 
through the excessive secretion of parathyroid 
hormone (PTH). The classic bone disease in 
hyperparathyroidism is osteitis fibrosa cystica, 
which results in pain and sometimes 
pathological fractures. Other bone diseases 
associated with hyperparathyroidism are 
osteoporosis, osteomalacia, and arthritis.  
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Radiotherapy  Radiotherapy is the use of high energy x-rays 
and similar rays (such as electrons) to treat 
disease. 
RANK (receptor activator of 
NFkB) 
RANK is a type I membrane protein expressed 
on the surface of osteoclasts. 
RANKL (the receptor 
activator of nuclear factor 
kappa-B ligand)  
RANKL is a member of the tumor necrosis 
factor (TNF) cytokine family and primarily 
expressed by osteoblast precursors acting as a 
key factor for osteoclast differentiation.  
Remodelling Process of renewal of bone by resorption and 
formation, conducted by osteoclasts and 
osteoblasts. 
SLRPs (Small leucine-rich 
proteoglycans) 
SLRPs are a family of proteins that are present 
in extracellular matrix. 
TGF-β (Transforming growth 
factor beta) 
TGF-β is a protein that controls proliferation, 
cellular differentiation, and other functions in 
most cells. 
Thyroid Hormone The thyroid hormones are tyrosine-based 
hormones produced by the thyroid gland 
primarily responsible for regulation of 
metabolism. 
Trabecular Thin bar or plate of bone found in cancellous 
(or trabecular) bone. 
Uncommitted progenitors Mesenchymal stem cells which are able to 
differentiate into different cell types, including 
osteoblastic cells, myocytes and adipocytes. 
VCAM-1 (vascular cell 
adhesion molecule-1) 
VCAM-1 is a protein in humans which is 
encoded by the VCAM1 gene, with the 
function of cell adhesion molecule. 
VEGF (vascular endothelial 
growth factor) 
Vascular endothelial growth factor is a signal 
protein produced by cells that stimulates 
vasculogenesis and angiogenesis.  
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VLA-4 (α4β1 integrin 
presents on the surface of 
multiple myeloma cells) 
VLA-4 is a member of the integrin family of 
adhesion receptors and involves both cell-
extracellular matrix and cell-cell adhesion. 
Wnt signalling pathway Wnt signalling pathway is a network of 
proteins that pass signals from receptors on the 
surface of the cell to DNA expression in the 
nucleus, which controls cell-cell 
communication in the embryo and adult.  
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1. INTRODUCTION 
Bone is a remarkable dynamic tissue which continuously repairs, renews and adapts 
in response to localized environmental changes, maintaining its function to provide 
structural support and a mineral reservoir (Parfitt, 1994; Sommerfeldt and Rubin, 
2001). This dynamic behaviour is achieved through the remodelling process, which 
occurs at the basic multicelluar unit (BMU) (Frost, 1986). Bone remodelling is a 
coupled process of bone resorption, carried out by osteoclasts, and bone formation, 
carried out by osteoblasts. The balance between the volume of resorbed and newly 
formed bone, and the activation frequency (remodelling rate) of the BMU, 
determines the integrity of the bone structure and strength throughout its life 
(Christiansen, 2001; Seeman and Delmas, 2006).  
Positive balance and rapid remodelling cycles in healthy young individuals 
result in increasing bone mass and density, and therefore strengthen the bone. As 
juvenile growth ceases with epiphyseal closure, the remodelling rate decreases and 
the balance gradually shifts towards zero (Parfitt, 2000). The balance in healthy adult 
bone is approximately zero and the mean activation frequency is about 0.33 per year 
for trabecular bone (Agerbaek et al., 1991; Eriksen et al., 1985, 1986b), where 
Eriksen et al. (1985) defines activation frequency as the formation rate of a new 
remodelling cycle at a particular point. Thus, remodelling of a point will occur every 
three years or so. The remodelling balance becomes negative throughout the ageing 
process and disuse (Zaidi, 2007), with bone loss beginning between the ages of 18 
and 30 years old, although the process is slow because the activation frequency is so 
low (Gilsanz et al., 1988). Pathologies such as hyperthyroidism, oestrogen 
deficiency, thyrotoxicosis and hypogonadism, can speed up the bone loss process 
(high-turnover osteoporosis) and cause structural damage, decreased bone strength 
and increased fracture risk (Eriksen et al., 1985; Seeman and Delmas, 2006; Zaidi, 
2007). However, there are also some pathological conditions, such as 
hypothyroidism, which can induce a positive remodelling balance (Eriksen et al., 
1986a). In this case, the positive balance is due to the significant reduction of bone 
resorption compared to healthy bone, whilst bone formation remains unchanged.  
The BMU cycle suggests that osteoporosis and other bone-loss diseases can 
be treated by the repeated use of selected agents that affect different parts of the 
remodelling process, and therefore create an overall incremental gain in bone mass 
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(Frost, 1979). For example, the use of therapeutic agents to increase BMU 
activations, in conjunction with reducing osteoclast activity while maintaining 
osteoblast activity, will lead to an accumulation of new bone, in a similar way to that 
of hypothyroidism. This has led to the development of anti-resorptive therapies for 
post-menopausal bone loss, which includes oestrogens, the selective oestrogen 
receptor modulator tamoxifen and raloxifene, bisphosphonates and calcitonin (Rodan 
and Martin, 2000; Zaidi, 2007). These developments suggest that a comprehensive 
understanding of the remodelling process at the BMU level, could lead to better 
methods for manipulating the remodelling cycle in treating bone loss diseases.  
Recent reviews of the bone remodelling process have revealed a growing 
number of factors that are involved in its regulation (Allori et al., 2008; Zaidi, 2007). 
These include autocrine and paracrine signalling molecules, systemic hormones and 
extracellular matrix components that affect cell-to-cell communication, migration, 
adhesion, proliferation and differentiation. Most of these findings are obtained from 
isolated observations of either in vitro studies or in vivo experiments using 
genetically manipulated animals. These findings have shown that osteoblasts are able 
to regulate the activity of osteoclasts, for example, expression of receptor activator of 
NFB ligand (RANKL) by osteoblasts directly interacts with RANK on osteoclast 
progenitors to drive osteoclastogenesis. This process also depends on the level of 
osteoprotegerin (OPG) that can act as a soluble decoy receptor for RANKL, thereby 
inhibiting RANK-mediated osteoclastogenesis (for a review see Boyce and Xing 
(2008)). However, bone remodelling is a very complex and integrated process, and 
these localized findings only give limited information about the overall effects of 
these factors on the bone remodelling process. This highlights the need for tools 
which can integrate these partial observations to a set of rules that define the 
behaviour of this complex system. Mathematical modelling has been proven to be a 
powerful tool in modelling and understanding biological processes.  
Bone can resist the invasion of the majority of arriving cancerous cells due to 
its special properties. Diseases such as multiple myeloma (MM), breast cancer and 
prostate cancer can develop and survive within the bone microenvironment, due to 
phenotypic properties which influence the bone microenvironment to facilitate their 
growth and survival (Smith and Martin, 2011). MM is the second most frequent 
hematological malignancy, and MM-induced bone disease is a major cause of 
morbidity (Fowler et al., 2011). MM cells enhance bone resorption and suppress 
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bone formation, which consequently leads to a negative bone balance and results in 
osteolytic lesions that rarely heal (Matsumoto and Abe, 2011; Roodman, 2011). 
Histomorphometric studies reveal that the increased bone resorption arises due to the 
remodelling sites developing increased resorption surfaces and depth (Taube et al., 
1992; Wittrant et al., 2004). In addition, the coupling between bone resorption and 
formation is also disturbed in MM patients (Calvani et al., 2004). 
The interaction between MM cells and the bone microenvironment (MM-
bone interaction) plays an important role in the development of MM bone disease, as 
it promotes tumour growth and survival, as well as the consequent bone destruction 
(Fowler et al., 2011). Cytokines with osteoclast activating functions, such as the 
receptor activator of nuclear factor kappa-B ligand (RANKL), macrophage colony 
stimulating factor (M-CSF), interleukin-6 (IL-6), IL-11 and IL-1β (Terpos and 
Dimopoulos, 2005) are produced or stimulated by MM-bone interaction and further 
stimulate osteoclast activation and proliferation, therefore lead to increased bone 
resorption. In turn, growth factors released from bone resorption stimulate the growth 
of myeloma cells (Wittrant et al., 2004), including transforming growth factor-beta 
(TGF-β), bone morphogenetic proteins (BMP), heparin-binding fibroblast growth 
factors and insulin-like growth factor I (Blum et al., 2004; Guise and Chirgwin, 
2003). Such reciprocal interaction produces a ‘vicious cycle’ between MM cells and 
the bone microenvironment, stimulating both tumour development and bone 
destruction (Fowler et al., 2011; Wittrant et al., 2004).  
The research in this thesis consists of two major parts. Firstly, a novel 
predator-prey based mathematical model has been developed to describe the 
temporal dynamic interaction between osteoclasts and osteoblasts at a single BMU, 
with their corresponding bone resorption and formation activities. The model was 
developed to mimic the reconstructed remodelling cycles (curves) in both normal and 
pathological conditions, which are obtained from histomorphometric analysis  
(Agerbaek et al., 1991; Eriksen et al., 1984b; Eriksen et al., 1985, 1986a), and to 
replicate the observed dynamic interaction between osteoclasts and osteoblasts 
during the remodelling process. To our knowledge, this is the first attempt to develop 
mathematical models which are able to replicate such reconstructed remodelling 
curves quantitatively. The model has the potential to be used in modelling of 
pathological conditions and in the analysis of the underlying mechanisms of their 
treatment. Secondly, a mathematical model was developed to simulate the pathology 
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of MM-induced bone disease. It was developed in parallel with the recently 
published model of Wang et al. (2011), and similarly based on the earlier work of 
Pivonka et al. (2008, 2010), but importantly also included the underlying 
mechanisms involved in the inhibition of osteoblasts and their role in the 
development of MM bone disease. Wang et al. (2011) did not include this half of the 
bone remodelling process. The model can simulate the development of MM cells and 
the induced bone destruction, and explains why MM induced bone lesions rarely heal 
even after the complete removal of MM cells. The model reconstructs the variation 
of cell concentrations and the resultant bone destruction after the invasion and then 
the removal of the tumor cells, which matches published experimental observations. 
The model could also be used to test and evaluate proposed therapeutic interventions 
for MM bone disease (e.g. bisphosphonate, Bortezomib and inhibition of TGF-β) and 
even propose new treatments. 
This thesis consists of seven chapters, plus a glossary to define key biological 
and technical terms and one appendix. The appendix contains a summary of 
publications associated with this study. A brief description of the contents of each 
chapter follows. 
Chapter 2 briefly discusses some basic background knowledge of bone 
biology, including bone structure, bone composition, the underlying biological 
mechanisms of bone remodelling cycles and the biochemical factors regulating the 
bone remodelling process. 
Chapter 3 reviews a group of recently developed mathematical models of the 
bone remodelling process at the cellular level. They demonstrate great potential in 
developing our understanding of the bone remodelling process. 
Chapter 4 introduces a proposed predator-prey based mathematical model of 
bone remodelling at the cellular level in trabecular bone. The relevant literature 
regarding mathematical modelling is firstly introduced, including definition of the 
mathematical modelling and the process to build a mathematical model. Secondly, 
the development of the predator-prey based mathematical model is discussed, 
including model equations, model calculations, and simulation results and analysis. 
Chapter 5 describes the development of a mathematical model which 
demonstrates how the interaction between MM cells and the bone microenvironment, 
drives the development of MM and consequent bone destruction. Initially, a model 
based on the work of Pivonka et al. (2008) was developed to simulate the bone 
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microenvironment under normal condition. This model was then extended to mimic 
the pathology of MM-induced bone disease, by including the invasion of the tumour 
cells. The equations used to construct these two models are discussed in detail, along 
with the simulation results and subsequent analysis. The model was validated by 
comparing model predictions with published experimental observations. 
Chapter 6 gives a summary of the key results of the previous chapters and 
discusses how they fit into the current literature regarding the relevant bone biology 
and the mathematical models of the bone remodelling process. 
Chapter 7 outlines the main conclusions from the current research and 
suggest the direction of future work. 
Hence, the main contributions of this work are summarised as follow: 
1. To develop a mathematical model to simulate the bone remodelling cycles for 
trabecular bone based on a predator-prey model; 
2. To understand the roles of biochemical factors, including RANKL, OPG, TGF-β 
and systemic hormones (such as PTH) in the bone remodelling process; 
3. To model the pathologies of bone related diseases, such as hypothyroidism and 
primary hyperparathyroidism; 
4. To develop a mathematical model to simulate the pathology of MM-induced 
bone disease; 
5. To investigate the role of the interaction between MM cells and the bone 
microenvironment, in the development of the tumour cells and the subsequent 
bone destruction; 
6. To simulate current therapies and evaluate the efficacy of potential therapies of 
MM-induced bone disease.  
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2. LITERATURE REVIEW-BASIC BONE BIOLOGY 
2.1 INTRODUCTION 
This chapter reviews basic bone biology and provides the underpinning knowledge 
of bone structures and cellular activity required for this project. Bone structures, 
composition and cells are introduced first, followed by principles and regulatory 
factors of bone remodelling, together with bone metabolic diseases resulting from 
disorders of bone remodelling cycles. 
2.2 BONE STRUCTURE AND COMPOSITION 
The skeletal system plays both a biomechanical and metabolical role in the human 
body, and consists of a series of individual bones which are connected by soft tissue 
structures (Jee, 2001). Bone is the main constituent of the skeletal system and differs 
from connective tissue in terms of rigidity and hardness, enabling the skeleton 
system to maintain the shape of the body, protect the internal organs, supply the 
framework for the bone marrow and transmit the forces induced by muscular 
contractions during movement.  
The skeleton is divided into axial and appendicular subdivisions according to 
its different compositions and functions as shown in Table 2.1. 
 
Feature Axial Appendicular 
Main bone tissue Cancellous Cortical 
Adjacent soft tissue Viscera Muscle 
Cortices Thin Thick 
Marrow Hematopoietic Fatty 
Turnover High Low 
Cortical Mechanical Mechanical 
Cancellous Metabolic Mechanical 
 
Table 2.1: Compositions and functions of axial and appendicular subdivisions of the 
skeleton. Reproduced from Bronner and Worrell (1999). 
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The long bones such as humerus, femur and tibia are usually used as the 
classical model to introduce the macroscopic structure of bone (Jee, 2001). A typical 
adult long bone comprises of a diaphysis in the middle, which is enclosed by two 
more wider and rounded epiphyses. The diaphysis is connected with each epiphysis 
by a conical region named the metaphysis. The main composition of the diaphysis is 
cortical bone (or compact bone), while the epiphysis is primarily constructed from 
trabecular (or cancellous) bone which is encapsulated by cortical bone (Figure 2.1). 
Cortical bone is a dense, solid mass with only microscopic channels. It accounts for 
approximately 80% of the skeletal mass in the adult human skeleton, forms the outer 
wall of all bones and is responsible for the support and protection of the skeleton. 
Trabecular bone accounts for the remaining 20% and is located in the internal 
structure of bones. Cortical bones differ from trabecular bone in terms of their 
development, architecture, function, proximity to bone marrow, blood supply, 
rapidity of turnover time and magnitude of age-dependent changes and fractures (Jee, 
2001).   
 
 
Figure 2.1: Schematic diagram of the macroscopic structure of a long bone.  
Reproduced from Physical Education: The skeleton bones and joints [Online], 
http://www.bbc.co.uk/schools/gcsebitesize/pe/appliedanatomy/2_anatomy_skeleton_
rev4.shtml [Accessed 25, May 2011]. 
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The main structural unit of cortical bone is different from that of trabecular 
bone. It is the osteon (Haversian system), which is a cylinder about 200 to 500 µm 
(micrometre) in diameter, and accounts for two thirds of the volume; whilst the 
remaining one third is interstitial bone, which is composed of the remnants of past 
generations of osteons and circumferential lamellae. In comparison, the trabecular 
packet (hemiosteon) serves as the structural unit of trabecular bone and is a shallow 
crescent-shaped hemiosteon which has a 600 µm radius, 50 µm thick and 1 mm 
length. Table 2.2 shows details of BMUs of cortical and trabecular bone as below.  
 
Parameter 
Cortical 
(Osteonal) 
Cancellous 
(Trabecular Packet) 
Length (mm) 2.5 1.0 
Circumference (mm) 0.6 0.6 
Wall thickness (mm) 0.075 0.040 
Number/mm
3
 bone volume 15 40 
Total number in skeleton 21 × 10
6 
14 × 10
6 
Duration of resorption (days) 24 21 
Duration of formation (days) 124 91 
Remodelling period (days) 148 112 
Bone turnover rate (%/year) 43 26 
 
Table 2.2: Comparison of adult cortical and cancellous bone multicellular units. 
Modified from Recker (1983). 
 
The composition of bone includes minerals, organic matrix, cells and water. 
Minerals account for 65% of bone and can be found within collagen fibres in the 
form of small crystals in the shape of needles, plates and rods. The mineral is largely 
impure hydroxyapatite (Ca10 (PO4)6 (OH)2), which contains carbonate, citrate, 
magnesium, fluoride and strontium. These constituents are incorporated into the 
crystal lattice or absorbed onto the crystal surface (Gehron and Boskey, 1996; Lian et 
al., 1999). The organic matrix accounts for the remaining 35% of bone and is made 
up of 90% collagen and about 10% of various non-collagenous proteins, and has a 
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wide variety of functioned roles and determines the structural, mechanical and 
biochemical properties of the tissue (Gehron and Boskey, 1996; Gorski, 1998; Lian 
et al., 1999). 
2.3 BONE CELLS 
Bone cells include osteoblasts, osteoclasts, the immune regulatory system that 
supplies the precursor cells and regulates bone growth and maintenance, osteocytes, 
bone lining cells and cells of the marrow compartment (Jee, 2001). Only osteoclasts, 
osteoblasts, bone lining cells and osteocytes are discussed in this chapter, as these are 
the most relevant cells to this study. 
OSTEOCLASTS 
Osteoclasts are multinucleated giant cells which range in diameter from 20 to over 
100µm, with one osteoclast containing from 1 to more than 50 nuclei (Figure 2.2) 
(Jee, 2001). Osteoclasts are responsible for resorbing bone during the remodelling 
cycle. The surface of an osteoclast adjacent to the bone surface has a striated 
appearance and a ruffled border, and secretes products which lead to bone resorption. 
 
 
 
Figure 2.2: Light micrograph of an osteoclast. Reproduced from Hill M, 
Musculoskeletal System – Bone Development [Online].  
Available:http://php.med.unsw.edu.au/embryology/index.php?title=Musculoskeletal
_System_-_Bone_Development#Introduction [Accessed 30, March 2011]. 
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The differentiation of osteoclasts from their early precursors involves several 
stages as summarized in Figure 2.3 (Roodman, 2006). Osteoclasts are derived from 
cells in the mononuclear/phagocytic lineage of the hematopoietic marrow. The 
granulocyte-macrophage colony-forming unit (CFU-GM) is capable of 
differentiating into granulocytes, monocytes and osteoclasts, and is identified as the 
earliest osteoclastic precursor. CFU-GM-derived cells first differentiate into 
osteoclastic precursors, which later fuse to form multinucleated osteoclasts 
(Roodman, 2006). Active osteoclasts are usually observed in cavities on the surface 
of trabecular bone or internally in cortical bone in Howship’s lacunae. The life span 
of osteoclasts in vivo is reported to be up to 7 weeks, after which they undergo 
apoptosis (Majeska, 2001). 
 
 
Figure 2.3: The osteoclast life cycle from proliferation and differentiation to 
apoptosis. Reproduced from Roodman (2006). 
 
 
 
11 
 
OSTEOBLASTS 
Osteoblasts are responsible for building new bone by synthesizing and secreting 
unmineralized bone matrix, and also participate in the bone calcification (Jee, 2001). 
They control the flow of calcium and phosphate in and out of bone and regulate bone 
resorption indirectly by interacting with osteoclastic cells. Active osteoblasts are 
cuboidal in shape, and are typically 15 to 30 µm thick (Figure 2.4) (Jee, 2001). 
Osteoblasts are derived from mesenchymal progenitors and their life consists 
of the several differentiation steps illustrated in Figure 2.5 (Eijken, 2007). Firstly, 
mesenchymal stem cells commit to the osteoblastic lineage, which then proliferates 
and differentiates into pre-osteoblasts. These pre-osteoblasts are able to produce 
extracellular matrix, and differentiate into mature osteoblasts that are capable of 
synthesizing extracellular matrix and initiating its mineralization. Several mature 
osteoblasts are eventually deposited within the newly formed bone matrix as 
osteocytes. The remaining mature osteoblasts undergo apoptosis or become bone 
lining cells (Eijken, 2007).  
 
 
 
Figure 2.4: Light micrograph of an osteoblast and osteocyte. Reproduced from 
Laboratory Exercises: intramembranous Bone Development [Online]. Available: 
http://microanatomy.net/bone/devbone2_lab.htm [Accessed 30, March 2011]. 
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Figure 2.5: The differentiation stages of the osteoblast from stem cells. Reproduced 
from Eijken (2007). 
 
BONE LINING CELLS  
Bone lining cells are situated on the quiescent bone surface. They are a distinct 
morphological phenotype with a thin, flat nuclear profile with attenuated (1 µm thick 
and up to 12 µm long) cytoplasm (Jee, 2001). Gap junctions exist between adjacent 
bone lining cells, and between bone lining cells and osteocytes (Jee, 2001). Bone 
lining cells are derived from inactive osteoblasts and osteoblast precursors, which 
have ceased activity or differentiation (Jee, 2001).  
Bone lining cells build three-dimensional networks with osteocytes. It is 
believed that these three-dimensional networks, in which the cells communicate with 
each other, are able to sense the stress and strain experienced within a bone, and 
subsequently transmit signals to the bone surface to initiate the remodelling process 
(Baron, 1999; Burr, 1997; Parfitt, 1983; Roodman, 1996).  
OSTEOCYTES 
Osteocytes are the most abundant cell type in mature bone, with about ten times 
more osteocytes than osteoblasts in healthy human bone. Osteocytes are formed from 
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the osteoblasts deposited in the newly formed osteoid during bone formation (see 
Figure 2.6) (Bonewald, 2004; Jee, 2001).  
The location of osteocytes makes them capable of sensing the magnitude and 
distribution of strains, and translate these signals into biochemical signals 
(Bonewald, 2004; Jee, 2001). Their functions can be summarized in two ways: (1) 
they stabilize bone mineral by maintaining an appropriate level of local ionic milieu, 
and control the efflux of calcium ions in collaboration with bone lining cells (Holtrop 
and Weinger, 1972; Miller et al., 1980; Miller and Jee, 1987; Talmage, 1969); (2) 
they detect micro-damage of bone (Bentolila et al., 1998; Lanyon, 1996; Lanyon et 
al., 1993; Mori and Burr, 1993) and respond to mechanical strain induced within 
bone tissue through cell-cell interaction (Lanyon et al., 1993). 
 
 
 
Figure 2.6: Microphotograph of several layers of osteocytes in the lacunae of 
Harversian canal. Reproduced from Compact Bone Histology [Online]. Available: 
http://www.cytochemistry.net/microanatomy/bone/compact_bone_histology.htm 
[Accessed 30, March 2011]. 
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2.4 BONE REMODELLING 
Bone formation begins in utero and continues throughout adolescence by 
“modelling” until skeletal maturity is reached (Einhorn, 1996). Bone is a 
metabolically active organ that is able to adapt its structural and material properties 
to the mechanical demands placed upon it, via a localized process termed “bone 
remodelling” (Raisz, 1999). The bone remodelling cycle consists of a series of highly 
regulated sequential steps involving the interactions of osteoclastic and osteoblastic 
lineages, the mesenchymal osteoblastic lineage and the hematopoietic osteoclastic 
lineage (Raisz, 1999). In addition, bone remodelling processes are able to maintain 
mineral homeostasis and the biomechanical integrity of the skeleton via repairing 
fatigue damage (Mundy and Boyce, 1996). 
Bone remodelling is a continuous process of bone resorption performed by 
osteoclasts, followed by bone formation performed by osteoblasts, and occurs in the 
skeleton of vertebrates throughout their lifetime (Mundy, 1999). It occurs 
asynchronously at multiple spatially and temporally discrete sites of the skeleton in 
order to repair damaged portions or replace older bone with new bone (Pivonka et 
al., 2008). 
An ideal condition consists of the amount of newly formed bone equalling the 
amount of the resorbed bone, thereby preserving bone mass (Glowacki, 1996; 
Kessenich and Rosen, 1996). This balance is maintained by the tight coupling 
between osteoclastic and osteoblastic cells, i.e. the activation of an osteoclast cannot 
usually occur in the absence of osteoblasts. In fact, the bone remodelling cycle is 
initiated by osteoblastic cell signalling to generate osteoclast-active cytokines, and 
this mechanism ensures that bone remodelling begins and ends with osteoblast 
activity (Kessenich and Rosen, 1996). Osteoblasts indirectly regulate the bone 
resorption performed by osteoclasts via the RANKL-RANK-OPG pathway (Bell, 
2003; Boyce and Xing, 2008). 
AIMS OF BONE REMODELLING 
Bone remodelling is carried out to achieve three main aims (Burr, 2002): (1) to 
regulate the balance of essential minerals in the body by changing their concentration 
in serum; (2) to enable the skeleton to adapt to its mechanical environment, which 
reduces the risk of fracture; (3) to provide a mechanism for repairing bone damage. 
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The first aim can be carried out by site-independent bone remodelling, as the 
location of bone remodelling is not important, providing bone integrity is not 
challenged and the mineral balance is maintained (Burr, 2002). However, the other 
two aims require site-dependent remodelling, since it is unnecessary for the 
remodelling system to increase its turnover rate throughout the whole skeletal when 
only a single location is damaged (Burr, 2002). 
THE BONE MULTICELLULAR UNIT 
A BMU is a temporal association of a group of cells that accomplish one quantum of 
bone turnover, i.e. removal and replacement of existing bone with a new structural 
unit (Hernandez et al., 2000). The BMU originates within the bone and progresses 
across the trabecular bone surface (or through the Haversian canal in cortical bone) 
during its lifespan (Figure 2.7). 
 
 
Figure 2.7: The basic multicelluar unit (BMU) in cortical and cancellous bone. 
Reproduced from Hernandez et al. (2000). 
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As shown in Figure 2.8, the life cycle of a BMU consists of six stages: 
resting, activation, resorption, reversal (coupling), formation, mineralization and 
back to resting (Jee, 2001). 
Resting 
In the resting phase the bone surfaces are inactive with respective to bone 
remodelling. Almost 80% of trabecular and cortical bone surfaces in large adult 
animals, including humans, are in the resting phase at any given time (Jee, 2001). 
The resting bone surfaces are covered by bone lining cells that may function as 
osteogenic precursor cells and an endosteal membrane.  
Activation 
The activation of bone remodelling refers to the conversion of a bone surface from a 
state of resting into a period of resorption. It is still not completely clear which factor 
initiates this activation, although local structural and biomechanical requirements are 
believed to be involved (Jee, 2001). 
Resorption  
The resorption phase begins when osteoclasts arrive and make contact with the bone 
surface. Osteoclasts resorb bone and form Howship’s lacunae in trabecular bone, and 
Haversian canals in cortical bone (Jee, 2001). The mean resorption depths in 
trabecular and cortical bone are 60 µm in radius and 100 µm in diameter, 
respectively (Jaworski et al., 1975). 
Reversal (Coupling) 
After the maximum resorption depth has been achieved by the osteoclasts, the 
reversal phase begins. There is a 1 to 2 weeks duration between the completion of 
bone resorption and the commencement of bone formation. From a histology 
perspective, the reversal phase is a period when there are no osteoclasts in the 
Howship’s lacunae and Haversian canals (Jee and Ma, 1997). During the reversal 
phase osteoclasts undergo apoptosis, while macrophage-like cells appear on the bone 
surface. These latter cells may release factors that are able to suppress osteoclast 
activity and stimulate osteoblast activity.  
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Formation and Mineralization  
Bone formation involves bone matrix synthesis followed by extracellular 
mineralization. Osteoblasts begin to build a layer of matrix called the osteoid seam. 
The osteoid seam achieves about 70% of its final mineralization after 5 to 10 days, 
with complete mineralization taking about 3 to 6 months in both cortical and 
cancellous bone (Ericksen et al., 1994; Frost, 1995; Jee, 1988; Parfitt et al., 1987; 
Recker, 1983). 
 
 
Figure 2.8: The different phases of the bone remodelling cycle. Reproduced from 
Medicina Oral, Patología Oral y Cirugía Bucal [Online].  
Available: http://scielo.isciii.es/scielo.php?pid=S1698-
69462006000200012&script=sci_arttext&tlng=en [Accessed 30, March 2011]. 
 
REGULATORY FATORS OF BONE REMODELLING 
Many factors can regulate bone remodelling and thereby influence the peak bone 
mass and the remodelling rate, including environmental factors (such as diet, calcium 
intake and level of exercise), local factors in the bone microenvironment and 
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systemic hormones. Bone remodelling is regulated by local factors, such as cytokines 
(both paracrine and autocrine), growth factors, cell to cell communications (Bland, 
2000; Mundy and Boyce, 1996) and systemic factors (e.g. systemic hormones). 
Systemic factors regulate bone remodelling indirectly via local factors or directly by 
binding to their own receptors (Figure 2.9) (Lemaire et al., 2004). Systemic and local 
factors affect osteoblastic and osteoclastic cells by regulating the replication of 
undifferentiated cells, the recruitment of cells and the differentiated function of cells 
(Canalis, 1993).  
 
 
Figure 2.9: Schematic representation of the regulation of bone remodelling by 
hormones and local factors. Reproduced from Canalis (1993). 
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2.4.1 HORMONAL REGULATION OF BONE REMODELLING 
Bone remodelling is regulated by a variety of systemic hormones, such as 
parathyroid hormone, calcitonin, insulin, growth hormone and steroids (e.g. vitamin 
D, glucocorticoids, sex steroids and thyroid hormone) (Canalis, 1993). The effect of 
parathyroid and thyroid hormone on bone remodelling is discussed here. 
Parathyroid Hormone 
Parathyroid hormone (PTH) is a polypeptide with a molecular weight of 9500, and is 
regarded as the most important hormone regulating calcium homeostasis and bone 
remodelling (Parfitt, 1976). It has been used in numerous clinical trials as an anabolic 
agent for the treatment of osteoporosis. Interestingly, PTH has a dual effect on bone: 
catabolic when released into plasma quasi-continuously or continuously; and 
anabolic when injected intermittently (Dempster et al., 1993; Meng et al., 1996; 
Watson et al., 1999). 
Osteoclasts do not have PTH receptors, although they are expressed on the 
osteoblast surface, and PTH can stimulate bone resorption by osteoclasts indirectly 
via osteoblasts (Goltzman, 1999; Teitelbaum, 2000). For example, quasi-steady state 
levels of plasma PTH stimulate the production of RANKL by osteoblasts, however it 
inhibits the production of OPG by osteoblasts, therefore causing an increase in 
population of active osteoclasts (Aubin and Bonnelye, 2000; Halladay et al., 2001; 
Ma et al., 2001; Teitelbaum, 2000). Thus, the observed catabolic effect of PTH 
requires the presence of osteoblasts or osteoblast-derived factors. Continuous 
treatment with PTH suppresses bone formation in vitro as it directly inhibits bone 
collagen synthesis. In contrast, intermittent treatment with PTH results in a 
stimulation of bone collagen synthesis and bone formation (Canalis et al., 1989). 
Thyroid Hormone 
Thyroid hormones are potent stimulators of osteoclasts and osteoblasts (Melsen and 
Mosekilde, 1977; Mosekilde and Melsen, 1978a, b; Mundy et al., 1976) and play an 
important role in the skeletal growth and development in children (Altabas et al., 
2007). Thyroid hormone deficiency in childhood causes retardation of skeletal 
development and growth arrest. In comparison, excessive production of thyroid 
hormones results in accelerated growth and can even prematurely close the growth 
plates and cranial sutures. In adult thyrotoxicosis, accelerated bone remodelling 
paralleling an imbalance between bone resorption and bone formation, leads to net 
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bone loss and increased risk of bone fracture (Bassett and Williams, 2003). 
Therefore, thyroid hormones are important in skeletal development and metabolism. 
Excessive levels of thyroid hormones increase the activity of both osteoblasts 
and osteoclasts, which can result in accelerated bone remodelling (Altabas et al., 
2007). Thyroid hormone deficiency causes reduced bone remodelling rates and 
elevated bone mineral density in adults. However, the exact molecular mechanisms 
of thyroid hormone acting on bone are not completely understood (Altabas et al., 
2007). 
2.4.2 LOCAL REGULATION OF BONE REMODELLING 
In addition to systemic regulatory factors, bone remodelling is also under the control 
of local factors, since bone remodelling is a local phenomenon happening in the bone 
microenvironment (Lemaire et al., 2004; Mundy and Boyce, 1996). Most of the local 
factors are produced by skeletal cells, however some are derived from cells of the 
immune or hematological system that are present in the bone microenvironment 
(Canalis, 1993).  
Early attempts to understand the structural adaptation of the skeleton 
theorised that bone remodelling must be regulated by local factors (McLeod et al., 
1998), although it remained unknown which factors were involved. One of the first 
to be identified was cytokines (Raisz, 1999). These “osteoclast-activating factors”, 
which can be produced by inflammatory cells (such as macrophages), are involved in 
the local bone loss associated with periodontal disease and inflammatory arthritis 
(Lorenzo, 1991). At about the same time, prostaglandins (particularly prostaglandin 
E2) were demonstrated to stimulate bone resorption (Kawaguchi et al., 1995). To date 
a large number of cytokines and growth factors which are capable of affecting bone 
cell functions have been identified (Horwood et al., 1998b; Mizuno et al., 1998; 
Raisz, 1999; Yasuda et al., 1998). 
Communication between osteoclastic cells and osteoblastic cells plays an 
important role in bone remodelling. For many years it has been hypothesized that 
osteoclast development and activity are under the control of osteoblasts or stromal 
cells (Rodan and Martin, 2000). However, details of the molecular and physiological 
mechanisms were not identified until the end 1990s, when some of the proteins 
responsible for the interaction between cells of osteoclastic and osteoblastic lineages 
were discovered. The mechanism by which such proteins pass messages between 
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osteoclastic and osteoblastic cells is called the RANK-RANKL-OPG signalling 
pathway (Hofbauer and Schoppet, 2004; Martin, 2004; Robling et al., 2006). 
The RANK-RANKL-OPG Pathway  
The RANK-RANKL-OPG pathway involves three components: (1) receptor 
activator of nuclear factor kappa beta (NF-κ) ligand (RANKL), a protein primarily 
produced by osteoblastic precursors as a soluble form; (2) receptor activator of 
nuclear factor kappa beta (NF-κ) (RANK) expressed on the surface of hematopoietic 
precursor cells (referred to as osteoclastic precursor cells); (3) osteoprotegrin (OPG), 
a “decoy receptor” primarily released by mature osteoblasts (Martin, 2004; Pivonka 
et al., 2008; Simonet et al., 1997). RANKL interacts with its receptor (RANK) and 
thereby promotes osteoclast formation (as well as maintaining their viability and 
activity) (Martin, 2004; Pivonka et al., 2008). OPG can suppress the interaction of 
RANKL/RANK by binding to RANKL as a soluble decoy receptor (Pivonka et al., 
2008). Its signalling pathway is called the RANK–RANKL–OPG pathway and plays 
an important role in the coupling between bone resorption by osteoclasts, and bone 
formation by osteoblasts. 
Bone contains many growth factors, such as TGF-β (transforming growth 
factor beta), whose content in dried bone powder is approximately 1000-fold greater 
than the levels required for osteoblastic stimulation (Hauschka, 1989). These growth 
factors released during bone resorption can influence the osteoblastic cells. The 
effect of TGF-β on the osteoblastic lineage is bi-directional and dependent upon the 
state of osteoblasts (Hauschka, 1989; Simmons and Grynpas, 1990). On one hand, 
TGF-β has the potential to stimulate osteoblast recruitment, migration and 
proliferation of osteoblast precursors (Bonewald and Dallas, 1994b; Eriksen and 
Kassem, 1992; Mundy and Boyce, 1996). On the other hand, TGF-β suppresses the 
differentiation of osteoblastic precursors into active osteoblasts (Alliston et al., 
2001). Therefore, TGF-β inhibits the population of active osteoblasts until it is 
removed or becomes inactive (Mundy, 1999).  
2.4.3 RELATIONSHIP BETWEEN LOCAL AND SYSTEMIC 
FACTORS 
The RANK-RANKL-OPG pathway, together with the dual action of TGF-β on 
osteoblasts, builds a control network through which systemic factors can regulate 
bone remodelling (Lemaire et al., 2004; Manolagas, 2000). Many factors regulate 
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bone resorption such as parathyroid hormones (PTH), prostaglandins, interleukins, 
vitamin D3 and corticosteroids, and exert an indirect effect. They signal to the 
osteoblast/stromal cells, and these signals are then translated into different levels of 
RANKL and OPG expression, which in turn regulate osteoclast formation (Bell, 
2003; Martin, 2004). For example, the receptors of PTH are expressed on the surface 
of osteoblasts (Goltzman, 1999; Teitelbaum, 2000). Quasi-steady state levels of PTH 
increase the production of RANKL and inhibit the production of OPG by osteoblasts 
(Aubin and Bonnelye, 2000; Halladay et al., 2001; Ma et al., 2001; Teitelbaum, 
2000), which as a result increases the population of active osteoclasts. The RANK-
RANKL-OPG pathway is described as the ‘convergence hypothesis’, because of its 
importance as the control mechanism (Hofbauer et al., 2000). Many bone diseases 
are caused by disorders of the RANKL/OPG ratio, such as osteoporosis, Paget's 
disease, tumor metastasis, humoral hypercalcemia of malignancy, and multiple 
myeloma (Boyle et al., 2003; Hofbauer et al., 2000; Hofbauer et al., 2004; Rodan and 
Martin, 2000). 
2.5 BONE DISEASES CAUSED BY DISORDERS OF BONE 
REMODELLING 
Bone remodelling is a highly integrated process of bone resorption by osteoclasts and 
successive bone formation by osteoblasts, thus it maintains skeletal mass with 
renewal of the mineralized matrix. Disorders of bone remodelling can result in 
metabolic bone diseases, and some key examples are given below.   
Osteoporosis  
Osteoporosis is an age-related bone disease, which often leads to spine, wrist and hip 
fracture, and is charactered by low bone mass and microarchitectural deterioration of 
bone tissue (Ismal, 1997). Bone loss is an inevitable age-related condition and is 
determined by the remodelling rate and the negative bone balance between bone 
resorption and formation (Seeman, 2003). It appears to begin between the ages of 18 
to 30 years, onsetting after the rapid increase during adolescence, however this 
process is slow because the remodelling rate is low (Gilsanz et al., 1988; Ji et al., in 
press). Osteoporosis refers to a condition when bone mass decreases to a critical 
level, below which fracture risk is substantially high (Riggs and Melton, 1992). 
Osteoporosis is a worldwide health problem and affects millions of people, including 
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postmenopausal women and the majority of the elderly (Christiansen, 1999), and can 
complicate a variety of sporadic behavioural, nutritional and environmental factors 
(Riggs, 1991).  
Osteoporosis can be classified into primary osteoporosis and secondary 
osteoporosis, depending on whether or not an identifiable aetiological mechanism is 
recognized (Kassem et al., 1996; Kleerekoper and Avioli, 1990). In addition, 
osteoporosis can also be classified into juvenile osteoporosis and ‘involutional 
osteoporosis’, which includes postmenopausal osteoporosis and senile osteoporosis 
(Kassem et al., 1996). In 1982, Riggs characterized two distinct syndromes of 
involutional osteoporosis: high turnover and low turnover osteoporosis. High 
turnover osteoporosis occurs in postmenopausal women between the ages of 50 and 
65 years old, and is pathogenetically related to oestrogen deficiency. Low turnover 
osteoporosis occurs in both men and women aged predominantly over 75, and affects 
both trabecular and cortical bone. It is caused by an age-related decline in osteoblast 
function and can lead to hip and vertebral fractures (Kanis, 1996). Such a 
classification of osteoporosis is straightforward, however it is may be too simple to 
cover all cases. Under some conditions, the mechanisms of bone loss involve 
abnormalities of both bone resorption and formation (Kanis, 1996). 
Paget’s Disease 
Paget’s disease is characterized by excessive and abnormal bone remodelling, and is 
caused by increased osteoclastic resorption located in one region of the skeleton, 
such as the skull, pelvis or the ends of long bones. In tissues affected by Paget’s 
disease, osteoclasts are abundant and may contain up to 100 nuclei per cell. 
However, the factors which cause this increase in population and activity of 
osteoclasts have not been identified (Glowacki, 1996). The consequences of Paget’s 
disease include susceptibility to bone deformity, pain, degenerative arthritis and 
secondary neurological abnormalities (Glowacki, 1996). 
Primary Hyperparathyroidism  
Primary hyperparathyroidism is characterized by hypercalcemia resulting from 
overproduction of parathyroid hormones by the parathyroid gland (Bilezikian, 1993). 
Primary hyperparathyroidism is a relatively common disease, with estimates of 
incidence as high as 0.1% to 0.2% (Bilezikian, 1990). The condition can occur in 
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people of all ages, however it happens more frequently in those aged over 60 and in 
women (by a ratio of 3:2 compared to men) (Bilezikian, 1993).  
Two major organs affected by primary hyperparathyroidism are bones and 
the kidneys (Bilezikian, 1993). Within patients suffering from primary 
hyperparathyroidism, the total amount of work performed by osteoclasts and 
osteoblasts reduces, producing a near zero balance between bone resorption and 
formation at the end of bone remodelling cycle. However, the bone remodelling rate 
at a given point on the trabecular surface in patients with primary 
hyperparathyroidism is increased compared to a healthy individual (Eriksen et al., 
1986b). The kidneys may also suffer renal stones (nephrolithiasis) or diffuse 
calcium-phosphate complexes the in parenchyma (nephrocalcinosis) of patients with 
primary hyperparathyroidism (Bilezikian, 1993).  
Hypothyroidism and Hyperthyroidism 
Thyroid hormones are stimulators of osteoclasts and osteoblasts (Mosekilde and 
Melsen, 1978a, b; Mundy et al., 1976), and can promote bone resorption directly and 
indirectly via osteoblasts (Ishikawa et al., 1998; Zaidi et al., 2009). Hypothyroidism 
is caused by the deficiency of thyroid hormones in humans and other vertebrates, and 
can be associated with an abnormality in the thyroid gland, or less commonly, the 
pituitary or hypothalamus. Hyperthyroidism is the opposite of hypothyroidism and is 
caused by the excessive production of thyroid hormones (Torre et al., 2008).  
During the bone remodelling cycle in patients with hypothyroidism, the bone 
resorption rate decreases, while the bone resorption period is prolonged compared to 
a normal condition. The bone resorption depth, which is dependent on both the bone 
resorption rate and period, decreases in comparison to normal controls  as the rate of 
change in the bone resorption decrease is larger than that of the bone resorption 
period increase (Eriksen et al., 1986a). For patients with hypothyroidism, the bone 
formation rate decreases, while the bone formation period increases. The bone 
formation depth, which is determined by both the bone formation period and rate, 
increases in comparison to normal controls as the rate of change in the formation 
period increase is larger than that of the formation rate decrease. Thus, a positive 
balance is created at the end of a bone remodelling cycle. However, the obvious 
increase in bone mass cannot be observed during a relatively a short period, since the 
bone turnover rate decreases compared to the normal condition. 
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For patients with hyperthyroidism, both bone resorption and formation rates 
increase, while resorption, formation and quiescent periods all decrease in 
comparison to the normal condition (Eriksen et al., 1985, 1986a). The amount of 
resorbed bone is relatively similar with that in healthy condition. However, the 
amount of deposited bone decreases due to a reduction in the formation period, 
which leads to a negative balance at the end of a bone remodelling cycle (Eriksen et 
al., 1985, 1986a). 
Multiple Myeloma 
Bone can prevent the invasion of most cancer cells due to its special properties 
(Smith and Martin, 2011). However, MM cells are able to survive and develop 
within the bone microenvironment and can alter its characteristics to facilitate their 
growth and survival (Smith and Martin, 2011). MM is the second most frequent 
hematological malignancy and is associated with high morbidity rates and short 
lifespan after diagnosis (Fowler et al., 2011). The American Cancer Society 
estimates that there are approximately 20000 new cases of MM diagnosed and 10800 
deaths associated with MM each year in the United States alone (Jemal et al., 2004). 
MM-induced bone disease is a major cause of morbidity for patients suffering from 
MM, with up to 60% experiencing bone fractures (Fowler et al., 2011). MM can 
induce a negative bone balance and osteolytic lesions via increasing bone resorption, 
while suppressing bone formation (Matsumoto and Abe, 2011; Roodman, 2011).  
2.6 DISCUSSION  
Bone remodelling is a vital process that enables the continuous renewal of bone 
throughout its life. The purpose, stages and regulatory factors involved in bone 
remodelling are introduced in this chapter, together with the details of several 
metabolic bone diseases resulting from disorders of bone remodelling. 
It should be recognized that some issues discussed in this chapter are still not 
completely understood. While it is known that PTH has an important effect on bone 
resorption as well as bone formation, the mechanisms by which PTH regulates bone 
remodelling are still not fully understood, and further research is still required.  
Inevitably, this chapter does not cover all aspects of bone biology. For 
instance, in addition to PTH and thyroid hormones discussed in this chapter, other 
hormones, such as insulin, growth hormone, glucocorticoids and sex steroids, also 
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influence bone remodelling. Mechanical stress or strain on bone is also a driver of 
bone remodelling. The relationship between mechanical stress and bone remodelling 
is not discussed in this chapter, since it only focuses on local biochemical factors and 
systemic hormones. 
This chapter has reviewed the basic biological knowledge relevant to this 
study. Chapter 3 follows with another review to discuss several previously developed 
mathematical models of the bone remodelling cycle, in order to provide a general 
overview of the developments in mathematical modelling.  
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3. LITERATURE REVIEW-MATHEMATICAL 
MODELLING OF BONE REMODELLING CYCLES 
AT THE CELLULAR LEVEL 
3.1 INTRODUCTION 
Understanding the bone remodelling process at the BMU level could lead to 
improved methods for manipulating the remodelling cycle for the treatment of bone 
diseases. For example, the use of therapeutic agents to increase BMU activations, in 
conjunction with a reduction in osteoclast activity while maintaining osteoblast 
activity, will lead to an accumulation of new bone, in a similar way to the process of 
hypothyroidism (Rodan and Martin, 2000; Zaidi, 2007). Indeed, this approach has 
already led to the development of anti-resorptive therapies for post-menopausal bone 
loss, including oestrogens, raloxifene, bisphosphonates and calcitonin. 
Recent reviews have revealed a growing number of factors involved in the 
regulation of bone remodelling (Allori et al., 2008; Zaidi, 2007). These include 
autocrine and paracrine signalling molecules, systemic hormones and extracellular 
matrix components, all of which affect cell-to-cell communication, migration, 
adhesion, proliferation and differentiation. Most of these findings were obtained 
from isolated observations of either in vitro studies, or in vivo experiments using 
genetically manipulated animals. These findings have shown that osteoblasts are able 
to regulate the activity of osteoclasts; for example expression of RANKL by 
osteoblasts, directly interacts with RANK on osteoclast progenitors to drive 
osteoclastogenesis. This process also depends on the level of OPG that can act as a 
soluble decoy receptor for RANKL (for a review, see Boyce and Xing (2008)). 
However, these findings only give limited information about the overall effects of 
these factors. This highlights the need for tools which can integrate these partial 
observations into a set of rules that define the behaviour of this complex system. 
In contrast to in vivo and in vitro, which refer to biological experiments 
performed inside and outside of living organisms, experiments performed via 
computer simulation are termed in silico (Miramontes, 1992). In silico experiments 
are being increasingly used to understand and predict the quantitative behaviour of 
biological systems, since computer simulations have several advantages over 
biological experiments (Di Ventura et al., 2006). In particularly, in vivo and in vitro 
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experiments can be time consuming and expensive. For example, one single cycle of 
bone remodelling in a healthy individual takes over 200 days (Eriksen et al., 1984b; 
Eriksen et al., 1984a), and there is also around a 900 day quiescent period before the 
next remodelling cycle occurs (Eriksen et al., 1986a). In silico simulations are able to 
model this process much quicker and at a reduced cost. Additionally, ethical 
considerations often prevent the performance of certain experiments on humans, as 
they can pose health risks. 
In recent years a number of mathematical models of the bone remodelling 
process at the cellular level have been developed, and have helped develop the 
understanding of the process, solve disputed issues and propose potential therapies 
for prevalent bone related diseases. These models have demonstrated a great 
potential in furthering our understanding of this complex biological process, and are 
reviewed in this chapter. 
3.2 MATHEMATICAL MODELS OF BONE REMODELLING 
AT THE CELLULAR LEVEL  
The mechanostat theory developed by Frost in 1987 has led to the development of a 
series of mathematical models explaining the biomechanical properties of bone 
(Frost, 1987; Martin, 1995; Turner, 1999). However limited attempts have been 
performed to mimic bone remodelling cycles at the cellular level. The details of 
existing mathematical models of the bone remodelling process that have been 
developed are summarized below. 
Kroll and Rattanakul’s Models 
As discussed in Chapter 2, parathyroid hormones (PTH) results in net bone loss 
when administered in a continuous way; however it causes net bone formation when 
administered intermittently. In order to explain such paradoxical behaviour, Kroll 
(2000) developed a mathematical model to simulate the dynamic interaction of pre-
osteoblasts, osteoblasts and osteoclasts in response to PTH. This model aimed to 
provide a basis for PTH-based therapies treating bone related disease. 
The model developed by Kroll (2000) proposed that PTH regulates 
osteoclasts indirectly via osteoblastic cells, because osteoclastic cells do not have the 
receptors for PTH (in contrast to preosteoblastic precursors and preosteoblasts). PTH 
stimulates the differentiation of preosteoblastic precursors into preosteoblasts, but 
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inhibits the differentiation of preosteoblasts into osteoblasts, via binding to the 
receptors (Kroll, 2000).  
Kroll’s model consisted of four ordinary differential equations which describe 
the temporal variation in concentrations of preosteoblasts, osteoblasts, osteoclasts 
and PTH. The ratio of osteoblasts to osteoclasts was used to indicate the net effect of 
PTH on bone resorption and bone formation. The simulation results demonstrated 
that intermittent PTH administration increases bone formation, however constant 
PTH administration increases bone loss. These are consistent with the mechanism of 
osteoporosis proposed by Samuels et al. (1993) and confirms biological experimental 
observations.  
Assumptions were made to facilitate the construction of this model. The 
delay time for the differentiation of preosteoblastic precursors into preosteoblasts, 
and the differentiation of preosteoblasts into osteoblasts, were set at 1 and 2 hours, 
respectively. Additionally, the proliferative effect of PTH on both osteoblast and 
osteoclast cell populations was dependent on temporal aspects. However, the model 
of Kroll (2000) assumed that PTH exerts a constant, progressive effect on the 
development of osteoclasts. 
Rattanakul et al. (2003) extended Kroll’s model by including the effect of 
oestrogen stimulation on the dynamics of osteoblast and osteoclast populations, and 
observed the underlying mechanisms of PTH mediating the bone remodelling 
process. Rattanakul’s model was made up of three ordinary differential equations, 
which describe the dynamic of PTH level and the concentrations of osteoclast and 
osteoblast. This model was biologically based on clinical observations reported 
within literature (Burgess et al., 1999; Dempster et al., 1993; Hock and Gera, 1992; 
Kong et al., 1999; Momsen and Schwarz, 1997; Takahashi et al., 1999). 
It assumed that a nonlinear system to simulate the temporal effect of PTH as 
well as the action of oestrogen replacement therapy, while assuming that the removal 
rate of PTH from the system is proportional to its current level. The model 
demonstrated that limit cycle behaviour could develop into chaotic dynamics for 
certain ranges of the system’s parametric values (Rattanakul et al., 2003).  
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Komarova’s Model 
Interactions between osteoclastic and osteoblastic cells are clearly critical in the 
regulation of bone remodelling. Komarova et al. (2003) constructed a mathematical 
model to replicate autocrine and paracrine interactions among osteoclastic and 
osteoblastic lineages, based on the assumption that local effectors secreted by 
osteoclasts and osteoblasts can regulate their formation rates. The model consisted of 
three ordinary differential equations, which describe the variation in the 
concentrations of osteoclasts, osteoblasts and bone volume with time. This was the 
first model to mimic the temporal dynamics of bone remodelling cycles at a single 
BMU. 
Komarova et al. (2003) proposed a simplified interaction between osteoclasts 
and osteoblasts, where mature cells and their precursors are not distinguished and 
considered as one variable (as shown schematically in Figure 3.1). The rates of 
overall production of each cell population represented the net effect of the 
recruitment of precursors and the formation of mature cells. The rates of cell removal 
reflected cell death, as well as the differentiation of osteoblasts into osteocytes and 
bone lining cells. Finally, it was assumed that cells were able to interact with each 
other via effectors, which are released or activated by bone cells and act in an 
autocrine or paracrine manner. 
 
 
Figure 3.1: Schematic representation of the interaction between osteoclast lineage 
and osteoblast lineage included in the model of Komarova et al. (2003). Reproduced 
from Komarova et al. (2003). 
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The model was capable of simulating the temporal variation in cell 
populations and bone mass during a cycle of bone remodelling at a discrete site. The 
model simulation indicated that the system exists in two stable modes, (1) a 
remodelling cycle in response to an external stimulus and (2) a series of internally 
initiated cycles of bone remodelling, which correspond to targeted and random bone 
remodelling, respectively. Additionally, the system also exists in an unstable mode, 
characterized by unstable oscillatory changes in cell numbers and bone mass with 
increasing amplitude. The behaviour of this unstable mode is very similar to bone 
remodelling in individuals with Paget’s disease. The model also showed that the 
dynamic behaviour of the system was dependent on the parameters representing 
autocrine regulation of osteoclasts. 
Inevitably, there are some limitations in Komarova’s model: (1) only two cell 
types were considered; (2) paracrine and autocrine factors were assumed to regulate 
only the formation of osteoblasts and osteoclasts, while cellular activity and death 
were assumed to be proportional to cell population; and (3) parameters describing the 
effectiveness of autocrine and paracrine regulation included the actions of multiple 
factors. 
Moroz’s Model 
The model of Komarova et al. (2003) reconstructed the variation in populations of 
osteoclasts and osteoblasts, and bone mass during a remodelling cycle at a single site, 
and predicted the existence of variable modes of dynamic behaviour of the BMU in 
remodelling cycles. However, the paracrine and autocrine regulation loops were 
defined through a range of parameters which exceed biological capabilities. In 
addition, osteocytes were not included in this model, depite their importance in the 
regulation of bone remodelling (Bonewald, 2004; Noble, 2003; Taylor et al., 2003).   
Moroz et al. (2006) further developed the model of Komarova et al. (2003) by 
defining autocrine and paracrine parameters within biological capabilities, and 
including the role of osteocyte apoptosis in the bone remodelling process. The model 
structure is shown in Figure 3.2. It consisted of four ordinary differential equations, 
which represented the temporal variation in populations of osteoclasts, osteoblasts 
and osteocytes, as well as bone volume. 
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Figure 3.2: Schematic representation of the interaction between osteoclastic and 
osteoblastic lineages included in the model of Moroz et al. (2006). Reproduced from 
Moroz et al. (2006). 
 
Moroz’s model demonstrated the existence of a basic steady state, with the 
existence of a surface in a four dimensional ‘osteoclast - osteoblast - osteocyte – 
bone’ space indicating that there is a first integral for this dynamic system, which can 
be explained as a conservative value. The model also demonstrated the existence of 
the recovering potential, which is directed against both mechanical and 
biomechanical damage to the bone. This model was validated by comparison to the 
normal bone remodelling process; however more work is needed to study a broader 
range of constants. 
Lemaire’s Model 
The RANK-RANKL-OPG pathway is an important factor in the interaction between 
osteoclasts and osteoblasts, and serves as a control network for regulating the bone 
remodelling process (Lemaire et al., 2004; Manolagas, 2000; Simonet et al., 1997). 
The model of Lemaire et al. (2004) was the first attempt to incorporate the RANK-
RANKL-OPG pathway into mathematical modelling, and was based on the idea that 
the relative proportions of immature and mature osteoblasts control the degree of 
osteoclastic activity; while osteoclasts regulate osteoblasts depending on their stage 
of differentiation.  
Unlike the simulation of bone remodelling cycles at discrete sites performed 
by Komarova et al. (2003), Lemaire’s model analysed the stable state of many BMUs 
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over a finite volume of bone, since observable states in biological systems usually 
correspond to stable states of the system. It also distinguished between the different 
stages of osteoclastic and osteoblastic lineages. Four stages of osteoblastic lineage 
(uncommitted progenitors, osteoblasts precursors, active osteoblasts and osteocytes, 
bone lining cells and apoptotic osteoblasts) and three stages of osteoclastic lineage 
(osteoclast precursors, active osteoclasts and apoptotic osteoclasts) were considered. 
The structure of this model is shown in Figure 3.3. 
 
Figure 3.3: Schematic representation of the basic structure of the model of Lemaire 
et al. (2004). Reproduced from Lemaire et al. (2004). 
 
The model consisted of three ordinary differential equations which describe 
the variation in concentrations of osteoblast precursors, osteoblasts and osteoclasts. It 
simulated the tight coupling between osteoclasts and osteoblasts, the catabolic effect 
induced by continuous administration of PTH and the catabolic action of RANKL (as 
well as its reversal by soluble antagonist OPG). In addition, the model also simulated 
several skeletal diseases by inserting dysfunctional connections in the coupling 
network, explored different diseases hypotheses and investigated potential 
therapeutic interventions. 
The work of Lemaire not only switched researcher focus from a bone 
remodelling cycle to the spatial average of many BMUs, but also incorporated more 
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biological factors into mathematical modelling. However, in the model it was 
presented that OPG was secreted by osteoblastic precursors, while RANKL was 
secreted by active (mature) osteoblasts. This is an obvious mistake since it is 
generally accepted that RANKL is primarily produced by osteoblastic precursors, 
while OPG is primarily produced by active (mature) osteoblasts (Pivonka et al., 
2008). Further discussion of this point is included below. 
Pivonka’s Model 
RANKL and OPG are primarily expressed in osteoblastic precursor cells and active 
(mature) osteoblasts, respectively (Aubin and Bonnelye, 2000; Collin-Osdoby et al., 
2001; Hofbauer et al., 2000; Pivonka et al., 2008). However, the functional utility of 
this particular ligand-decoy-receptor expression profile was not reported before the 
work of Pivonka et al. (2008). In order to understand the functional implications of 
this particular RANKL/OPG expression proﬁle on bone volume, Pivonka et al. (2008) 
developed the work of Lemaire et al. (2004) and proposed an extended bone-cell 
dynamics model, which described the functional behaviour of BMUs. 
The model of Pivonka et al. (2008) consisted of four ordinary differential 
equations, which described the temporal variation in concentrations of osteoblast 
precursors, osteoblasts and osteoclasts, and bone volume. The model incorporated 
the following signiﬁant modifications to the model of Lemaire et al. (2004): (1) one 
differential equation was added to describe temporal changes in bone volume; (2) 
one differential equation was added to describe the role of TGF-ß released from the 
bone matrix during bone resorption; and (3) OPG and RANKL were expressed on 
both osteoblastic cell lines, and the activator/repressor functions were modified. The 
biological mechanisms of the model are presented in Figure 3.4. 
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Figure 3.4: Schematic representation of the basic structure of the model of 
Pivonka et al. (2008). Reproduced from Pivonka et al. (2008). 
 
 
Bone volume was selected as the criterion to identify the functional utility of 
the ligand expression on particular cell types. The simulation results indicated that 
the ligand expression profile (RANKL expressed on osteoblastic precursors, while 
OPG expressed on mature osteoblasts) permitted BMUs to be at their most 
functionally responsive. This implied that BMUs produce the greatest change in bone 
volume in response to changes in differentiation rates. The authors also identified a 
small number of parameter combinations corresponding to physiological responses 
(two of which were related to TGF-β), which provided a partial explanation for the 
physiological action of TGF-β on bone. 
Pivonka et al. (2010) developed their work further by building another 
mathematical model to investigate the effect of the RANK-RANKL-OPG signalling 
pathway on the bone remodelling process. The simulation results indicated that bone 
diseases resulting from the disorder in the RANK-RANKL-OPG pathway, are more 
effective in producing bone resorption than bone formation. This agrees with 
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Hofbauer’s “convergence hypothesis”, which theorised that catabolic bone diseases 
act most effectively through the RANK-RANKL-OPG system. Additionally, the 
model results demonstrated that the severity of catabolic bone diseases is positively 
proportional to the number of affected components of this pathway. Several 
successful virtual therapies for different diseases states, using both single and dual 
therapies, were identified through optimization algorithms and the theoretical model 
(Pivonka et al., 2010). 
Ryser’s Model 
The bone remodelling process is influenced by the spatial organization of BMUs. In 
order to study the spatial properties of BMUs, Ryser et al. (2007) developed a spatio-
temporal model to simulate the dynamics of bone cell populations, as well as 
RANKL and OPG for a trabecular BMU at the cellular level. 
Several assumptions were made in this model: (1) the cell populations were 
assumed as a continuum, therefore cell densities rather than individual cells were 
modelled; (2) only three types of bone cells (osteoclasts, osteoblasts and osteocytes) 
were considered; and (3) the mechanical factors responsible for the BMU steering 
(microscopic strains and damages) were modelled implicitly in the form of 
appreciate RANKL distribution in the initial field (Ryser et al., 2007). 
The model was made up of five nonlinear partial differential equations. This 
enabled it to simulate the spatial and temporal features of the cutting cone and the 
movement of BMU. The model also identified the relationship between biochemical 
factors and the known population dynamics of bone cells, evaluated biological 
experimental findings and proposed new therapies. The model has been 
demonstrated to successfully reconstruct the dynamics of a BMU and the distinct 
features of the cutting cone. 
Buenzli’s Model 
Following the spatio-temporal model of Ryser et al. (2007) for trabecular bone, 
Buenzli et al. (2011) extended the purely temporal model of Pivonka et al. (2008), 
and proposed another spatio-temporal model to investigate the cell distribution and 
regulatory factors in cortical bone. This model integrated some of the most important 
interaction pathways existing between osteoclastic and osteoblastic cells, and was 
constructed through a number of additional material-balance equations. 
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The structure of BMUs (shown in Figure 3.5) is well understood at the 
descriptive level (Martin et al., 1998; Parfitt, 1994), however, no work had been 
performed to identify the link between the structure of BMUs and the underlying 
cellular interaction mechanisms. Buenzli et al. (2011) built such links and tested their 
ability to reconstruct the spatio-temporal dynamics of individual BMUs. The 
experimentally observed cell distribution of cortical BMUs was retrieved under 
particular conditions. In addition to cell distribution, the spatial distribution of 
regulatory factors could also be calculated, providing new insights into how different 
regulatory factors exert their action on bone cells. 
 
 
Figure 3.5: Schematic figure of the internal organisation of cortical BMU. 
Reproduced from Buenzli et al. (2011).  
Osteoclasts resorb the bone matrix at the front while osteoblasts lay down osteoid 
towards the back to refill the cavity. The central capillary provides a supply of 
precursor cells, as well as various nutrients.  
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Zumsande’s Model 
Bone remodelling cycles should reside in a stable state, where under physiological 
conditions and in the absence of external stimuli, populations of osteoclasts and 
osteoblasts remain approximately the same over time. Such a stable state is 
dynamical and has to be robust against variations in model parameters. Zumsande et 
al. (2011) declared that the physiological state of the bone remodelling system is 
possibly characterized by parameter values close to a bifurcation point (the critical 
threshold is where the stability to perturbations is lost), as this is when the system 
exhibits the strongest response of steady states to parameter changes.  
Zumsande and colleagues applied a generalized modelling method to analyse 
a large number of models with respect to their bifurcation properties. The simulation 
results demonstrated that the stability of the steady state in a two-dimensional model 
requires OPG to dominate over RANKL. It is known that several bone related 
diseases (such as postmenopausal osteoporosis, Paget's disease, osteopetrosis and 
osteopenia) are results of dysfunctions in bone remodelling. They suggested that 
such diseases are caused by the transition of a steady state due to an instability in a 
Hopf bifurcation, although this theory is yet to be substantiated. Any future 
confirmation would imply the importance of this bifurcation theory in the analysis of 
such diseases. 
3.3 DISCUSSION 
Mathematical models are a natural extension of conceptual models and are able to 
provide dynamic, qualitative or quantitative descriptions of biological systems 
(Defranoux et al., 2005). Mathematical models create the ability to simulate the 
natural behaviour of a system, as well as its modulation by therapeutic or dietetic 
interventions. 
In this chapter, a series of mathematical models of bone modelling at the 
cellular level have been reviewed in order to give a general view of the development 
in this area. The schematic diagram shown in Figure 3.6 displays the relationship 
between these mathematical models. There are four subgroups. The first two (the 
models of Kroll (2000) and Rattanakul et al. (2003)), focus on explaining the 
paradoxical effect of PTH on bone remodelling. Models of the third subgroup, 
originating from the model of Komarova et al. (2003), simulate the tight interaction 
between osteoblastic and osteoclastic cells, and replicate the variation in cell 
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populations and bone mass during bone remodelling cycles. The final subgroup 
consists of four models originated from the model of Lemaire et al. (2004), which 
incorporates the RANK-RANKL-OPG signalling pathway when rebuilding bone 
remodelling cycles. Zumsande et al. (2011) reviewed previously proposed 
mathematical models and developed a large class of models using a generalized 
modelling method, without employing specific function forms. 
 
 
Figure 3.6: Schematic diagram of the development of mathematical models of bone 
remodelling at the cellular level. 
 
 
The mathematical models discussed in this chapter all consist of a set of 
differential equations, which describe the rate of change of different cell types 
involved the bone remodelling cycle. In order to simulate the complicated bone 
remodelling process via a group of differential equations, simplifications are 
inevitably required to facilitate the construction of models. Therefore, all the models 
covered in this chapter have their own limitations. However, the encouraging results 
obtained from them have demonstrated the great potential of mathematical modelling 
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in developing the understanding of bone remodelling, combining the fragmentary 
experimental results, and evaluating and proposing prospective therapies. 
The differential equations describing the models in this chapter were 
developed based on biological knowledge and model parameters were related to 
biochemical factors or signalling pathways. However, these mathematical models 
have not yet reconstructed the bone remodelling process in a quantitative way. They 
are only qualitative and as a result, it is impossible to make a quantitative comparison 
between these model simulations and experimental observations.  
This chapter has demonstrated the need to develop a quantitative model of the 
bone remodelling process, and subsequent validation through comparisons between 
theoretical predictions and experimental observations. This produces a practical 
method of investigating the bone remodelling process and therapeutic interventions. 
The details of such a mathematical model are discussed in Chapter 4. 
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4. A PREDATOR-PREY BASED MATHEMATICAL 
MODEL OF THE BONE REMODELLING 
PROCESS 
The simulation results of the mathematical models reviewed in Chapter 3 generally 
agree with published experimental results, which demonstrate the potential 
application of mathematical modelling in furthering understanding of the bone 
remodelling process. However, so far these models were built on a qualitative 
analysis of the bone remodelling process. 
This thesis proposes a novel predator-prey based mathematical model to 
quantitatively reconstruct bone remodelling cycles at the cellular level. The model 
describes the temporal dynamic interaction between osteoclasts and osteoblasts at a 
single BMU (basic multicellular unit), and their corresponding bone resorption and 
formation activities. The model mimics the variation in bone thickness at a particular 
point during the bone remodelling process in both normal and pathological 
conditions, which were obtained from histomorphometric analysis (Agerbaek et al., 
1991; Eriksen et al., 1984b; Eriksen et al., 1985, 1986a), and replicates the observed 
dynamic interaction between osteoclasts and osteoblasts.  
There are three novelties of the proposed model: (1) the adoption of a 
predator-prey model to replicate the sequential dynamic interaction of osteoclasts 
and osteoblasts at a BMU; (2) the bone remodelling cycles are reconstructed 
quantitatively for the first time; and (3) a feedback mechanism is used to maintain 
the balance of bone thickness during a remodelling cycle.  
4.1 INTRODUCTION OF MATHEMATICAL MODELLING 
Before discussing the development of the predator-prey based mathematical model, it 
is necessary to introduce the basic knowledge of mathematical modelling (i.e. the 
definition of mathematical modelling and the general rules which govern their 
construction). 
Nagle et al. (2008) defined mathematical modelling as mimicking reality by 
mathematical language. Mathematical modelling can assist us to comprehend nature 
and find solutions to practical problems. Figure 4.1 illustrates several steps that are 
required to build a mathematical model (Nagle et al., 2008). The initial step, termed 
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‘formulate the problem’, entails translating the realistic problem into mathematical 
language. Secondly, ‘develop the model’ requires the definition of assumptions and 
the fixation of relationships between the modelled problem and mathematical 
equations. Such problems are often complicated, and involve many factors and 
interrelated processes. It is impossible for a single model to include all of these 
factors and processes, and a compromise is usually required between model 
simplicity and the complexity of realistic problems. It is necessary to distinguish 
between critical and uncritical factors, as only critical factors are considered in 
mathematical modelling. The relationship between the modelled problem and 
mathematical equations consists of a single or a series of mathematical equations. In 
most cases, the chosen mathematical equations need to be modified several times in 
order to build a successful model. Finally, ‘test the model’ is used to check whether 
or not the model meets the expected requirements and provides an acceptable 
accuracy. This is usually achieved by comparing the model predictions with 
experimental results.  
 
 
Figure 4.1: General steps of mathematical modelling of practical problems. Modified 
from Nagle et al. (2008). 
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4.2 PREDATOR-PREY MODELS 
The proposed mathematical model of the bone remodelling process is based on a 
predator-prey relationship. A predator-prey model consists of two first order, non-
linear differential equations, to represent the interaction between predators and preys 
in biological systems, such as foxes and rabbits, and rabbits and grasses (Brauer and 
Castillo-Chávez, 2001; Hoppensteadt, 2006). A class of Gause-type predator-prey 
model can be represented in the following form (Gause et al., 1936; Kuang, 1990): 
))()(()( tytxtx                                             (4-1) 
  ̇   ))()(( tyty                                             (4-2) 
where, 
 x(t) and y(t) represent the populations of the prey and predator, respectively; 
  ̇    and  ̇    represent the variations in the populations of the prey and predator 
with time; and 
 α, β, γ and δ are model parameters defining the interaction between the prey and 
predator. 
The predator-prey model contains several assumptions (Hiorns et al., 1981): 
(1) the prey has a unlimited food supply, while the food of the predator is completely 
dependent on the prey’s population; (2) the variation in the populations of prey and 
predator with time is assumed to be proportional to their population size; and (3) the 
environment keeps constant (in favourable conditions for both species) and the effect 
of genetic adaptation is ignored.  
An example of the predator-prey theory is shown in Figure 4.2, which 
demonstrates the interaction between baboons (prey) and cheetahs (predator) (Hiorns 
et al., 1981). The initial values of baboons and cheetahs are assumed to be 80 and 40, 
respectively.  
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Figure 4.2: The interaction between baboons and cheetahs in a predator-prey 
relationship. Reproduced from Lotka-Volterra equation [online]. Available at: 
http://en.wikipedia.org/wiki/Lotka%E2%80%93Volterra_equation [Accessed on 02 
August 2011]. 
 
4.3 DEVELOPMENT OF THE MODEL OF THE BONE 
REMODELLING PROCESS 
4.3.1 MODEL EQUATIONS 
The proposed mathematical model simulates the dynamic interaction between 
osteoclasts and osteoblasts and their corresponding resorption and formation 
activities at a BMU (basic multicellular unit) during the bone remodelling process, 
where the interaction is based on the competition model of a predator-prey system 
(Gause et al., 1936; Kuang, 1990). The motivation to adopt the predator-prey model 
was based on its key characteristic of competitive cyclic growth between the prey 
and predator populations, and the fact that their populations cannot decrease to 
negative values. These properties are similar to the growth of osteoclasts, which is 
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tightly coupled to the growth of osteoblasts during the remodelling process at a BMU 
(Parfitt, 2000; Udagawa et al., 2006). 
Differentiation into the osteoclastic and osteoblastic lineages involves several 
intermediate stages. For example, the osteoclast lineage develops from hematopoietic 
precursor cells through monocyte differentiation and fusion to osteoclast formation 
(Roodman, 1999; Teitelbaum, 2000), while the osteoblast lineage arises from 
mesenchymal stem cells through to preosteoblasts, mature bone-forming osteoblasts, 
osteocytes and bone lining cells (Aubin, 1998). In this current model, the terms 
‘osteoclast’ and ‘osteoblast’ include both precursor and mature cells. Therefore, the 
rate of change in cell populations includes the production of precursors, the 
formation of mature cells and their eventual removal or transformation. 
Based on this definition the model proposed that the osteoclast-osteoblast 
interaction was defined through the following set of differential equations:  
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where,  
 )(txoc and )(txob are the osteoclast and osteoblast populations, respectively; 
 dttdxtx ococ /)()(   and dttdxtx obob /)()(  represent the variations of )(txoc and 
)(txob  with time; and 
 a, b, c, d and     are unknown scalar parameters. 
The model defined by Eqs. (4-3) and (4-4) is based on an idea first proposed 
by Putra et al. (2009). It belongs to the class of Gause-type predator-prey models 
(Gause et al., 1936). The global stability of such Gause-type predator-prey systems 
has been discussed in the work of Kuang (1988, 1990). Its selection was not based on 
any specific underlying biological mechanisms, except the requirement to replicate 
the dynamics between osteoblasts and osteoclasts. For example, the terms of )(txob  
and )(2 txoc in Eqs. (4-3) and (4-4) respectively are selected in order to keep the effects 
of )(txoc and )(txob  in a similar degree, because the maximum population of )(txob  
is typically two orders of magnitude greater than the maximum population of 
osteoclasts. 
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However, following a detailed investigation of the results and a parameter 
sensitivity study, relationships between the parameters and some biological factors 
did become evident, as discussed later. It can be shown that all solutions for xoc(t) 
and xob(t) result in periodic orbits (Kuang, 1990). This property guarantees the 
periodicity of remodelling cycles and the coupling between osteoclast and osteoblast 
population growth. However, the factors activating the bone remodelling cycle (such 
as biological and mechanobiological signals) were not included and the periodicity of 
the model did not correspond to one single bone remodelling cycle, but rather 
reflects the average of many bone remodelling cycles. 
The model for the bone resorption and formation activities was proposed as: 
)()()()( res tFtFtFtD feedbackform 

                      
(4-5) 
where, 
 D(t) represents the instantaneous cavity depth created by a BMU during one 
single bone remodelling cycle. The initial value of D(t) is zero and then 
becomes negative during the resorption phase, before returning to zero or 
finishing with a negative or positive value, depending whether there is net 
bone resorption or formation; 
 dttdDtD )()(   represents the variation of that cavity depth with time; 
 Fform(t) and Fres(t) are the bone formation and resorption rates, respectively; 
and 
 Ffeedback(t) represents a feedback mechanism to co-regulate bone formation 
during the bone remodelling cycle. 
The bone resorption and formation rates are dependent on the resorptive and 
formative activities of osteoclasts and osteoblasts and population of cells (Lemaire et 
al., 2004), and it is assumed that each cell type has the same and constant level of 
activity during one bone remodelling cycle (Lemaire et al., 2004; Rodan and Martin, 
2000). Based on these assumptions, the bone resorption and formation rates were 
solely related to the population of osteoclasts and osteoblasts. The functions to define 
these relationships were proposed as follows: 
)(
)(
)(
txK
tx
etF
obob
ob
form

                                    (4-6) 
 )()(
2 tfxtF ocres                                                   (4-7) 
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where e, f and Kob are also unknown scalar parameters. The equation describing the 
feedback mechanism was defined as: 
)/))(exp(()( Mfeedback DtDDtF                            (4-8) 
where, 
 D  is defined as the reference value of D(t) and equals the balance between 
the cavity depth resorbed by osteoclasts, and the depth refilled by osteoblasts 
during one BMU remodelling cycle ( D  = maximum formation height – 
maximum resorption depth); and 
 The term ))(( tDD   represents the cavity depth needed to be refilled and is 
normalized by its maximal value DM  (DM  actually equals the maximum 
cavity depth resorbed by osteoclasts during one BMU remodelling cycle).  
The feedback mechanism is designed to sense the remaining cavity depth refilled by 
osteoblasts during one BMU remodelling cycle, and then regulate the bone formation 
rate. The proposed equations of the feedback mechanism satisfied this requirement 
completely: i.e. at the beginning of bone formation period, the term ))(( tDD   
reaches its maximal value since the cavity has not been refilled at all, and the 
feedback mechanism outputs its maximum; as the bone formation proceeds, the 
value of the term ))(( tDD   decreases as well as Ffeedback(t), since more of the cavity 
is being refilled. The exponent function )/))(exp(( MDtDD  in Eq. (4-8) is chosen 
in order to keep the value of )(tFfeedback  positive all the time. 
The feedback mechanism ensured that the rate of bone matrix formation was 
related to the current cavity depth. This allowed the model to exhibit the observed 
phenomenon that the apposition rates are large at the start of the formation period, 
and decrease gradually towards zero at the end (Eriksen et al., 1984b; Eriksen et al., 
1985, 1986b). 
Using Eqs. (4-6) to (4-8), Eq. (4-5) can be reformulated as: 
)()/))(exp((
)(
)(
)( 2 txfDtDD
txK
tx
etD ocM
obob
ob 

                (4-9) 
Thus the model for bone remodelling was based on Eqs. (4-3), (4-4) and 
(4-9), which were solved using the Matlab computational software package (v7.7.0, 
Mathworks, Natick, USA; with the Runge-Kutta integration method ode45 and a 
specified tolerance of 10
-10
). 
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4.3.2 MODEL CALCULATION 
The model equations contain eight parameters (a to f, Kob and Koc), all of which 
directly affect the resulting solutions. Different parameter combinations correspond 
to various biochemical conditions such as healthy condition, hypothyroidism (HT) 
and primary hyperparathyroidism (PHPT). In order to determine the parameters 
corresponding to these conditions, a genetic algorithm approach was used to search 
for the parameter values in the parameter space. Detailed information regarding the 
calculation of the model parameters and the solution of model equations is provided 
in the following sections. 
4.3.2.1 CALCULATION OF MODEL PARAMETERS 
Genetic algorithms are capable of searching for global solutions to both constrained 
and unconstrained problems in the form of        , by mimicking the principles 
of biological evolution based on rules modelled on gene combinations in 
reproduction (MathWorks, 2011). Genetic algorithms repeatedly modify a population 
of individual solutions and apply the principle of survival of the ﬁttest in searching 
potential solutions to the problem. At each step, a new generation is produced in a 
similar way in natural adaptation by selecting individuals in the fixed domain 
according to their fitting level and then breeding them together operators learned 
from natural genetics (MathWorks, 2011). Genetic algorithms usually provide a 
group of potential solutions to a problem, and then the best one could be chosen by 
users. Especially for the problems with multiple solutions, they can be found 
simultaneously. Genetic algorithms works in the following steps: creating a random 
initial population, producing a new sequence of new populations and stopping when 
the set criterion is met. 
Due to its random nature, the genetic algorithm approach improves the 
chance of finding a global solution and obtains several advantages compared to 
traditional search and optimization methods as follows (MathWorks, 2011): 
 The genetic algorithm searches a population of points in parallel rather than a 
single point, and the best point in the population approach an optimal 
solution;  
 The genetic algorithm does not require derivative information, and only 
objective function and corresponding fitness levels are required; 
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 The genetic algorithm can solve the problems whose objective functions are  
discontinuous, nondifferentiable, stochastic or highly nonlinear; 
 The genetic algorithm choose the next generation randomly rather that 
selecting next point in the sequence by a deterministic computation; and 
 The genetic algorithm uses an encoding of the parameter set rather than the 
parameter set itself except when real-valued individuals are used. 
A genetic algorithm was employed in this study to search for the values of 
model parameters corresponding to various biochemical conditions in the parameter 
space. Several steps are required to calculate the values of parameters for each 
condition by the genetic algorithm method. Figure 4.3 demonstrates the procedure 
required to calculate model parameters in the normal (healthy) condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Steps used to calculate model parameters in the healthy condition based 
on a genetic algorithm. 
 
 
Up to nine phenomena were used to characterize the normal bone 
remodelling cycle and they were defined in Table 4.1. 
 
Characterize the normal bone remodelling cycle 
Customize the fitness function F(X) 
Set the range of the parameter space 
Solve using the ‘Genetic Algorithm Solver’ 
(‘Global Optimization Toolbox’ of Matlab) 
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Phenomena Definition 
Resorption period initialres tt   
depthresorption Maximum  )()( resinitial tDtD   
periodFormation  resform tt   
heightformation Maximum  )()( resform tDtD   
 periodQuiescent  formend tt   
 rateresorptionMaximum   resinitialres ttttFMax ,)),((   
rateformationMaximum   formresfeedbackform ttttFtFMax ,)),()((   
populationosteoclastMaximum  ))(( txMax oc  
 populationosteoblastMaximum  ))(( txMax ob  
 
Table 4.1:  Definition of nine phenomena which were used to characterize the normal 
bone remodelling cycle. 
 
where, 
 initialt  
and rest  
represent the times when the bone resorption phase begins and 
ends; 
 formt  
and endt  
are the times when the bone formation phase and quiescent 
phase end; 
 )( initialtD , )( restD  and )( formtD are the cavity depth corresponding to times, 
initialt , res
t
 
and formt ; and 
 )(tFres and )()( tFtF feedbackform  represent the rates of bone resorption and 
formation. 
The published experimental data is incomplete for PHPT and HT; in 
particular, the osteoclast and osteoblast populations are not reported. Considering 
that it is not necessary to use all quantities in Table 4.1 to calculate model parameters 
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based on genetic algorithm, in the simulation only the first seven quantities in Table 
4.1 were used to optimize the values of model parameters for the normal, HT and 
PHPT conditions. However, the osteoclast and osteoblast populations predicted by 
the model for the normal condition can be used to confirm the validity of the 
approach, which provides a significant advantage. 
After characterization of normal bone remodelling by seven phenomena, the 
definition of a customable fitness function was required. Based on the fitness 
function, the genetic algorithm searches the solution space to minimise the difference 
between the model predictions and published experimental data. The fitness function 
was defined as follows: 
)))((()(
7:1
i
i
i EXPabsXF 
                                          
(4-10) 
],,,...,[ ocob KKfaX   
where, 
 ],,,...[ ocob KKfaX   is a row vector consisting of eight parameters in the 
model equations and represents one point in the parameter space; and 
 iXP )(  
and iE (i=1,…7) represent the model outputs corresponding to each 
point in the parameter space, and the experimental values of the first seven 
phenomena in Tables 4.1. 
For a random point in the parameter space we can obtain one group of data, iXP )(
(i=1,…7), and then calculate the difference between iXP )( (i=1,…7) and iE
(i=1,…7). The genetic algorithm was able to find a group of parameters that 
minimises the difference between the model predictions iXP )( (i=1,…7) and 
experimental data iE (i=1,…7) (for more specific details on this aspect see: 
http://www.mathworks.com/help/toolbox/gads/f6010dfi3.html). Once the genetic 
algorithm identified the optimum parameter values, Eqs. (4-3), (4-4) and (4-9) were 
subsequently used to calculate the detailed variations of xoc(t), xob(t) and D(t) with 
time. 
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4.3.2.2 THE SOLUTION OF MODEL EQUATIONS 
There are two forms of solutions to an ordinary differential equation: the analytical 
and numerical solution (Cox, 1996; Gray et al., 1997). An analytical solution of an 
ordinary differential equation is a differentiable function in terms of explicit or 
implicit elementary functions, such as a finite combination of powers, radicals, 
exponentials, logarithmic, trigonometric and inverse trigonometric functions (Cox, 
1996; Gray et al., 1997). The analytical solution is an accurate solution and is able to 
explain exactly how the model will behave under any circumstance (MyPhysicsLab, 
2011).  
However, not all ordinary differential equations can be solved in an analytical 
manner, and the Peano existence theorem is used to specify when an analytical 
solution exists (Cox, 1996). Although an analytical solution to a differential equation 
can exist, in some cases the complexity of the solution renders it unpractical to use. 
Consequently, numerical solutions are often used as an alternative method to analyse 
model behaviour, as they provide approximations to analytical solutions (Cox, 1996; 
Gray et al., 1997). 
The proposed mathematical model consists of a set of first order, nonlinear, 
ordinary differential equations. The initial conditions of these ordinary differential 
equations were defined as 1.0)()(  txtx oboc  and 0)( tD . The model equations 
belong to a first-order initial value problem. The solutions to the model equations 
represent the variation in the population of osteoclasts and osteoblasts, and the cavity 
depth over time. The numerical method was used to approximate the solution of such 
a first-order initial value problem. However, it should be noted that numerical 
solutions have some disadvantages (ODE Laboratories, 2011). For example, in 
comparison to an analytical solution which is a whole continuum of values, a 
numerical solution is made up of a finite group of values, and it naturally misses a lot 
of values. There are several numerical methods available to approximate the solution 
to ordinary differential equations, including Euler’s method, Heun’s method and 
Runge-Kutta’s method (Gray et al., 1997). 
Euler’s method 
Consider a first-order initial value problem is defined as follows (Gray et al., 1997): 
 ̇        , for                                              (4-11) 
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Firstly, divide the interval       into a set of equal subintervals:  
                 
where,           represents ‘step size’ of the solution, and is a positive small 
scalar less than 1. In order to deduce the formula of Euler’s method it is assumed that 
Eq. (4-11) has the analytical solution        According to Taylor series,      can be 
expanded as follows: 
                      ̇            
       
 
  
         
        =           ̇            
  
  
                                          (4-12) 
Since h is a relatively small number less than unit,          , should be even smaller. 
Therefore, it is reasonable that the terms including          can be eliminated to 
make the equation simpler. Therefore, Eq. (4-12) can be reformatted to the following: 
               ̇     
                                                   (4-13) 
If the initial condition of the equation is defined as         , and the left-hand 
term of Eq. (4-13) is defined as    , then Eq. (4-13) becomes: 
                                                                                                            (4-14) 
where,    is a numerical approximation of        Likewise, an approximation of 
      can be obtained, producing the following general approximate equality: 
           (    )                            (4-15) 
Eq. (4-15) is called Euler’s method. It was the first numerical method to solve 
ordinary different equations approximately, and serves as a foundation for more 
complicated numerical methods (such as the Runge-Kutta method). However, 
solutions of Euler’s method are not particularly accurate and some improvements are 
required to increase their accuracy (Gray et al., 1997).  
Heun’s method 
Euler’s method is rarely used in the solution of ordinary differential equations due to 
its inaccuracy (Zill, 2005). The underlying foundation of Euler’s method is to use the 
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tangent line to the actual solution curve at the left end-point (its coordinates have 
already been established) of the interval (also called step size), as an estimation of 
the coordinates of the right end-point of the interval (Gray et al., 1997; ODE 
Laboratories, 2011). Thus, for the concave-up curve in Figure 4.4, the tangent line at 
the left end-point of the interval underestimates the vertical coordinate of the next 
point at the right end-point of the interval. A similar effect is observed with a 
concave-down cave, but the next point is overestimated. In reality it is difficult to 
know whether or not the estimation of the next point is overestimated or 
underestimated. 
 
Figure 4.4: Prediction of coordinates of the next point based on the tangent line to the 
solution curve. Modified from ODE Laboratories [online]. Available at: 
http://calculuslab.deltacollege.edu/ODE/7-C-2/7-C-2-h.html [Accessed on 18 August 
2011]. 
 
In order to fix the problem of underestimation or overestimation, the tangent 
line to the curve at the next iteration point is considered. At this stage, the 
coordinates of the right end-point of the interval are unknown; therefore a prediction 
of their positioning is made. However, it is assumed that the coordinates are initially 
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known and the solution to this problem is discussed later (Gray et al., 1997; ODE 
Laboratories, 2011). Through taking the slope of the tangent line to the curve at the 
right end-point of the interval, a line can be created passing through the left end-point 
of the interval to predict the vertical coordinate of the next point. This is termed the 
predicted line based on the right tangent. As illustrated in Figure 4.5, ‘Predicted 
Point 2’ is produced by the predicted line based on the right tangent, and is higher 
than the ‘Ideal Point’ on the solution curve which is concave up. In addition, 
‘Predicted Point 1’ is produced by the tangent line to the curve at the left end-point.  
 
 
Figure 4.5: Prediction of coordinates of the next point based on the slope of the 
tangent line to the solution curve at the right end-point of the interval. Modified from 
ODE Laboratories [online]. Available at: http://calculuslab.deltacollege.edu/ODE/7-
C-2/7-C-2-h.html [Accessed on 18 August 2011]. 
Figure 4.5 shows that ‘Predicted Point 1’ and ‘Predicted Point 2’ result in an 
underestimation and overestimation for the concave-up solution curve, respectively 
(the situation is reversed for the concave-down curve). Heun’s method takes the 
average of the slopes of the left and right tangent lines and produces a line crossing 
an ‘Established Point’ (Gray et al., 1997; ODE Laboratories, 2011). As displayed in 
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Figure 4.6, ‘Predicted Point 3’ is produced by this line, and lies between ‘Predicted 
Point 1’ and ‘Predicted Point2’, which are respectively underestimated and 
overestimated compared to the ‘Ideal Point’. Therefore, ‘Predicted Point 3’ should be 
closer to the ‘Ideal Point’.  
 
 
Figure 4.6: Prediction of coordinates of the next point based on the average of slopes 
of the tangent line to the solution curve at the left and right end-point of the interval. 
Modified from ODE Laboratories [online]. Available at: 
http://calculuslab.deltacollege.edu/ODE/7-C-2/7-C-2-h.html [Accessed on 18 August 
2011]. 
Heun’s method uses the slope of the tangent line at the right end-point of the 
interval to predict the vertical coordinate of the right end-point (Gray et al., 1997; 
ODE Laboratories, 2011). This appears contradictory since it is impossible to 
determine the tangent line at the right end-point before the position of the right end-
point is known. Euler’s method is used to roughly estimate the coordinates of the 
right end-point. Euler’s method is usually referred to as a predictor algorithm, 
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whereas Heun’s method is referred to as a predictor-corrector algorithm. Based on 
the discussion above, the iteration formulas for Henu’s method is as follows: 
                                                                                                             (4-16) 
              (
 
 
)    (    )                                  (4-17) 
Runge-Kutta’s method 
Runge-Kutta’s method is actually a general class of algorithm and includes different 
Runge-Kutta’s methods of various orders (Gray et al., 1997; ODE Laboratories, 
2011). The formal derivation of Runge-Kutta’s method is not introduced since it is a 
rather complicated procedure. The general formula of Runge-Kutta’s method is as 
follows (Gray et al., 1997; ODE Laboratories, 2011): 
                                                                                                                 (4-18) 
                                                                                         (4-19) 
where,  
                  are a set of constants representing weighted coefficients, 
and satisfy the equation                ; and 
                 represents the estimated values of the solution curve 
evaluated at a series of selected points between the interval [       ].  
The part ‘                   ’ in Eq. (4-19) is a weighted average of 
estimations of a group of points in the solution curve located in the interval [       ], 
and are devised based on a Taylor polynomial of degree m. The order of Runge-
Kutta’s method is represented by ‘m’ in Eq. (4-19). The fourth-order Runge-Kutta 
method is widely applied, and thus is taken as an example here. The values of 
                 and                  are as follows: 
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      f (          ) 
where,  
 f (     ) denotes the derivative of the solution curve y (t) at the point (     ); 
    is the estimating slope of the tangent line to the solution curve at moment 
   obtained from Euler’s method; 
    and    estimate the slope of the tangent line to the solution curve at the 
point    
 
 
, and the calculation of    is dependent on   ; and 
    is the estimation of the slope of the tangent line to the solution curve at the 
moment     , based on   .  
when ‘m’ equals 1, Eq.(4-19) is altered to: 
                                                                                                (4-20) 
Eq. (4-20) is the same as the formula for Euler’s method, which means that Euler’s 
method is actually the first-order Runge-Kutta method. 
Adaptive methods 
Time steps are very important for the accuracy of numerical methods. A large time 
step is used for low frequency curves, while a small time step is used for high 
frequency curves [http://www.mathworks.com/support/tech-
notes/1500/1510.html#fixed], but it is possible that the frequency of a curve 
(function) may vary in that case. If the time step is too large, it possibly misses some 
points and the overall accuracy of the solution is affected; conversely, if the time step 
is too small, the associated computation time increases.  
These issues can be solved by adaptive methods, which are numerical 
solutions with a variable time step. One way of achieving adaptive methods is to 
combine two Runge-Kutta methods of different orders, such as the Runge-Kutta (2nd 
and 3rd order) integration methodand the Runge-Kutta (4th and 5th order) integration 
methods, with corresponding solvers (ode23 and ode45) in Matlab (Mathews and 
Fink, 2004). Two different approximations of the solution are produced at each step. 
A close comparison between the two results provides confidence in the suitability of 
the applied time step. However, if the difference between the two results exceeds a 
specified accuracy limit, the time step is deemed too large and re-calculation is 
required with a reduced time step. The process of reducing the time step should be 
repeated until the resultant approximations are in close agreement.  
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The Runge-Kutta (4 and 5th order) integration method, whose corresponding 
Matlab solver is ode45, was selected to solve the equations in the proposed 
mathematical model based on the following: (1) Runge-Kutta’s method is considered 
to be one of the most accurate numerical procedures in approximating solutions of a 
first-order initial-problem (Zill, 2005). (2) Runge-Kutta’s method includes a class of 
numerical solutions with different orders (i.e. fourth and fifth order). (3) Ode45 
belongs to an adaptive method and uses a variable time step to solve nonstiff model 
equations. Ode45 is cited as an ideal choice when solving equations using the 
adaptive method (http://www.mathworks.com/help/techdoc/ref/ode113.html) 
(accessed on 23th August 2011). 
A numerical method is stable when small changes in the initial condition only 
produce small variations in the computation results; otherwise it is unstable. It is 
necessary to analyse the stability of a numerical method, since each step after the 
first step of the numerical calculation produces another initial-value problem. The 
round-off error and error in the initial value will result in a deviation from the true 
value if numerical solution is not stable (Zill, 2005). 
To determine if a numerical solution is stable, the equations should be solved 
in two different time steps. If the error increases with smaller step sizes, the 
numerical method is deemed unstable (although such errors cannot be measured in 
most cases because the accurate solution is not known). Alternatively, the effect of 
adding a slight perturbation to the initial value can be simulated.  
4.3.3 SIMULATION RESULTS AND ANALYSIS 
Based on the proposed mathematical model, a normal bone remodelling cycle was 
reconstructed and the sensitivity of the results to the model parameters was 
investigated. Two pathological conditions, PHPT and HT, were subsequently 
examined to demonstrate how the model can be used to simulate other abnormal 
conditions. 
4.3.3.1  THE NORMAL BONE REMODELLING CYCLE 
Table 4.2 presents published experimental data for the normal trabecular bone 
remodelling cycle. Using the parameter values shown in Table 4.3 theoretical values 
of the histomorphometric measures were calculated using a genetic algorithm 
approach (see Table 4.2). The model predictions produced a close match with the 
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experimental data (with the exception of the maximum formation rate). Although a 
close match in the first seven quantities is to be expected, the predicted maximum 
osteoclast and osteoblast populations also agreed well with the experimental data, 
despite their exclusion from the solution process. However, it is should be noted that 
the cell populations quoted in Table 4.2 were estimated from experimental 
measurements of Haversian remodelling (Jaworski et al., 1981; Jaworski and 
Hooper, 1980; Parfitt, 1994). Based on examination of 86 remodelling sites, it was 
observed that the number of osteoclasts varied between 4 and 16. Thus assuming that 
the trench-shaped remodelling volume in trabecular bone is approximately half of 
that of the tunnel-shaped remodelling volume in cortical bone, the number of 
osteoclasts in trabecular bone remodelling was estimated to be approximately 8.  
 
 
Phenomena  
 Experimental 
(mean) values 
 Source 
     Model   
predictions 
Resorption depth  62 μm [1]  62.2μm 
Resorption period  48 days [1]  50.8 days 
Maximum resorption rate  3.9 μm/day [1]  3.8 μm/day 
Formation height  62 μm [2]  62.2 μm 
Formation period  145 days [2]  145 days 
Maximum formation rate  2.1 μm/day [2]  1.4 μm/day 
Quiescent period  902 days [3]  901.4 days 
Maximum osteoclast population   8 cells [4,5]  9.0 cells 
Maximum osteoblast population   2000 cells [4,5]  1930.7 cells 
 
Table 4.2:  Histomorphometric data for normal trabecular bone remodelling as 
reported in literature and predicted by the proposed mathematical model.  
[1] Eriksen et al., 1984a; [2] Eriksen et al., 1984b; [3] Eriksen et al., 1986; 
[4] Parfitt, 1994; [5] Jaworski et al., 1981]. 
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Parameter Value 
a 0.0558 day
-1 
b 0.0065 cells
-1/2
 day
-1
 
c 1.82×10
9 
day
-1 
d 0.0099 day
-1 
e 17.2 µm
-1 
f 0.0461 cells
-2
µm
-1 
koc 2.44×10
11
 cells
2 
kob 4.32×10
4 
cells 
 
Table 4.3: Parameter values derived by the mathematical model for the normal 
remodelling cycle. 
 
The simulations set the initial conditions to xoc(0)= xob(0)=0.1 so that the 
osteoclast and osteoblast populations were approximately zero at the start of the 
resorption period. Sensitivity studies (in section 4.3.3.2) revealed that the simulations 
were only marginally affected by the initial choice of these parameters. Experimental 
observations and BMU theory suggest that there should not be any osteoclasts and 
osteoblasts active during the quiescent period (Parfitt, 1994). Therefore, due to the 
requirement of the simulations to define xoc(t) and xob(t) (equations (4-3) and (4-4)) 
as real (rather than integer) terms, any values below 0.5 were regarded as zero (i.e. 
no active osteoclast or osteoblast). The end of the resorption period (and start of the 
formation period) was defined when the number of osteoclasts fell below 0.5. 
However, because the maximum number of osteoblasts is typically two orders of 
magnitude greater than the maximum number of osteoclasts, the end of the formation 
period (and the start of the quiescent period) was defined as the moment when the 
formed cavity depth D(t) reached 99.5% of its maximal value (as shown in Figure 
4.8) (rather than the time when the osteoblast population fell below 0.5). 
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Examination of the osteoblast population in Figure 4.7 suggested that there were still 
a significant number of non-active osteoblasts present when 99.5% of the cavity was 
refilled, which takes significantly longer to decay. The reason for this inconsistency 
lies in the underlying predator-prey equations, in which the preys (osteoclasts) thrive 
again as soon as the predators (osteoblasts) have decreased (and vice versa), and not 
after a period where neither population is present. Maintenance of so many inactive 
osteoblasts is physiologically unlikely, which highlights a limitation of the predator-
prey approach. 
The corresponding cyclic variations in the osteoblast and osteoclast 
populations, along with bone thickness, predicted by the model are presented in 
Figure 4.7 and Figure 4.8, respectively. The dynamic interaction between the 
osteoclasts and osteoblasts is shown in Figure 4.9. The latter illustrates how the 
remodelling cycle commences with the growth of the osteoclast population in the 
absence of osteoblasts. As the osteoclast population continues to grow, the osteoblast 
population also starts to increase; then, as the osteoblast growth increases further, the 
osteoclast numbers start to decline. While the osteoclast population is decreasing, the 
osteoblast population grows faster but starts to decrease again as the osteoclasts 
completely disappear. As the osteoblast population diminishes the BMU enters the 
quiescent period, with small values of the osteoblast population then being 
interpreted as quiescent-osteoblasts. It should be noted that Figure 4.9 does not 
reflect the difference in the rates at which these populations change, or the much 
shorter period of osteoclast activity compared to that of osteoblasts. However, this 
can be observed in Figure 4.7, which shows the rapid decline of the osteoclast 
population as the number of osteoblasts increase. 
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Figure 4.7: Model predictions of the variation in osteoclast and osteoblast 
populations during the normal bone remodelling cycle; (note the osteoblast scaling 
factor). 
 
Figure 4.8: Model predictions of the variation in bone thickness during the normal 
bone remodelling cycle (note the osteoblast scaling factor)(1: ( initialt , initialD ), 2: ( rest ,
resD ), 3: ( formt , formD ), 4: ( endt , endD )). 
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Figure 4.9: The periodic orbit of the osteoclast-osteoblast interaction during the 
normalbone remodelling cycle, which proceeds in an anti-clockwise direction. 
 
4.3.3.2  SENSITIVITY OF THE MODEL TO PARAMETER 
VARIATIONS 
The sensitivity of the simulations to variations in parameters a, b and Koc in Eqs. (4-
3) and (4-4), is shown in Figure 4.10. The deviation in the maximum number of 
osteoclasts and osteoblasts is presented when the parameters were varied between 0.5 
and 1.5 of the ‘normal’ value. This sensitivity analysis shows that: parameter a 
affects the growth of both osteoclasts and osteoblasts; parameter b affects mainly the 
growth of osteoblasts; while parameter Koc affects only the growth of osteoclasts. 
Parameter d (not shown) influences the apoptosis or elimination rate of osteoblasts 
and an increase in its value accelerates their removal. The parameter Kob in Eq. (4-9) 
is responsible for controlling the maximum formation rate. The values of parameters 
c, e and f were assumed to be constant in all simulations, because c and e are 
respectively dependent on Koc and Kob, and f is a scaling coefficient for the bone 
resorption. A summary of the sensitivity results is provided in Table 4.4. 
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Figure 4.10: The effects of independently varying each model parameter on the 
osteoblast and osteoclast populations. Parameter variance was normalized to the 
values of the base case (as defined in Tables 1 and 2), for example, the lines a:OB 
and a:OC demonstrate the variation in osteoblast and osteoclast populations as 
parameter a is varied between 0.5 and 1.5 times its base value. 
 
 
Parameters Observations 
a ↑ osteoclasts ↑   osteoblasts ↑ 
b ↓ osteoclasts −  osteoblasts ↑↑ 
d ↑ osteoclasts −   osteoblasts −  period ↓ 
Koc ↑ osteoclasts ↑   osteoblasts − 
Kob ↑ formation rate ↓ 
 
Table 4.4: Summary of the relationship between the model parameters and 
remodelling activity(Symbols: ↓ = decrease, ↑ = increase, ↑↑ = significant increase, − 
= little or no effect). 
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4.3.3.3  SIMULATIONS OF THE REMODELLING CYCLES IN 
PATHOLOGICAL CONDITIONS 
Once the basic equations describing the remodelling cycle are established, 
modifications can be made to simulate pathological conditions, with the potential of 
examining the effectiveness of different therapies. Histomorphometric analyses of 
trabecular bone samples from 19 primary PHPT patients (6 male and 13 females) and 
18 HT female patients have been reported (Eriksen et al., 1986a, 1986b). The key 
data is displayed in Table 4.5. 
The controlling parameters for these two pathologies was calculated using the 
procedures outlined above, and then compared to those of the normal remodelling 
cycle in Table 4.6. The resulting remodelling cycles for PHPT and HT conditions are 
shown in Figure 4.11 to Figure 4.14. The basic shapes of the curves were similar to 
those for normal remodelling (see Figure 4.7 and Figure 4.8) in both cases, although 
the maximum number and ratio of osteoclasts to osteoblasts are different in each 
case, as is the period of the remodelling cycle. A comparison between the histo-
morphometric data and the calculated theoretical values is provided in Table 4.5. The 
experimental and theoretical data generally produced a close comparison, although 
there are differences in the resorption and formation rates, along with an 18% 
difference in the PHPT resorption period. The model was also able to predict the 
osteoclast and osteoblast populations for each condition, which are not previously 
reported in the literature. The predicted osteoblast and osteoclast cell populations in 
the PHPT condition were nearly double those of the HT condition, with the number 
of PHPT osteoclasts and osteoblasts 26% and 29% higher than the ‘normal’ case, 
respectively (see Table 4.2). As a result, the osteoblast to osteoclast ratio for these 
two conditions was 219.8 and 233.2 respectively, while the ratio for normal 
remodelling was 214.5. 
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  PHPT  HT 
Phenomena  
 Experimental 
(mean) values 
Model 
predictions 
 Experimental 
(mean) values 
Model 
predictions 
Resorption depth   45.2 μm 45.2 μm  42.1 μm 42.1 μm 
Resorption period   31 days 25.4 days  76 days 75.9 days 
Maximum resorption 
rate  
 5.7 μm/day 5.9 μm/day  2.9 μm/day 1.4 μm/day 
Formation height  45.2 μm 45.2 μm  59.0 μm 59.0 μm 
Formation period   172 days 172 days  620 days 625.9 days 
Maximum formation 
rate 
 2.2 μm/day 1.1 μm/day  0.74 μm/day 0.3 μm/day 
Quiescent period   390 days 393 days  2098 days 2068.6 days 
Maximum osteoclast 
population  
 – 11.3 cells  – 5.5 cells 
Maximum osteoblast 
population  
 – 2483.8 cells  – 1280.1 cells 
 
Table 4.5: Comparison of the experimental and predicted remodelling cycles in 
PHPT and HT with experimental data from Eriksen et al. (1986a, b). 
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Parameters HT Normal PHPT 
a 0.0327 day
-1
 0.0558 day
-1
 0.1231 day
-1
 
b 0.0044 cells
-1/2
 day
-1
 0.0065cells
-1/2
 day
-1
 0.0129 cells
-1/2
 day
-1
 
c*  1.82×10
9
 day
-1
  
d 0.0025 day
-1
 0.0099 day
-1
 0.0150 day
-1
 
e*  17.2 µm
-1
  
f* 0.0461 cells
-2
µm
-1
 
koc 1.81×10
11
 cells
2
 2.44×10
11
 cells
2
 1.74×10
11
 cells
2
 
kob 9.64×10
4
 cells 4.32×10
4
 cells 6.42×10
4
 cells 
 
Table 4.6: Comparison of parameter values derived by the model for normal and 
disease conditions (* parameters c, e and f are assumed to be constant). 
 
Figure 4.11: Model predictions of the variation in osteoclast and osteoblast 
populations during the remodelling cycle with PHPT(note the osteoblast scaling 
factor). 
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Figure 4.12: Model predictions of the bone thickness during the remodelling cycle 
with PHPT. 
 
Figure 4.13: Model predictions of the variation in osteoclast and osteoblast 
populations during the remodelling cycle with HT. 
(note: the osteoblast scaling factor).  
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Figure 4.14: Model predictions of the variation in bone thickness during the 
remodelling cycle with HT. 
 
 
4.3.3.4  STABILITY ANALYSIS OF THE SOLUTIONS 
As discussed in section 4.3.4, it is necessary to check the stability of the numerical 
solution to an initial-value problem of ordinary differential equation. The method 
adopted to check the stability of the numerical solution by observing the effect of 
adding a disturbance to the initial condition. The model simulated the variation in the 
population of osteoblasts and osteoclasts, and the resultant bone mass, with the initial 
conditions of xoc(0)=xob(0)=0.1 and  ̅   . A slight perturbation was subsequently 
added to the initial condition so that xoc(0) =xob(0) =0.11 and  ̅      . The 
simulation was repeated with the perturbed initial condition and the simulation 
results were correspondingly compared to those obtained through the original initial 
condition.  
Figure 4.15 to Figure 4.17 demonstrate that the perturbation in the initial 
condition resulted in maximal changes of the osteoclast and osteoblast populations, 
and bone mass during normal bone remodelling cycles of 15%, 21.4% and 6.5%, 
respectively (where maximal change was defined as the maximal change caused by 
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the perturbation divided by maximal quantity under the unperturbed initial condition). 
The maximal changes of the osteoclast and osteoblast populations, and bone mass 
during the remodelling cycle with PHPT were 9.7%, 10.6% and 8.4%, respectively 
(see Figure 4.18 to Figure 4.20). During the remodelling cycle with HT, the maximal 
changes of osteoclast and osteoblast populations, and bone mass were 11%, 12.4% 
and 10.6%, respectively (see Figure 4.21 to Figure 4.23). 
Considering that the initial conditions of the osteoclast and osteoblast 
populations were both varied by 10% (note the percentage variation in the initial 
condition of bone mass could not be calculated since the original initial value of bone 
mass equals zero), the resultant changes were not significant and the trends of the 
solution curves remained consistent. Therefore, it was concluded that the numerical 
solutions used in the proposed model were stable under normal and two pathological 
conditions.  
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Figure 4.15: (a) Model predictions of the variations in osteoclast population under 
the unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle; (b) Difference between the variations in osteoclast population produced by the 
unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle. 
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Figure 4.16: (a) Model predictions of the variations in osteoblast population under 
the unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle; (b) Difference between the variations in the osteoblast population produced by 
the unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle. 
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Figure 4.17: (a) Model predictions of the variations in bone thickness under the 
unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle; (b) Difference between the variations in bone thickness produced by the 
unperturbed and perturbed initial conditions, during the normal bone remodelling 
cycle. 
 
 
 
 
0 100 200 300 400 500 600 700 800 900 1000 1100
-70
-60
-50
-40
-30
-20
-10
0
10
Time[day]
(a
) 
B
o
n
e
 T
h
ic
k
n
e
s
s
[µ
m
]
 
 
the variation in bone thickness under the unperturbed initial condition 
the variation in bone thickness under the perturbed initial condition
0 100 200 300 400 500 600 700 800 900 1000 1100
-8
-6
-4
-2
0
2
4
6
(b
) 
R
e
la
ti
v
e
 d
if
fe
re
n
c
e
[%
]
75 
 
 
 
 
 
 
Figure 4.18: (a) Model predictions of the variations in osteoclast population under 
the unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT; (b) Difference in the variations in the osteoclast population produced by the 
unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT. 
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Figure 4.19: (a) Model predictions of the variations in osteoblast population under 
the unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT; (b) Difference between the variations in osteoblast population produced by 
the unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT. 
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Figure 4.20: (a) Model predictions of the variations in bone thickness under the 
unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT. (b) Difference between the variations in bone thickness produced by the 
unperturbed and perturbed initial conditions, during the remodelling cycle with 
PHPT.  
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Figure 4.21: (a) Model predictions of the variations in osteoclast population under 
the unperturbed and perturbed initial conditions, during the remodelling cycle with 
HT. (b) Difference between the variations in osteoclast population produced by the 
unperturbed and perturbed initial conditions, during the remodelling cycle with HT. 
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Figure 4.22: (a) Model predictions of the variations in osteoblast population under 
the unperturbed and perturbed initial conditions, during the remodelling cycle with 
HT. (b) Difference between the variations in osteoblast population produced by the 
unperturbed and perturbed initial conditions, during the remodelling cycle with HT. 
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Figure 4.23: (a) Model predictions of the variations in bone thickness under the 
unperturbed and perturbed initial conditions, during the remodelling cycle with HT; 
(b) Difference between the variations in bone thickness produced by the unperturbed 
and perturbed initial conditions, during the remodelling cycle with HT.  
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4.4 MODEL PARAMETERS AND BIOCHEMICAL FACTORS 
4.4.1 RELATING THE MODEL PARAMETERS TO BIOCHEMICAL 
FACTORS 
The predator-prey based mathematical model shows significant potential to simulate 
the interaction between bone cells, and predict the resulting change of bone mass for 
the normal condition and two pathological conditions. The reconstructed bone 
remodelling cycles and the resultant bone volume were consistent with experimental 
data. The model was partially validated through comparing the model predictions for 
the osteoclast and osteoclast populations in a single BMU of normal bone 
remodelling, with experimental data. However, further data is required to validate the 
model predictions for the osteoclast and osteoblast populations in the cases of PHPT 
and HT. In order to understand the underlying mechanism of these two pathological 
conditions, and simulate potential therapies based on the proposed predator-prey 
based mathematical model, it is necessary to construct a connection between the 
model parameters and biochemical factors.  
The RANK-RANKL-OPG pathway, together with the action of growth 
factors, constructs a basic control network of bone remodelling (Canalis, 1993; 
Manolagas, 2000). Disturbance of the RANKL:OPG ratio caused by local or 
systemic dysfunctions (Manolagas, 2000) may result in various bone diseases, 
including osteoporosis, Paget’s disease, tumor metastasis, humoral hypercalcemia of 
malignancy and multiple myeloma (Boyle et al., 2003; Hofbauer et al., 2004; 
Hofbauer et al., 2001; Hofbauer and Schoppet, 2004; Rodan and Martin, 2000).  
The sensitivity analysis of the model demonstrated that parameter ‘a’ 
stimulates the differentiation of osteoclasts, which is similar to the behaviour of 
RANKL, while parameter ‘b’ inhibits the differentiation of osteoclasts, which is 
similar to the behaviour of OPG. Based on these observations, it is assumed that 
model parameters ‘a’ and ‘b’ are related to RANKL and OPG respectively, with the 
a:b ratio representing the RANKL: OPG ratio. It should be noted that the effects of 
RANKL and OPG are dependent on each other since OPG acts through the inhibition 
of the production of RANKL. However, they were represented as two independent 
parameters in the proposed mathematical model for simplicity, which highlights a 
limitation of the model. 
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In a normal bone remodelling cycle the equivalent amount of bone resorbed 
by osteoclasts is formed by osteoblasts. A coupling mechanism between osteoblasts 
and osteoclasts is responsible for this ideally zero bone balance in the normal bone 
remodelling cycle (Matsuo and Irie, 2008). Osteoclasts are able to liberate, secrete or 
produce coupling factors which act on osteoblast precursors to stimulate bone 
formation, and maintain the bone balance in remodelling cycles (Martin and Sims, 
2005; Matsuo and Irie, 2008). For example, liberated coupling factors include TGF-
β, bone morphogenetic proteins (BMPs) and insulin-like growth factor (IGF)-II, all 
of which are released by bone resorption from the bone matrix (Matsuo and Irie, 
2008; Pfeilschifter and Mundy, 1987; Wozney et al., 1988). The defined variation of 
osteoblasts in Eq. (4-4) demonstrates that model parameters ‘Koc’ and ‘ ’ are both 
related with the coupling interaction between osteoclasts and osteoblasts. Therefore, 
the complex term ‘
 
     
’ is used here to represent the coefficient of the coupling 
mechanism. An increase in ‘
 
     
’ will represents an enhancement in the coupling 
between osteoblasts and osteoclasts, while a decrease will result in an impairment in 
the coupling.  
Similarly, the bone formation rate defined in Eq. (4-6) includes the parameter 
‘   ’ which is negatively related to the bone formation rate. Thus, ‘
 
   
’ is used to 
represent the osteoblastic activity, and an increase or decrease in this term indicates 
the promotion or suppression of osteoblastic activity, respectively.  
The remaining model parameters (c, e and f) were defined as constants (the 
reasoning for this is discussed in section 4.3.3.2) to reduce the number of parameters 
required to be related with biochemical factors. As a result, the proposed connections 
between the model parameters and biochemical factors are summarized in Table 4.7. 
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Parameters Biochemical Factors 
a RANKL 
b OPG 
a/b ratio of RANKL to OPG 
 
     
 coupling coefficient between osteoclasts and osteoblasts; 
represent the ratio of osteoblast to osteoclast 
 
   
 osteoblast activity 
c, e, f constants 
 
Table 4.7: Possible connections between the model parameters and biochemical 
factors involved in the bone remodelling process. 
 
4.4.2 VALIDATION OF THE PROPOSED CONNECTIONS 
To validate the proposed connections between the model parameters and biochemical 
factors, the values of the parameters listed in Table 4.7 were calculated under the 
normal condition, PHPT and HT (see Table 4.8). Since these parameters are 
connected with the biochemical factors (as shown in Table 4.7), the analysis of the 
values in Table 4.8 can determine the variation of these biochemical factors in the 
normal and pathological conditions. The proposed connections between model 
parameters and biochemical factors then can be validated by comparing model 
predictions with published observations involving biochemical factors. 
As observed in Table 4.8, parameters ‘a’ and ‘b’ for HT were lower than 
those related to the normal condition, which indicates that the levels of RANKL and 
OPG are reduced (see Table 4.7). This partially agrees within the findings of 
Kanatani et al. (2004), who reported a decline in OPG in the case of HT, although no 
change in RANKL was observed. However, Miura et al. (2002) indicated that the 
RANKL level can decrease under this condition. As shown in Table 4.8, the model 
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predicted an increase in the levels of RANKL and OPG in PHPT compared to the 
normal condition. The prediction is confirmed in part by literature that has observed 
increased RANKL levels in patients with PHPT (Horwood et al., 1998a; Itoh et al., 
2000; Lee and Lorenzo, 1999; Nakchbandi et al., 2008). Validation of the prediction 
of OPG levels requires further investigation, since the effect of PTH on the 
production of OPG remains controversial. Several in vitro studies indicated that OPG 
secretion is suppressed by PTH (Itoh et al., 2000; Lee and Lorenzo, 1999; Onyia et 
al., 2000), while in vivo experiments provided conflicting results (Nakchbandi et al., 
2008; Stilgren et al., 2003). 
The a:b ratio for HT was lower than that for the normal condition (7.43 
compared to 8.58) (see Table 4.8), suggesting a decrease in the RANKL:OPG ratio 
and a resultant decline in osteoclast population, since RANKL simulates the 
differentiation and activation of osteoclasts (Aubin and Bonnelye, 2000; Burgess et 
al., 1999; Hofbauer et al., 2000), while OPG inhibits the differentiation and 
activation of osteoclasts (Filvaroff and Derynck, 1998; Greenfield et al., 1999; 
Gunther and Schinke, 2000). A tight coupling exists between osteoclasts and 
osteoblasts as the differentiation of osteoblast precursors is stimulated by osteoclasts 
(Matsuo and Irie, 2008), thus a decrease in osteoclast population will lead to the 
decline in osteoblast population. The model predication that the populations of 
osteoclasts and osteoblasts decrease is confirmed by the work of Eriksen et al. 
(1986a). Eriksen et al. (1986a) reported that the decreased level of thyroid hormone 
in HT led to a decline in the populations of osteoclasts and osteoblasts, since thyroid 
hormone is a potent stimulator of osteoclasts and osteoblasts. 
In addition, the a:b ratio for PHPT was higher than that for the normal 
condition (9.54 compared to 8.58) (see Table 4.8). Likewise, the increased a:b ratio 
leads to the increase in the populations of osteoclasts and osteoblasts, which is 
confirmed by observations that osteoclast and osteoblast populations increase in 
patients with PHPT (Chappard et al., 1996; Schulz et al., 1976; Singer and Eyre, 
2008; Vera et al., 2011). 
Table 4.8 indicates that ‘
 
     
’ in HT equated to 2.21×10-9, which was higher 
than the value associated with the normal condition (4.14×10
-10
). This suggests that 
the coupling coefficient between osteoblasts and osteoclasts for HT is more intensive 
compared to normal condition, causing the ratio of OBa:OCa in HT to be higher. This 
agrees with the model predictions as the OBa:OCa ratio is larger in HT compared to 
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the normal condition (232.7 and 217.4, respectively). As a result, the increased ratio 
of OBa:OCa in HT will lead to a positive bone balance at the end of bone remodelling 
cycles, which is confirmed by the experimental observations of higher amount of 
bone formation compared to resorption within individuals with this condition (as 
shown in Table 4.5). In addition, ‘
 
     
’ in PHPT was similar to that associated with 
the normal condition (3.83×10
10 
and 4.14×10
-10
, respectively) indicating that the 
coupling coefficient between osteoblasts and osteoclasts should be similar in both 
cases. Again, this is consistent with the predicted OBa:OCa ratios for PHPT and the 
normal condition (219.8 and 217.4, respectively). 
Finally, the term ‘
 
   
’ is related to osteoblastic activity and its value in HT 
was lower than that corresponding to the normal condition (respective values of 
1.03×10
-5 
and 2.31×10
-5 
are shown in Table 4.8), which indicates a decrease in 
osteoblastic activity in individuals with HT. This is consistent with experimental 
observations of the mean bone formation rate in HT (59 μm/620 day) being lower 
than that under normal condition (45.2 μm/172 day) (Ji et al., 2012). In addition, ‘
 
   
’ 
in PHPT equalled to 1.56×10
-5
, which was lower than that under the normal 
condition (2.31×10
-5
), indicating a decrease in osteoclastic activity in PHPT 
compared to the normal condition. This was also confirmed by decreasing mean bone 
formation rate in PHPT (45.2 μm/172 day) compared to the normal condition (62 
μm/145 day) (Ji et al., in press). 
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Parameters HT Normal PHPT 
a 0.0327 day
-1
 0.0558 day
-1
 0.1231 day
-1
 
b 0.0044 cells
-1/2
 day
-1
 0.0065cells
-1/2
 day
-1
 0.0129 cells
-1/2
 day
-1
 
a/b 7.43 8.58 9.54 
Koc 1.81×10
11
 cells
2
 2.44×10
11
 cells
2
 1.74×10
11
 cells
2
 
d 0.0025 day
-1
 0.0099 day
-1
 0.0150 day
-1
 
 
     
 2.21×10
-9
 4.14×10
-10
 3.83×10
-10
 
Kob 9.64×10
4
 cells 4.32×10
4
 cells 6.42×10
4
 cells 
 
   
 1.03×10
-5
 2.31×10
-5
 1.56×10
-5
 
 
Table 4.8:  Calculations of parameter values for normal and two pathological 
conditions, HT and PHPT. 
 
4.5 DISCUSSION 
Bone remodelling is most commonly considered at BMU level, which integrates the 
osteoclastic removal and osteoblastic formation processes. The sequence of activities 
that take place during remodelling occur over an extended timeframe, for example 
typically 200 days for normal remodelling (Eriksen et al., 1984b; Eriksen et al., 
1984a) followed by a quiescent period of possibly 900 days (Eriksen et al., 1986b). 
In the ideal situation, the volume of bone removed and deposited should be the same, 
but whether this occurs in reality depends on many complex factors. In the simplest 
terms, it relies on the number of cells involved and the period and rate of the cellular 
resorption and formation processes. A change in any of these will lead to a variation 
in the remodelling outcome and a net loss or gain in bone volume.  
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The aim of the proposed mathematical model was to simulate the activity and 
interactions between the cells and thereby predict the resultant effect on the bone. A 
predator-prey based mathematical relationship was used to define the basic 
associations, although the gaps between bouts of activity are much longer than would 
normally be expected in predator-prey situations. In this first application of the 
model, the model parameters were initially established for normal (healthy) 
remodelling, with the resultant governing equations then used to confirm that the 
predicted cellular activity matched the primary histomorphometry data (as would be 
expected); but in addition, the pattern of the whole remodelling cycles are predicted. 
However, it should be noted that this primary data is limited and was collated from a 
number of different sources, therefore the values of the model parameters require 
cautious consideration. Also, there will be some inevitable statistical variation in the 
experimental data, the effect of which requires further investigation. In the future this 
variability could be included automatically in the solution phase of the model, to 
provide an envelope of bone remodelling behaviour.  
The potential of the model to investigate the bone remodelling cycle and the 
effects of different pathological conditions was demonstrated by considering PHPT 
and HT. The natural histories of these two conditions are quite different (as shown in 
Table 4.5) (Eriksen et al., 1986a, 1986b), although the model enables reconstruction 
of the remodelling cycles, along with prediction of the complex temporal interaction 
between the osteoblasts and osteoclasts, and the resultant effect on bone thickness. In 
contrast to the ‘normal’ case, the number of cells involved in BMU remodelling in 
these two conditions is not reported within literature, but they can be predicted by 
simulation. Despite the fact that the two conditions are very different (for example, 
the formation periods and the predicted numbers of cells vary), it is interesting to 
note that the OBa:OCa ratios were similar. Unfortunately, at the present time, there is 
no published data available to confirm these predictions.  
The bone remodelling activity is initiated and regulated by molecular 
reactions and processes. In an attempt to examine the sensitivity of the simulation 
results to the model parameters and thereby identify possible relationships with 
biochemical factors, the effects of parameter variations on the remodelling process 
and results were examined (see Table 4.4). 
Based on sensitivity studies and model equations, relationship were built 
between the model parameters and regulatory biochemical factors of bone 
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remodelling cycles. The predictions based on suggested connections between model 
parameters and biochemical factors were consistent with published experimental 
observations, thus validating the proposed connections. 
Further work is required to validate the proposed model, but the predicted 
histomorphometric measures and remodelling cycles compare well with the sample 
input data. It was concluded that this shows that the model has merit and predictive 
potential, especially in the future modelling of pathological conditions and in the 
optimisation of their treatment. 
In this chapter a predator-prey based model of the bone remodelling cycle has 
been described. However, the model does not consider the complex cellular 
interactions which are involved in the bone remodelling process. In the following 
Chapter 5, a second mathematical model is developed which includes these cellular 
interactions in both normal and chronic pathological (multiple myeloma) conditions. 
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5. MATHEMATICAL MODELLING OF THE 
PATHOLOGY OF MULTIPLE MYELOMA 
INDUCED BONE DISEASE 
5.1 INTRODUCTION 
Bone can prevent the invasion of the majority of cancer cells due to its special 
properties (Smith and Martin, 2011). However, multiple myeloma (MM) as well as 
breast and prostate cancers can develop and survive within the bone 
microenvironment, as their phenotypic properties are capable of changing the bone 
microenvironment in ways that favour growth and survival of the tumour cells. MM 
is the second most frequent haematological malignancy (Fowler et al., 2011) and can 
induce a destructive bone disease, which leads to bone removal, bone pain and 
pathological fractures. It is reported that 60% to 70% of individuals with MM 
experience either bone pain or fracture at the time of diagnosis, while 90% of 
patients develop bone lesions during the course of the disease (Heider et al., 2005; 
Nau and Lewis, 2008; Roodman, 2004). MM-induced bone disease is a major cause 
of morbidity for patients with MM. The American Cancer Society estimated there 
were approximately 20,000 patients diagnosed with MM within the United States in 
2004, with 10,800 associated deaths (Jemal et al., 2004). 
MM induces an increase in bone resorption and suppresses bone formation, 
resulting in a negative bone balance and osteolytic lesions that rarely heal 
(Matsumoto and Abe, 2011; Roodman, 2011). Histomorphometric studies have 
revealed that the increased resorption arises from enlarged resorption surfaces and 
deeper resorption depths at individual bone remodelling sites (Taube et al., 1992; 
Wittrant et al., 2004). In parallel, uncoupling between bone resorption and bone 
formation is also observed in MM patients (Calvani et al., 2004). 
The interaction between MM cells and the bone microenvironment (MM-
bone interaction) plays an important role in the development of MM-induced bone 
disease. It promotes tumour growth and survival, as well as the consequent bone 
destruction (Fowler et al., 2011). Recently, many biochemical factors have been 
implicated in the development of MM-induced bone disease, such as cytokines with 
osteoclast activating function (e.g. the receptor activator of nuclear factor kappa-B 
ligand) (Gittoes and Franklyn), macrophage colony stimulating factor (M-CSF), 
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interleukin-6 (IL-6) and IL-11, IL-1β (Terpos and Dimopoulos, 2005)), which are 
produced or stimulated by MM-bone interaction and further stimulate osteoclast 
activation and proliferation. In turn, the growth of myeloma cells are stimulated by 
growth factors released from bone resorption (Wittrant et al., 2004), which include 
transforming growth factor-beta (TGF-β), bone morphogenetic proteins (BMP), 
heparin-binding fibroblast growth factors and insulin-like growth factor (Blum et al., 
2004; Guise and Chirgwin, 2003). Such reciprocal interaction produces a ‘vicious 
cycle’ between MM cells and the bone microenvironment, stimulating both tumour 
development and bone destruction (Fowler et al., 2011; Wittrant et al., 2004).  
Only two models have been developed previously to analyse the role of MM-
bone interaction in the development of MM disease. Ayati et al. (2010) proposed a 
model to simulate the dynamics of normal bone remodelling and MM disease. 
However, this model did not include the specific molecular mechanisms involved in 
the development of MM-induced bone disease, and the model parameters were not 
based on biological evidence. Wang et al. (2011) constructed another model to 
mimic MM-bone interaction and identify the signalling mechanisms which are 
believed to drive the progression of MM disease. This model included IL-6 and 
signalling pathways involved in MM and bone marrow stromal cell (BMSC) 
adhesion. However, Wang et al. (2011) did not consider the MM induced inhibition 
of osteoblastic activity, despite the fact that the suppression of osteoblast activity and 
the enhancement of osteoclast activity play an equally important role in bone 
destruction and development of tumour cells in MM patients (Matsumoto and Abe, 
2011; Terpos and Dimopoulos, 2005).  
Suppression of osteoblast activity is caused by soluble factors produced by 
MM cells and MM-bone interaction, which prevent their precursors from 
differentiating into mature osteoblasts (Roodman, 2011). Reduction in osteoblast 
activity not only increases the ratio of RANKL to OPG, enhancing 
osteoclastogenesis and bone resorption, but also stimulates anti-apoptotic and growth 
factors for MM cells, which forms a positive feedback between osteoblast 
suppression and the growth of MM cells (Fowler et al., 2011; Roodman, 2011). 
Importantly, several treatments of MM disease target suppression of osteoblastic 
activity, such as Bortezomib related therapy (Roodman, 2011) and inhibition of 
TGF-β (Matsumoto and Abe, 2011).  
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A mathematical model is described in this chapter that simulates the 
development of tumour cells and MM-induced bone disease. It was developed in 
parallel with the recently published model of Wang et al. (2011), which in turn was 
based on the earlier work of Pivonka et al. (2008). However, unlike the model of 
Wang et al. (2011), this model includes the underlying mechanisms of osteoblast 
inhibition and its role in the development of MM-induced bone disease. The model 
can simulate the development of MM and the induced bone destruction, and explain 
why MM induced bone lesions rarely heal after the complete removal of MM cells, 
as well as simulate the effects of different treatment therapies. 
5.2 DEVELOPMENT OF THE MODEL OF THE NORMAL 
BONE ENVIRONMENT 
A basic mathematical model is discussed initially which simulates the variation of 
bone cell concentrations in the bone microenvironment, and the resultant change of 
bone volume with time under normal conditions. It is based on the work of Pivonka 
et al. (2008). The model also simulates how variations in OPG, RANKL and PTH 
level influence cell concentrations, bone volume and of OBa:OCa ratio. This model is 
then extended to simulate the pathology of MM-induced bone disease, through the 
incorporation of the interaction between MM cells and the bone microenvironment. 
5.2.1  BASIC STRUCTURE OF THE MODEL  
The bone microenvironment consists of many different components including 
multiple cell types, matrix proteins and endothelial cells. This study only focuses on 
osteoclastic and osteoblastic lineages, since they are responsible for the resorption 
and formation of bone, respectively, and play an important role in bone remodelling 
cycles. The osteoblastic lineage communicates with the osteoclastic lineage within 
the basic multiple unit (BMU) by at least three ways: cell-to-cell contact, diffusible 
paracrine factors and cell-to-bone matrix interaction (Matsuo and Irie, 2008). Cell-to-
cell contact comprises of intercellular interaction between membrane-bound ligands 
and receptors, and transportation of small water-soluble molecules through gap 
junctions between two cell types. Osteoclast-to-osteoblast communication through 
diffusible paracrine factors means that diffusible paracrine factors (such as growth 
factor, cytokines and other small molecules) secreted by one cell type act on the 
other via diffusion. Cell-to-bone matrix interaction represents the interaction between 
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growth factors released by osteoclasts during bone resorption, and cells in 
osteoclastic and osteoblastic lineages (Pfeilschifter and Mundy, 1987).  
Bone remodelling cycles can be categorised into three stages of initiation, 
transition and termination of remodelling (Matsuo and Irie, 2008). The initiation 
phase is defined as the period when osteoblast precursors are recruited, osteoclasts 
are differentiated and activated, and bone resorption commences. During the 
transition phase, bone resorption is inhibited, osteoclasts undergo apoptosis, 
osteoblasts are recruited and differentiated, and bone resorption is reversed into bone 
formation. The termination of remodelling marks the formation of new bone and the 
start of the quiescent period.    
Many cytokines, biochemical mechanisms and signalling pathways are 
involved in the remodelling cycle, however not all these factors were considered in 
this study for simplicity. The basic structure of the model under normal remodelling 
conditions is presented in Figure 3.4. Differentiation into active osteoclasts and 
osteoblasts from their progenitors involves several intermediate stages. A total of 
seven stages have been identified in the differentiation of osteoblasts from 
mesenchymal stem cells to osteocytes and bone lining cells (Aubin, 1998), while the 
osteoclast lineage develops from hematopoietic precursor cells through monocyte 
differentiation and fusion to osteoclast formation (Roodman, 1999; Teitelbaum, 
2000). This study only considers four stages of osteoblastic differentiation 
(uncommitted progenitors; osteoblasts precursors; active osteoblasts; and osteocytes, 
bone lining cells or apoptotic osteoblasts) and three stages of osteoclastic 
differentiation (osteoclast precursors; active osteoclasts; and apoptotic osteoclasts), 
similar to that of Pivonka et al. (2008).  
During the initiation phase shown in Figure 3.4, RANKL secreted by 
osteoblast precursors is able to induce osteoclast differentiation through binding to 
RANK expressed on osteoclast precursors, while OPG is produced by active 
osteoblasts to inhibit the differentiation of osteoclasts via binding to RANKL (Boyce 
and Xing, 2008). Bone is a major reservoir of growth factors such as TGF-β and 
IGFs (Cohen, 1997; Roodman, 1999). Growth factors are released to the bone 
microenvironment by osteoclasts during bone resorption. The effect of TGF-β on the 
osteoblastic lineage is dependent on the stages of cell maturation (Erlebacher et al., 
1998). TGF-β is able to promote differentiation from uncommitted progenitors (OBu) 
into osteoblast precursors (OBp), while suppressing osteoblast precursor 
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differentiation into active osteoblasts (OBa) (Janssens et al., 2005). In addition, TGF-
β influences the osteoclast lineage, and has been reported to promote the apoptosis of 
active osteoclasts (Fuller et al., 2000).  
5.2.2  MODEL EQUATIONS 
Based on the underlying mechanisms illustrated in Figure 3.4, three ordinary 
differential equations were proposed to represent the communication between 
osteoclastic and osteoblastic lineages. Although differentiation of progenitors into 
active osteoclasts and osteoblasts contains several intermediate stages, the model 
only considered four osteoblastic lineages and three osteoclastic lineages, contained 
three state variables: osteoblast precursors, active osteoblasts, and active osteoclasts. 
Again, based on the ideas of Pivonka et al. (2008), Eqs. (5-1) to (5-3) were defined to 
describe the temporal variation in osteoblastic precursors, active osteoblasts and 
active osteoclasts, respectively.  
    
  
             
    
                 
    
                                               (5-1) 
    
  
             
    
                                                                        (5-2) 
    
  
               
                   
    
                                                   (5-3) 
where, 
    ,     and     represent concentrations of osteoblast precursors, active 
osteoblasts, and active osteoclasts, respectively; 
  
    
  
, 
    
  
 and 
    
  
 denote the variations of    ,     and    , respectively; 
     and     are concentrations of uncommitted osteoblastic progenitors and 
osteoclastic precursors, respectively, with their values set as constants in the 
model due to their relatively large populations; 
           and      represent the differentiation rates of uncommitted 
osteoblast progenitors, osteoblast precursors and osteoclast precursors, 
respectively;  
      and       are apoptosis rates of active osteoblasts and active osteoclasts, 
respectively; and 
 π functions denote the stimulating or inhibiting functions of ligand to receptor 
binding. 
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As demonstrated in Figure 3.4, the communications between osteoclastic and 
osteoblastic lineages are performed through cell-to-cell contact and cell-to-bone 
matrix interaction, which are all related to various receptor-ligand interactions. These 
can promote or inhibit cell responses such as differentiation, proliferation, apoptosis 
and production of molecules. ‘Hill functions’ are used to represent the cellular 
interaction via the single ligand to receptor binding denoted by π functions (Pivonka 
et al., 2008), with Eqs. (5-4) and (5-5) describing the stimulating and inhibiting 
functions of the binding of the ligand-receptor. ‘L’ represents the concentration of 
the ligand; ‘ ’ represents maximal expression level of the promoter and is assumed 
to equal 1 in the model following the work of Pivonka et al. (2008); ‘n’ is the 
coefficient which regulates the steepness of the function ‘π’ and is also assumed to 
equal 1 following the work of Pivonka et al. (2008); ‘  ’ and ‘  ’ represent the 
dissociation constant, respectively.  
           
     
       
                                        (5-4) 
           
 
   
 
  
  
                                        (5-5) 
The RANK-RANKL-OPG pathway plays an important role in the regulation 
of osteoclast activity, as osteoclastogenesis is stimulated by RANKL (via binding to 
RANK on the osteoclast progenitors) and inhibited by OPG (a soluble decoy receptor 
for RANKL) (Boyce and Xing, 2008). Growth factors (such as TGF-β) released 
during bone resorption can stimulate osteoblast recruitment, and migration and 
proliferation of osteoblast precursors (Bonewald and Dallas, 1994; Eriksen and 
Kassem, 1992; Mundy et al., 1996), while inhibiting the production of mature 
osteoblasts. Again similar to the modelling of Pivonka et al. (2008),        
    
, 
       
    
,         
    
and          
     in Eqs. (5-1) to (5-3) represent the effect of TGF-  
and RANKL on osteoclastic and osteoblastic lineages, respectively, where, 
        
    
represents the stimulation of uncommitted osteoblastic progenitors 
into osteoblastic precursors; 
        
    
represents the inhibition of the differentiation of osteoblastic 
precursors into active osteoblasts; 
         
    
denotes that TGF-β is able to promote the apoptosis of active 
osteoclasts; and 
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         
     denotes that RANKL produced by osteoblastic precursors stimulates 
the differentiation of osteoclastic precursors into active osteoclasts. This also 
includes OPG secreted by active osteoblasts inhibiting the differentiation 
osteoclastic precursors, by binding to RANK expressed on osteoclastic 
precursors. 
According to the proposed forms of ‘Hill function’ in Eqs. (5-4) and (5-5), π 
functions involving TGF-  and RANKL were defined as follows: 
       
     
    
             
                                                (5-6) 
       
    
 
 
                
                                           (5-7) 
        
    
 
    
            
                                              (5-8) 
        
      
     
             
                                            (5-9) 
where, 
      and       represent the concentrations of TGF-β and RANKL, 
respectively; and 
 The definitions and values of         ,         ,         and         are 
included in Table 5.1. 
In the model, parameters without corresponding experimental data, which are 
usually related with experimental data (e.g.      and      involve the experimental 
data of the population of    ), are estimated or calculated via the genetic algorithm 
as shown in Table 5.1. The estimation of values of model parameters is achieved 
through trying different values in a domain and then picking up the most fitting one 
with corresponding experimental data. Based on the estimated values, the remaining 
unknown model parameters are calculated according to relevant experimental data 
through the genetic algorithm following the same procedure discussed in Chapter 4. 
Although all the unknown model parameters could be calculated via the genetic 
algorithm, it would greatly increases the complexity and consuming time.   
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Parameters Value Description 
     3.24e+2 /day (estimated) 
Differentiation rate of 
osteoblast progenitors 
     3.67e-1 /day (estimated) 
Differentiation rate of 
osteoblast precursors 
     3.00e-1 /day (Pivonka et al., 2008) 
Rate of elimination of 
active osteoblasts 
     1.73e-1 /day (estimated) 
Differentiation rate of 
osteoclast precursors 
     1.20 /day (estimated) 
Rate of elimination of 
active osteoclasts 
         4.28e-4 pM (Pivonka et al., 2008) 
Activation coefficient 
related to growth factors 
binding on     
         2.19e-4 pM (Pivonka et al., 2008) 
Repression coefficient 
related to growth factors 
binding on     
         4.28e-4 pM (Pivonka et al., 2008) 
Activation coefficient 
related to growth factors 
binding on     
       2.09e+1 pM (calculation by GA) 
Activation coefficient for 
RANKL production 
related to PTH binding 
       2.21e-1 pM (calculation by GA) 
Repression coefficient for 
OPG production related to 
PTH binding 
        4.12e+1 pM (estimated) 
Activation coefficient 
related to RANKL 
binding to RANK 
α 1.00 pM/% (Pivonka et al., 2008) 
TGF-  co  e   stored in 
bone matrix 
 ̃     2.00e+2 /day (Wakefield et al., 1990) 
Rate of degradation of 
     
Table 5.1: Definitions and values of model parameters used in the model  
(GA = genetic algorithm).   
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     9.74e+2 pM/day (Schmitt et al., 1998) 
Rate of synthesis of 
systemic PTH 
 ̃    3.84e+2 /day (Schmitt et al., 1998) 
Rate of degradation of 
PTH 
     5.02e+6 /day (estimated) 
Minimum rate of 
production 
of OPG per active 
osteoblast 
 ̃    4.16 /day (Hideshima et al., 2007) 
Rate of degradation of 
OPG 
       7.98e+2       e  o  e            
Maximum possible OPG 
concentration 
       8.25e+5 /day (estimated) 
Production rate of 
RANKL per cell 
 ̃      4.16 /day (Fan et al., 2004) 
Rate of degradation of 
RANKL 
       3.00e+6 (Pivonka et al., 2008) 
Maximum number of 
RANKL on the surface 
of each osteoblastic 
precursor 
       7.19e-2 /pM (Cheng et al., 2004) 
Association rate constant 
for RANKL binding to 
RANK. 
     
2.00e+2% /(pM*day) (Kuehl and 
Bergsagel, 2002) 
Relative rate of bone 
resorption (normalized 
with respect to normal 
bone resorption) 
      
3.32e+1% /(pM*day) (calculation by 
GA) 
Relative rate of bone 
formation (normalized 
with respect to normal 
bone resorption) 
Table 5.1(cont): Definitions and values of model parameters used in the model  
(GA = genetic algorithm).  
 
In the work of Pivonka et al. (2008), the concentration of TGF-β is proposed as: 
     
                
 ̃    
                                           (5-10)  
where, the definitions and values of α,     ,       and  ̃     in Eq. (5-10) are also 
included in Table 5.1. 
Since the concentration of RANKL is regulated by OPG, the concentration of 
OPG is introduced first. Also, the production of OPG is down-regulated by PTH, and 
the concentration was therefore defined as: 
    
                      
   
               
   
      
     
                                  (5-11) 
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where,         
    represents the repression of the differentiation of     by PTH. The 
definitions and values of      ,     ,        and      in Eq. (5-11) are included 
in Table 5.1. The concentration of PTH and        
   used in Eq. (5-11) are defined 
as: 
    
             
 ̃   
                                                 (5-12) 
       
    
 
             
                                                (5-13) 
 
where, the definitions and values of     ,         ,  ̃    and        in Eqs.(5-12) 
and (5-13) are included in Table 5.1. The concentration of RANKL is proposed as: 
      
                  
                           
      
                
           
     (5-14) 
 
where,          
    represents the PTH stimulation of the production of RANKL and 
its definition is given by: 
         
    
   
          
                                        (5-15) 
The definitions and values of        ,       ,      ,       ,  
     ,        
and        in Eqs.(5-14) and (5-15) are included in Table 5.1. 
The model is also able to describe the temporal variation of bone volume 
during bong remodelling cycles, through the following equation: 
   
  
                                                  (5-16) 
where,    represents the normalized bone volume and the definitions and values of 
     and       in Eq. (5-16) are included in Table 5.1. 
5.2.3  SIMULATION RESULTS AND DISCUSSION 
The model of the normal bone microenvironment is able to reconstruct the 
concentrations of osteoblastic precursors, active osteoblasts and active osteoclasts, 
and also analyse how variations in OPG, RANKL and PTH influence cell 
concentrations, bone volume and the OBa:OCa ratio.  
Figure 5.1 presents the temporal variation in concentrations of OBp, OBa and 
OCa in the normal bone microenvironment, and confirms that they remain constant 
with time. Figure 5.2 displays that bone volume also stays constant with time in the 
normal condition. These results agree with the conclusion that the bone 
microenvironment always remains in a dynamic steady-state, as do other biological 
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systems under physiological conditions without external stimuli (Lemaire et al., 
2004; Zumsande et al., 2011).  
 Figures 5.3 to 5.5 reveal how the cell concentrations, bone volume and 
OBa:OCa ratio vary when injecting 10 or 20 pM/day of OPG into the system. As 
demonstrated in Figure 5.3, an increase in the level of OPG leads to a rapid decline 
in     and    , followed by a relatively smaller decrease in    , which agrees with 
the experimental observation that OPG suppresses the differentiation of     and 
promotes the apoptosis of     (Hofbauer et al., 2001). The injection of OPG at 10 or 
20 pM/day causes the OBa:OCa ratio to initially increase by 1.2% or 2.4%, but drops 
down to 0.4% or 0.7% (shown in Figure 5.5), which results in an increase of 1.7% or 
3.7% in bone volume (shown in Figure 5.4). The rising level of OPG results in the 
increase in bone volume, which is confirmed by the observation of Simonet et al. 
(1997). The simulation results also indicate that the influence of the OPG injection 
on cell concentrations, bone volume and OBa:OCa ratio is positively related to the 
injection rate (e.g. the rapid injection rate, 20pM/day, results in a larger drop in cell 
concentrations, and increase in bone volume and OBa:OCa ratio, compared to that of 
10pM/day). 
Figures 5.6 to 5.8 demonstrate the effect of an external injection of RANKL 
at 5 or 10 pM/day on cell concentrations, bone volume and the OBa:OCa ratio, 
respectively. The rising RANKL level causes an increase in     and     followed 
by a less pronounced increase in    and the quicker injection rate produces a larger 
increase in cell concentrations (shown in Figure 5.6). The OBa:OCa ratio undergoes 
an initial 0.4% or 0.7% decrease and then returns to a stable level, 99.7% or 99.9% of 
its initial value, due to the injection of RANKL at 5 or 10 pM/day (shown in Figure 
5.8), resulting in an 0.6% or 1.4% decrease in bone volume (shown in Figure 5.7). 
These simulation results are consistent with the experimental findings (Filvaroff and 
Derynck, 1998; Manolagas, 2000).  
Figures 5.9 and 5.11 show that how an increase in PTH level of 500 or 1000 
pM/day induces variations in cell concentrations, bone volume and OBa:OCa ratio, 
respectively. As shown in Figure 5.9, the increasing level of PTH induces an increase 
in concentrations of of    ,     and    , and the rate of 1000 pM/day results in a 
bigger increase in cell concentrations compared to that of 500 pM/day. The OBa:OCa 
ratio declines after the injection of PTH (shown in Figure 5.11), which results in a 
decrease in bone volume (shown in Figure 5.10). The proportionate decreases in 
100 
 
OBa:OCa ratio and bone volume are both positively related to the injection rate. 
These simulation results agree with the experimental and clinical observations that 
PTH can induce an increase in the concentrations of    ,     and    , and a 
decrease in bone volume (Tam et al., 1982; Watson et al., 1999). It should be noted 
that Figure 5.3 to Figure 5.11 also demonstrate that the bone microenvironment is 
dynamically stable against small perturbations and is able to return to the stable state 
again after small perturbations, although there is a net change to the bone volume. 
 
 
 
 
Figure 5.1: Model simulations of the variation in the concentrations of osteoblast 
precursors, active osteoblasts and active osteoclasts in the normal (healthy) 
condition. 
101 
 
 
Figure 5.2: Model simulations of the variation in bone volume in the normal (healthy) 
condition. 
 
Figure 5.3: Model simulations of the variation in normalized cell concentrations with 
respect to its initial value after injection of OPG at the rate of 10 or 20 pM /day from 
day 50 to day 300.   
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Figure 5.4: Model simulations of the variation in normalized bone volume with 
respect to its initial value after injection of OPG at the rate of 10 or 20 pM /day from 
day 50 to day 300. 
 
Figure 5.5: Model simulations of the variation in the normalized ratio of OBa:OCa 
with respect to its initial value after injection of OPG at the rate of 10 or 20 pM /day 
from day 50 to day 300.   
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Figure 5.6: Model simulations of the variation in normalized cell concentration with 
respect to its initial value after injection of RANKL at the rate of 5 or 10 pM/day 
from day 50 to day 300.  
 
Figure 5.7: Model simulations of the variation in normalized bone volume with 
respect to its initial value after injection of RANKL at the rate of 5 or 10 pM /day 
from day 50 to day 300. 
0 50 100 150 200 250 300 350
0.995
1
1.005
1.01
1.015
Time [day]
V
a
ri
a
ti
o
n
 o
f 
n
o
rm
a
liz
e
d
 c
e
ll 
c
o
n
c
e
n
tr
a
ti
o
n
s
 [
fo
ld
]
 
 
Concentration of OBp (5 pM/day)
Concentration of OBa (5 pM/day)
Concentration of OCa (5 pM/day)
Concentration of OBp (10 pM/day)
Concentration of OBa (10 pM/day)
Concentration of OCa (10 pM/day)
RANKL Injection stops 
RANKL injection starts
0 50 100 150 200 250 300 350
99.984
99.986
99.988
99.99
99.992
99.994
99.996
99.998
100
100.002
Time [day]
V
a
ri
a
ti
o
n
 o
f 
n
o
rm
a
rl
iz
e
d
 b
o
n
e
 v
o
lu
m
e
 [
%
]
 
 
Bone Volume(5 pM/day)
Bone Volume(10 pM/day)
RANKL injection stops
RANKL injection starts
104 
 
 
Figure 5.8: Model simulations of the variation in the normalized ratio of OBa:OCa 
with respect to its initial value after injection of RANKL at the rate of 5 or 10 pM 
/day from day 50 to day 300. 
 
Figure 5.9: Model simulations of the variation in normalized cell concentrations with 
respect to its initial value after injection of PTH at the rate of 500 or 1000 pM/day 
from day 50 to day 300. 
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Figure 5.10: Model simulations of the variation in normalized bone volume with 
respect to its initial value after injection of PTH at the rate of 500 or 1000 pM/day 
from day 50 to day 300. 
 
Figure 5.11: Model simulations of the variation in the normalized ratio of OBa:OCa 
with respect to its initial value after injection of PTH at the rate of 500 or 1000 
pM/day from day 50 to day 300. 
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5.3 DEVELOPMENT OF THE MODEL OF MULTIPLE 
MYELOMA-INDUCED BONE DISEASE 
The model introduced in the previous section has been shown to simulate the normal 
state of the bone microenvironment by describing the variations in cell 
concentrations and bone volume with time. The following section now describes how 
the model was extended to simulate the development of MM cells and MM-induced 
bone disease.  
5.3.1  BASIC STRUCTURE OF THE MODEL  
The bone microenvironment consists of many different components including 
multiple cell types, matrix proteins and endothelial cells. The contribution of each of 
these components to the progress and survival of tumour cells is still not completely 
clear (Fowler et al., 2011; Roodman, 2011). However, it is certain that the 
suppression of osteoblast activity and enhancement of osteoclast activity, are both 
key factors in development of tumour cells and the bone destruction (Matsumoto and 
Abe, 2011; Terpos and Dimopoulos, 2005).  
The basic structure of the model of MM-induced bone disease is shown in 
Figure 5.12. It demonstrates the ‘vicious cycle’ associated with MM disease, with the 
appearance of MM cells changing the bone microenvironment, resulting in 
osteolysis, which in turn promotes the proliferation of further MM cells (Wittrant et 
al., 2004). The model structure consists of two parts: part A (in blue) is associated 
with osteoclasts and the bone resorption aspects of the disease, while part B (in red) 
deals with osteoblasts and bone formation activities.  
Part A describes how MM cells increase bone resorption, which in turn 
stimulates the further proliferation of MM cells. Two positive feedback cycles exist 
in part A. Firstly, IL-6 secreted by bone marrow stromal cell (BMSC) stimulates the 
production of RANKL (Kwan Tat et al., 2004), while MM cells suppress the 
production of OPG (Terpos and Dimopoulos, 2005). Consequently, the increased 
RANKL-OPG ratio promotes bone resorption (Terpos and Dimopoulos, 2005). In 
turn, TGF-β released from the bone resorption stimulates the secretion of IL-6 by 
BMSC (Hideshima et al., 2007; Teoh and Anderson, 1997), where the production of 
IL-6 can also be enhanced by the BMSC-MM cell adhesion (Urashima et al., 1996). 
Secondly, IL-6 and BMSC-MM cell adhesion promotes the proliferation of MM 
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cells, which in turn further stimulates further production of IL-6 and BMSC-MM cell 
adhesion (Hideshima et al., 2007; Klein et al., 1995; Urashima et al., 1996).  
Part B describes the reciprocal relationship between the suppression of 
osteoblastic activity and the stimulation of MM cell production. Both BMSC-MM 
cell adhesion and soluble factors (produced or induced by MM cells) can block the 
differentiation of mesenchymal progenitors into mature osteoblasts, while at the 
same time stimulate osteoblast apoptosis, resulting in an inhibition of osteoblast 
activity and bone formation (Bataille et al., 1986, 1990, 1991; Calvani et al., 2004; 
Roodman, 2011). Conversely, preventing the differentiation into mature osteoblasts 
can stimulate MM cell production, since immature osteoblasts support growth and 
survival of MM cells; while mature osteoblasts enhance apoptosis of myeloma cells 
(Matsumoto and Abe, 2011). Therefore, in the underlying mechanism, IL-6 
expressed by immature osteoblasts (mesenchymal stem cells) promotes MM cell 
growth and resistance to apoptosis (Stewart and Shaughnessy, 2006), while small 
leucrine-rich proteoglycans (SLRPs) (such as decorin expressed and produced by 
mature osteoblasts) have an anti-myeloma effect (Li et al., 2008). 
Part A and Part B also have direct connections with each other, i.e. the 
blockade of differentiation into mature osteoblasts contributes to an increase in the 
RANKL/OPG ratio, since immature osteoblasts produce RANKL, while mature 
osteoclasts produce OPG (labelled as arrow 5 in Figure 5.12) (Atkins et al., 2003). In 
addition, TGF-β released by bone resorption inhibits later phases of osteoblast 
differentiation and maturation (labelled as arrow 6 in Figure 5.12) (Matsumoto and 
Abe, 2011).  
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Figure 5.12: Proposed cellular interactions in MM development. (For references, see 
below). 
 
1. BMSC-MM cells adhesion enhances the production of IL-6 by BMSCs (bone 
marrow stromal cells) [10]; 2. TGF-β stimulates the production of IL-6 [1,9]; 3. IL-6 
stimulates the proliferation of MM cells [1,9,11]; 4. Immature osteoblasts support the 
growth and survival of MM cells, while mature osteoblasts enhance the apoptosis of 
MM cells; 5. the blockade of differentiation into mature osteoblasts contributes to the 
increase of the ratio of RANKL/OPG; and 6. TGF-β potentially inhibits later phases 
of osteoblast differentiation and maturation. 
[1] Hideshima et al., 2007; [2] Lauta, 2001; [3] Bataille et al., 1992; [4] Chauhan et 
al., 1996; [5] Kwan et al., 2004; [6] Terpos and Dimopoulos, 2005; [7] Calvani et al., 
2004; [8] Roodman, 2011; [9] Teoh and Anderson, 1997; [10] Urashima et al., 1996; 
[11] Klein et al., 1995. 
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5.3.2  MODEL EQUATIONS 
The model equations are mathematical representations of the basic mechanisms and 
relationships shown in Figure 5.12. In addition to the four equations describing the 
normal temporal variations of bone cells and bone volume (detailed in Section 5.2), 
another equation was introduced to describe the temporal variation of MM cells. In 
the model of MM-induced bone disease, only three stages of MM cells (MM cell 
precursors, active MM cells and apoptotic MM cells) were considered. 
The model subsequently contained four state variables: osteoblast precursors 
(OBp), active osteoblasts (OBa), active osteoclasts (OCa) and active MM cells (MM). 
Using the same nomenclature as Section 5.2, the equations describing the dynamics 
of cell concentrations are as follows:  
    
  
             
    
                 
    
         
                                 (5-17) 
    
  
             
    
         
                        
                                (5-18) 
    
  
              
                   
    
                                                  (5-19) 
   
  
             
           
            
  
     
             
           (5-20) 
The definitions of some variables, functions and parameters have been described 
previously in section 5.2.2, but also: 
    represents the concentration of MM cells; 
 
   
  
 is the variation of   with time; 
     represents the differentiation rates of the MM cell precursors; 
     is the apoptosis rate of active MM cells; 
       is the maximum concentration of MM cells;  
     represents the proliferation of MM cells regulated by IL-6 and BMSC-
MM cell adhesion; and 
 π functions denote the stimulating or inhibiting functions of ligand to 
receptor binding. 
The production of MM cells is regulated by several soluble factors, such as IL-6, 
insulin-like growth factor 1 (IGF-1), vascular endothelial growth factor (VEGF) and 
macrophage inflammatory protein-1 (MIP-1α) (Fowler et al., 2011; Terpos and 
Dimopoulos, 2005; Wittrant et al., 2004). 
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The model of MM-induced bone disease includes four additional Hill 
functions:        
   ,        
     ,         
      and         
     , where, 
        
    represents IL-6 regulation of the proliferation of MM cells. MM-
bone interaction is carried out through the binding of a cell adhesion 
molecule (CAMs), such as VLA-4 (α4β1 integrin present on the surface of 
MM cells), to a vascular cell adhesion molecule-1 (VCAM-1), which is 
expressed on BMSC (Terpos and Dimopoulos, 2005); 
        
      represents the effect of MM-BMSC on the proliferation of MM 
cells; 
          
      represents BMSC-MM cell adhesion that blocks the differentiation 
of mature osteoblasts from their progenitors; 
         
     represents BMSC-MM cell adhesion stimulating the apoptosis of 
osteoblasts; and 
       
     represents small leucine-rich proteoglycans (SLRPs) produced by 
mature osteoblasts suppressing the proliferation of MM cells (Roodman, 
2011).  
The definitions of these   functions are as follows: 
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                            (5-23) 
        
      
     
                   
                              (5-24) 
       
      
 
                        
                             (5-25) 
where,    ,       and       represent the concentrations of    ,       and 
     , respectively. The definitions and values of             ,              , 
                                                              and 
               are included in Table 5.2. 
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Parameters Value Description 
     3.24e+2/day (estimated) 
Differentiation rate of 
osteoblast progenitors 
     3.67e-1/day (estimated) 
Differentiation rate of 
osteoblast precursors 
     3.00e-1 /day (Pivonka et al., 2008) 
Rate of elimination of 
active osteoblasts 
     1.73e-1/day (estimated) 
Differentiation rate of 
osteoclast precursors 
     1.20 /day (Pivonka et al., 2008) 
Rate of elimination of 
active osteoclasts 
         
4.28e-4 pM (calculation by genetic 
algorithm (GA)) 
Activation coefficient 
related to growth factors 
binding on     
         2.19e-4 pM (Pivonka et al., 2008) 
Repression coefficient 
related to growth factors 
binding on     
         4.28e-4 pM (Pivonka et al., 2008) 
Activation coefficient 
related to growth factors 
binding on     
       2.09e+1 pM (calculation by GA) 
Activation coefficient for 
RANKL production 
related to PTH binding 
       2.21e-1 pM (Pivonka et al., 2008) 
Repression coefficient for 
OPG production related to 
PTH binding 
                1.2e-4 pM (calculation by GA) 
Half-maximal 
concentration of TGF  on 
promoting the production 
of IL-6 
                0.2 pM (calculation by GA) 
Half-maximal 
concentration of IL6 on 
promoting the production 
of RANKL 
        4.12e+1 pM (estimated) 
Activation coefficient 
related to RANKL binding 
to RANK 
α 1.00 pM/% (Pivonka et al., 2008) 
TGF-  co  e     o ed    
bone matrix 
Table 5.2: Definitions and values of model parameters used in the model of MM-
induced bone disease. (GA = genetic algorithm). 
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 ̃     
2.00e+2 /day (Wakefield et al., 
1990) 
Rate of degradation of 
     
     
9.74e+2 pM/day (Schmitt et al., 
1998) 
Rate of synthesis of 
systemic PTH 
 ̃    
3.84e+2 /day (Schmitt et al., 
1998) 
Rate of degradation of 
PTH 
     
1.20e+7/day (Klein et al., 1995; 
Wong et al., 2003) 
Rate of synthesis of     
per cell 
     
4.99e+1/day (van Zaanen et al., 
1996) 
The degradation rate of 
IL6 
       
8.04e-1pM (Alexandrakis et al., 
2003) 
The maximum 
concentration of IL-6 
     5.02e+6/day (estimated) 
Minimum rate of 
production of OPG per 
active osteoblast 
 ̃    4.16/day (Hideshima et al., 2007) 
Rate of degradation of 
OPG 
       7.98e+2     e  o  e            
Maximum possible OPG 
concentration 
       8.25e+5/day (estimated) 
Production rate of 
RANKL per cell 
 ̃      4.16/day (Fan et al., 2004) 
Rate of degradation of 
RANKL 
       3.00e+6 (Pivonka et al., 2008) 
Maximum number of 
RANKL on the surface of 
each osteoblastic 
precursor 
RANK 1.28e+1pM (Pivonka et al., 2008) 
Fixed concentration of 
RANK 
      5.68e-2/pM (Cheng et al., 2004) 
Association rate constant 
for RANKL binding to 
OPG. 
       7.19e-2/pM (Cheng et al., 2004) 
Association rate constant 
for RANKL binding to 
RANK. 
     
2.00e+2%/(pM.day) (Kuehl and 
Bergsagel, 2002) 
Relative rate of bone 
resorption (normalized 
with respect to normal 
bone resorption) 
Table 5.2 (cont): Definitions and values of model parameters used in the model of 
MM-induced bone disease. (GA = genetic algorithm). 
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3.32e+1%/(pM.day) (calculation by 
GA) 
Relative rate of bone 
formation (normalized 
with respect to normal 
bone resorption) 
    5.50e-2/day (estimated) 
MM proliferation 
controlled by IL-6 and 
BMSC-MM adhesion 
    2.00e-3/day (Wols et al., 2002) 
Rate of elimination of 
active MM cells 
      1.98 pM (Salmon and Smith, 1970) 
Maximum possible MM 
concentration 
              1.5667e-4 /pM (calculation by GA) 
Half-maximal 
concentration of       
on promoting the MM 
cells production 
               1.88e+4/pM (calculation by GA) 
Half-maximal 
concentration of       
on promoting the IL-6 
production 
             1.2151e-5 pM (calculation by GA) 
Half-maximal 
concentration of      on 
promoting the MM cells 
production 
               1.306e+9 pM (calculation by GA) 
Half-maximal 
concentration of       
on promoting the MM 
cells production 
               1.4e-1pM (calculation by GA) 
Half-maximal 
concentration of       
on repressing the 
differentiation of     
              2.2e-1pM (calculation by GA) 
Half-maximal 
concentration of       
on promoting the 
apoptosis of     
      2.04e+6/day (estimated) 
Rate of synthesis of 
     per cell 
 ̃     1.5/day (estimated) 
Rate of degradation of 
VLA4 
      5.6e+4 (Zwartz et al., 2004) 
Maximum number of 
VLA4 expressed on the 
surface of MM cells 
Table 5.2 (cont): Definitions and values of model parameters used in the model of 
MM-induced bone disease. (GA = genetic algorithm). 
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         1.92pM (Zwartz et al., 2004) 
Total concentration of 
VCAM-1 
        8.3e-2/pM (Chigaev et al., 2001) 
The association rate for 
VLA-4 binding to VCAM-
1. 
       4.16/(pM.day) (estimated) 
The degradation rate of 
OPG by MM cells 
Table 5.2 (cont): Definitions and values of model parameters used in the model of 
MM-induced bone disease. (GA = genetic algorithm). 
 
The concentrations of    ,       and       are proposed as follows: 
    
                       
            
    
                 
            
    
      
     
                                  (5-26) 
      
       
              
                                          (5-27) 
      
                     
         
        
  ̃     
                                      (5-28) 
where, 
         
    
 denotes that      stimulates the production of IL-6 and         
    
 
    
                  
; 
         
     denotes that BMSC-MM cells adhesion enhances the production of 
IL-6 by BMSCs and         
     
    
                  
; and 
 The definitions and values of the parameters in Eqs. (5-26) to (5-28) are 
included in Table 5.2. 
Soluble factors produced by MM cells also suppress osteoblast differentiation 
via inhibiting Wnt signalling pathway (Matsumoto and Abe, 2011; Roodman, 2011), 
but were not considered in the model since the underlying mechanisms are not fully 
understood (Edwards et al., 2008; Yeh and Berenson, 2006). However, it is believed 
that the effect of these soluble factors is relatively minor compared to that of BMSC-
MM cell adhesion. The MM model describes the variation of bone volume through 
the same method detailed in Section 5.2 as follows: 
 
   
  
                                                  (5-29) 
where,    represents the normalized bone volume and the definitions and values of 
     and       in Eq. (5-29) are included in Table 5.2. 
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Note, in this model of MM-induced bone disease, the secretion of OPG by 
active osteoblasts is regulated by MM cells, while the production of RANKL by 
osteoblast precursors is regulated by MM-BMSC interaction. Thus, the definition of 
OPG and RANKL concentrations in the model of MM-induced bone disease must be 
updated as follows:  
    
                      
   
                
   
      
              
                    (5-30) 
      
                  
                           
      
                
             
           
   (5-31) 
where,           
    denotes that     stimulates the production of RANKL and 
          
    
   
                  
. The definitions of        
    and        
   have been 
defined before. The definitions and values of parameters in Eqs. (5-30) and (5-31) 
are included in Table 5.2. 
5.3.3  SIMULATION RESULTS 
As in the normal condition, the bone microenvironment should remain in a 
dynamical steady-state, as do other biological systems under physiological 
conditions without external stimuli, and able to return to the steady-state after 
perturbations are removed (Lemaire et al., 2004; Zumsande et al., 2011). The model 
was first used to simulate how cell concentrations fluctuate from their steady-state 
due to the invasion of MM cells, but then return to the steady-state after the removal 
of the MM cells. The variation in bone volume with time was also calculated to 
demonstrate the MM-induced bone destruction. The precise reason for the bone 
destruction was then examined by considering the variation in the ratios of active 
osteoblasts to osteoclasts. Also, a sensitivity study was undertaken to investigate how 
the variations of model parameters (    ,     ,     ,     ,     ,    , βOPG, 
βRANKL, βPTH, βIL6 and  ̃    ) affect MM concentration and bone volume. 
The initial values of the cell concentrations used in the model are listed in 
Table 5.3 (where the MM cells were added at day 201 in the simulation). The model 
parameters without biological meaning or corresponding experimental data are 
estimated or optimized by genetic algorithm, which is a method for solving 
optimization problems based on a natural selection process that mimics biological 
evolution and has a good performance due to its this random nature. The simulation 
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was carried using Matlab computational software package (v7.7.0, Mathworks, 
Natick, USA), where the solver of genetic algorithm is provided. 
 
 
Variables Values Unit 
    3.27e-6 [1,2] pM 
    7.67e-4 [3] pM 
    6.39e-4 [4,5] pM 
    1.28e-3 [6] pM 
    1.07e-4 [4,5] pM 
MM 3.26e-1 [7,8] pM 
 
Table 5.3: The initial values of cell concentrations in the model. 
[1] Caplan, 2007; [2] Cristy, 1981; [3] Wang et al., 2011; [4] Lerner, 2004; [5] 
Cowin, 2001; [6] Parfitt, 1994; [7] Salmon and Smith, 1970; [8] International 
Myeloma Working Group, 2003. 
(MM cell concentration is at day 201; other cell concentrations are at day 1)  
 
 
Figure 5.13 describes the variations of MM cells and bone cells during 
different periods: the normal period from day 1 to day 50, the invasion of MM cells 
from day 51 to day 300 and the removal of MM cells from day 301. It confirms that 
the bone microenvironment remains in a steady-state until the invasion of the MM 
cells at day 50, with the cell concentrations remaining constant at their initial values 
(given in Table 5.2). The steady-state is disturbed due to the appearance of MM cells 
after the 200th day, which causes a fluctuation of cell concentrations as illustrated in 
Figure 5.13. MM cells undergo a rapid initial increase and then gradually reach their 
5.8 fold at day 300. The concentrations of    ,     and     also increase to its 2.8, 
2 and 2.5 fold respectively due to the invasion of MM cells. Figures 5.14 and 5.15 
show how bone volume and    :    ratio vary after the invasion of MM cells. 
Figures 5.16 to 5.18 describe the variations in the concentrations of OPG, RANKL 
and IL-6 during the different periods respectively. 
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Figure 5.13: Model simulations of the variation in the normalized concentrations of 
osteoblast precursors, active osteoblasts, active osteoclasts and active tumour cells 
with respect to their initial values during different periods: the normal period from 
day 1 to day 50, the invasion of MM cells from day 51 to day 300 and removal of 
MM cells from day 301. 
 
Figure 5.14: Model simulations of the variation in normalized bone volume with 
respect to its initial value during different periods: the normal period from day 1 to 
day 50, the invasion of MM cells from day 51 to day 300 and removal of MM cells 
from day 301. 
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Figure 5.15: Model simulations of the variation in the normalized ratio of OBa:OCa 
with respect to its initial value during different periods: the normal period from day 1 
to day 50, the invasion of MM cells from day 51 to day 300 and removal of MM 
cells from day 301. 
 
Figure 5.16: Model simulations of the variation in normalized OPG concentration 
with respect to its initial value during different periods: the normal period from day 1 
to day 50, the invasion of MM cells from day 51 to day 300 and removal of MM 
cells from day 301. 
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Figure 5.17: Model simulations of the variation in normalized RANKL concentration 
with respect to its initial value during different periods: the normal period from day 1 
to day 50, the invasion of MM cells from day 51 to day 300 and removal of MM 
cells from day 301.  
 
Figure 5.18: Model simulations of the variation in normalized IL-6 concentration 
with respect to its initial value during different periods: the normal period from day 1 
to day 50, the invasion of MM cells from day 51 to day 300 and removal of MM 
cells from day 301. 
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5.3.4  SENSITIVITY STUDY 
Further information on the underlying biochemical mechanisms are elucidated by the 
sensitivity study of eleven of the key parameters of the model (namely     ,     , 
    ,     ,     ,    , βOPG, βRANKL, βPTH, βIL6 and  ̃    ), thereby suggesting 
possible strategies for management of MM. The parameters are varied individually 
between 50 to 150% of their initial base values (as defined in Table 5.2) and the 
effects on MM concentrations and bone volume are examined, normalized with 
respect to their (maximal) values at day 300 (in Figures 5.13 and 5.14). Thus, Figures 
5.19 and 5.20 demonstrate how the variation in each parameter influences MM 
concentration at day 300, and Figures 5.21 and 5.22 show how bone volume is 
affected.  
Figures 5.19 and 5.20 show that many of these eleven parameters have a 
significant influence on MM concentration. As some parameter values increase 
(between 50% and 150% of their base values) so MM concentration increases, while 
the opposite effect is observed with the other parameters. For example, as DOCp 
increases from 50% to 150% of its base value, MM concentration varies by 81% to 
121%. Conversely, for the same variation in     , a significant decrease in MM 
concentration (from 141% to 87% of its base value) is observed. Figures 5.21 and 
5.22 show this variation in parameter values affects bone volume. For example, a 
change in      and  ̃     (from 50% to 150% of base value) produces a variation in 
bone volume (between 106% to 97% and 104% to 98% respectively), while the same 
variation in     has a negligible effect. The variations in      and      (from 50% 
to 150% of its base value) cause a decrease (between 101% to 99%) and an increase 
(between 96.5% to 100.5%) in bone volume respectively.  
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Figure 5.19: The effects of independently varying each model parameter (    , 
    ,     ,     ,     and    ) on MM concentration at day 300. Parameter 
variance and MM concentration were normalized to the values of the base case. 
 
Figure 5.20: The effects of independently varying each model parameter (βOPG, 
βRANKL, βPTH, βIL6 and  ̃    ) on MM concentration at day 300. Parameter variance 
and MM concentration were normalized to the values of the base case. 
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Figure 5.21: The effects of independently varying each model parameter (    , 
    ,     ,     ,     and    ) on bone volume at day 300. Parameter variance 
and bone volume were normalized to the values of the base case. 
 
 
Figure 5.22: The effects of independently varying each model parameter (βOPG, 
βRANKL, βPTH, βIL6 and  ̃    ) on bone volume at day 300. Parameter variance and 
bone volume were normalized to the values of the base case. 
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5.3.5  DISCUSSION 
The increase in the concentrations of    ,    and MM cells after the introduction 
of MM cells (shown in Figure 5.13) agrees with the experimental observations of 
Alexandrakis et al. (2002), Diamond et al. (1997) and Terpos et al. (2003). The 
578% increase in MM cell concentration is similar to the 600% increase reported in 
the experimental work of Diamond et al. (1997).     concentration is seen to 
increase nearly threefold due to the invasion of MM cells, which arises because the 
MM cells inhibit the differentiation of     into     (Bataille et al. 1986, 1990, 
1991; Roodman 2011). Furthermore, Figure 5.14 confirms that the invasion of MM 
cells lead to bone destruction, which also agrees with the observation of a decline in 
bone volume within MM patients by Diamond et al. (1997). This can be explained by 
the variation in the ratio of    :   , as shown in Figure 5.15. In addition, the OPG 
concentration decreases to 75% of that in the healthy condition after the invasion of 
MM cells (shown in Figure 5.16), which again compares well with experimental data 
which ranges from 59 to 82% (Lipton et al., 2002; Seidel et al., 2001; Standal et al., 
2002; Terpos et al., 2003). Similarly, the increase in the IL-6 concentration to 1077% 
(shown in Figure 5.17) is consistent with the 979% increase reported by 
Alexandrakis et al. (2003). RANKL concentration increased to 924% (shown in 
Figure 5.18), which also within observed range of experimental data: 226% 
(Goranova-Marinova et al., 2007) to 1567% (Terpos et al., 2006). 
It can be seen that some cell concentrations and the ratio of     to     
experience a short period of oscillation, and then returned to their initial steady-state 
values after the removal of tumour cells, as shown in Figure 5.13  and Figure 5.15, 
This agrees with the observation that the steady-state of biological systems is 
dynamical, and they are capable of restoring themselves to a steady-state after the 
removal of external perturbations (Lemaire et al., 2004; Zumsande et al., 2011). The 
MM-induced bone destruction also ceased after removal of the tumour cells, 
however the bone volume remained at a lower level compared to its initial volume 
(as shown in Figure 5.14). This is consistent with the observation that MM-induced 
bone lesions rarely heal even after the removal of MM cells (Roodman, 2011; Terpos 
and Dimopoulos, 2005). It is explained by the observation that the     to     ratio 
returns to its initial steady-state value, meaning that near zero bone balance is 
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achieved at the end of each remodelling cycle, and thus there is an opportunity for 
additional bone building to take place and bone lesions to be healed. 
A sensitivity study is conducted to show how the variations in model 
parameters influence MM concentration and bone volume, thus suggesting the 
potential treatment for MM-induced bone disease. For example, the sensitivity study 
indicates that     and     are tightly related to MM concentration and bone 
volume. Thus the intervention targeting these two factors can be a potential treatment 
for reducing the tumour burden. This prediction is consistent with the mechanism of 
bisphosphonate treatment, which manages MM-induced bone disease by inhibiting 
the differentiation of osteoclast precursors into mature osteoclasts and promoting 
osteoclast apoptosis (Rogers et al. 2000; Shay and Rogers 2011).  
5.4 SIMULATION OF THERAPIES FOR MM-INDUCED BONE 
DISEASE 
Currently, several therapies are proposed to treat MM-induced bone disease 
including bisphosphonates, bortezomib, TGF-β inhibition, radiotherapy and surgery 
(Foundation, 2008; Matsumoto and Abe, 2011; Roodman, 2011; Terpos and 
Dimopoulos, 2005). In this thesis, bisphosphonates, bortezomib and TGF-β 
inhibition which work in quite different ways are examined by the model. 
5.4.1 BISPHOSPHONATE TREATMENT 
Bisphosphonates are able to target high turnover skeletal sites and then bind to the 
mineralized bone matrix within these sites, due to their special pharmacological 
properties (Luftner et al., 2007; Rogers et al., 2000; Shay and Rogers, 2011). After 
they are internalized by osteoclasts, bisphosphonates can inhibit osteoclast activity 
and the resultant bone resorption by suppressing the differentiation of osteoclast 
precursors into mature osteoclasts, promoting osteoclast apoptosis and disrupting 
osteoclast function (Rogers et al., 2000; Shay and Rogers, 2011). Bisphosphonates 
are first-line treatment for MM-induced bone disease (Luftner et al., 2007; Morgan 
and Lipton, 2010), although further investigation is required to determine the optimal 
duration of bisphosphonate therapy, and bisphosphonates may also result in some 
side effects (Foundation, 2008; Green et al., 2010; Sarro and Minutoli, 2012). 
In addition to inhibiting osteoclast-mediated bone resorption, several 
preclinical and clinical data suggest that bisphosphonates may also have a direct anti-
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tumour effect (e.g. induction of apoptosis and inhibition of tumour cell adhesion and 
invasion) or an indirect anti-tumour effect (e.g. inhibition of angiogenesis and cell 
migration) (Chlebowski et al., 2010; Coleman et al., 2010; Eidtmann et al., 2010; 
Gnant and Eidtmann, 2010; Gnant et al., 2009; Holen and Coleman, 2010; Newcomb 
et al., 2010; Rennert et al., 2010). However, several studies provide contradictory 
results and claim that bisphosphonates do not improve mortality of patients 
(McCloskey et al., 1998; Mhaskar et al., 2010; Musto et al., 2008).  
The possible anti-tumour effects of bisphosphonates are not included in the 
model, since further investigations are required to confirm this point. Thus, the 
model only considers the role of bisphosphonates inhibiting bone resorption by 
suppressing the differentiation of mature osteoclasts as well as promoting the 
apoptosis of osteoclasts. Thus, in the simulation, a parameter 
‘Factor.Bisphosphonate’ is used to represent the degree that the bisphosphonates 
inhibit bone resorption. For example, when ‘Factor.Bisphosphonate’ is set as 0.7, it 
means that the differentiation rate of active osteoclasts decreases to 70% (0.7), while 
the apoptosis of osteoclasts increases by 30% (0.3 = 1 - 0.7). 
Figures 5.23 to 5.25 demonstrate how a bisphosphonates therapy would 
influence cell concentrations and bone volume (Factor.Bisphosphonate = 0.7). Figure 
5.23 indicates that bisphosphonates therapy reduces MM concentrations by 10% (for 
the period considered) and helps bone cell concentrations return to their normal 
values (i.e. values before the invasion of tumour cells). It is should be noted that the 
anti-tumour effects of bisphosphonates are not considered, therefore, the decreased 
tumour burden is due to the inhibited osteoclast activity by bisphosphonates, which 
agrees with the experimental conclusion that the decrease in osteoclast activity can 
inhibit the proliferation of MM cells (Lauta, 2001; Terpos and Dimopoulos, 2005). 
As illustrated in Figure 5.25, the OBa:OCa ratio increases by 18% after the 
introduction of bisphosphonates therapy, which thus results in a significant 
slowdown of the bone destruction (shown in Figure 5.24). Again, this is confirmed 
by published data that shows bisphosphonates are beneficial to the suppression of 
MM-induced bone destruction (Rogers et al., 2000; Shay and Rogers, 2011). 
Figures 5.26 to 5.28 show the variations of MM concentration, bone volume 
and OBa:OCa ratio caused by bisphosphonates with different values of 
‘Factor.Bisphosphonate’ (0.7, 0.5 and 0.3) for the same treatment strategy. MM 
concentration decreases to 86.8%, 85.2% and 84% of its value at day 300, and 
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OBa:OCa ratio increases to 120%, 130% and 140%, when ‘Factor.Bisphosphonate’ is 
set as 0.7, 0.5 and 0.3 (shown in Figure 5.26 and 5.28). As illustrated in Figure 5.27, 
when ‘Factor.Bisphosphonate’ is set as 0.7, the bone destruction continues although 
its rate is decreased dramatically, due to the increasing OBa:OCa ratio, however when 
‘Factor.Bisphosphonate’ is set to 0.5 or 0.3, the bone destruction stops and bone 
volume begins to increase. Thus, the simulation results suggest that a smaller 
‘Factor.Bisphosphonate’ produces more significant inhibition of MM concentration 
and bone destruction.  
 
 
 
 
Figure 5.23: The variation of normalized cell concentrations with respect to their 
initial value during different periods: the normal period from day 1 to day 50, the 
invasion of MM cells from day 51 to day 300 and the intervention of the 
bisphosphonates therapy from day 301. 
0 50 100 150 200 250 300 350 400 450
0
1
2
3
4
5
6
Time [day]
N
o
rm
a
liz
e
d
 C
e
ll 
C
o
n
c
e
n
tr
a
to
s
 [
fo
ld
]
 
 
Concentration of OBp
Concentration of OBa
Concentration of OCa
Concentration of MM
127 
 
 
Figure 5.24: The variation of normalized bone volume with respect to its initial value 
during different periods: the normal period from day 1 to day 50, the invasion of MM 
cells from day 51 to day 300 and the intervention of the bisphosphonates therapy 
from day 301. 
 
Figure 5.25: The variation of normalized ratio of OBa:OCa with respect to its initial 
value during different periods: the normal period from day 1 to day 50, the invasion 
of MM cells from day 51 to day 300 and the intervention of the bisphosphonates 
therapy from day 301. 
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Figure 5.26: The variation of normalized MM concentration with respect to the value 
at day 300 after use of the bisphosphonates therapy with different values of 
‘Factor.Bisphosphonate’. 
 
Figure 5.27: The variation of normalized bone volume with respect to its initial value 
after use of the bisphosphonate therapy with different values of 
‘Factor.Bisphosphonate’. 
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Figure 5.28: The variation of normalized ratio of OBa:OCa with respect to the value 
at day 300 after use of the bisphosphonate therapy with different values of 
‘Factor.Bisphosphonate’. 
5.4.2 BORTEZOMIB TREATMENT 
Osteoblast suppression, which mainly occurs from the blockade of osteoblast 
precursors differentiating into mature osteoblast, can promote the growth of tumour 
cells as well as bone destruction by promoting the production of anti-apoptotic 
factors and growth factors for MM cells (Atkins et al., 2003; Roodman, 2011). Thus, 
the stimulation of osteoblast differentiation is thought to be able to reduce tumour 
burden and bone destruction in MM patients (Roodman, 2011; Yaccoby, 2010). 
Bortezomib, a boron containing molecule with the potential of enhancing osteoblast 
proliferation and bone formation in MM patients, has been proposed as a potential 
target for MM-induced bone disease.  
Therefore, in the simulation, a parameter ‘Factor.Bortezomib’ is used to 
represent the degree by which osteoblast differentiation is promoted. For example, 
when ‘Factor.Bortezomib’ is set to 2.0, it means that osteoblast activity is increased 
two fold.  
Figures 5.29 to 5.31 show the variations in cell concentrations, bone volume 
and the ratio of OBa:OCa after the intervention of bortezomib therapy from day 301, 
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when 
 ‘Factor.Bortezomib’ is set as 2.2. As shown in Figure 5.29, bortezomib causes 
a rapid decrease in the concentration of MM cells, which agrees with the 
experimental finding that increased osteoblast proliferation is able to reduce tumour 
burden in MM patients (Edwards, 2008; Qiang et al., 2008; Yaccoby, 2010). The 
concentrations of OBp, OBa and OCa also decrease after the introduction of 
Bortezomib and reach new equilibrium points around day 500, which are quite near 
their initial values before the invasion of MM cells. Figure 5.30 shows that MM-
induced bone loss nearly stops after a short period of fluctuation due to the 
intervention of bortezomib, while the OBa:OCa ratio (shown in Figure 5.31) 
undergoes a short period of fluctuation and then returns to a quite similar level to that 
without the tumour cells, which explains the termination or inhibition of MM-
induced bone loss due to bortezomib. 
 Figures 5.32 to 5.34 show the variations in cell concentrations, bone volume 
and the OBa:OCa ratio with different values of ‘Factor.Bortezomib’ (2.0, 2.2 and 
2.4), as a result of which MM concentration decreases to 96.7%, 96.3% and 95.7%, 
and the OBa:OCa ratio increases to 116%, 118% and 121%, respectively (shown in 
Figures 5.32 and 5.34). In Figure 5.33, when ‘Factor.Bortezomib’ equals 2.0, MM-
induced bone loss continues although its rate is greatly reduced, due to the rising 
OBa:OCa ratio; while when ‘Factor.Bortezomib’ is set as 2.2 or 2.4, a nearly zero or 
positive bone balance is achieved after the bortezomib therapy, which supports the 
fact that increasing osteoblast differentiation reduces bone destruction in MM 
patients (Yaccoby, 2010). The results suggest that the magnitudes of decreasing MM 
concentration and suppressing bone destruction are both positively related to the 
value of ‘Factor.Bortezomib’, and the stimulation of osteoblast activity can inhibit or 
even stop bone destruction as well as the tumour burden, and thus is an effective 
therapy for MM patients. 
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Figure 5.29: The variation of normalized cell concentrations with respect to their 
initial values during different periods: the normal period from day 1 to day 50, the 
invasion of MM cells from day 51 to day 300 and the intervention of bortezomib 
therapy from day 301. 
 
Figure 5.30: The variation of normalized bone volume  with respect to its initial 
value during different periods: the normal period from day 1 to day 50, the invasion 
of MM cells from day 51 to day 300 and the intervention of bortezomib therapy from 
day 301. 
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Figure 5.31: The variation of normalized ratio of OBa :OCa with respect to its initial 
value during different periods: the normal period from day 1 to day 50, the invasion 
of MM cells from day 51 to day 300 and the intervention of bortezomib therapy from 
day 301. 
 
Figure 5.32: The variation of normalized MM concentration with respect to the value 
at day 300 after use of the bortezomib therapy with different values of 
‘Factor.Bortezomib’. 
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Figure 5.33: The variation of normalized bone volume with respect to its initial value 
after use of the bortezomib therapy with different values of ‘Factor.Bortezomib’. 
 
Figure 5.34: The variation of normalized ratio of OBa:OCa with respect to the value 
at day 300 after use of the bortezomib therapy with different values of 
‘Factor.Bortezomib’. 
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5.4.3 TGF-β TREATMENT 
TGF-β is reported to contribute to the progression of MM-induced bone disease 
(Matsumoto and Abe, 2011). It is released with bone resorption and stimulates the 
production of osteoblast progenitors while inhibiting the differentiation of mature 
osteoblasts. This then suppresses bone formation and indirectly promotes the 
progression of MM cells (immature osteoblast cells facilitate the growth and survival 
of MM cells, while mature cells enhance apoptosis of MM cells). Thus, the 
suppression of TGF-β is proposed as a new approach to treat MM-induced bone 
disease. However, some controversies still exist and further investigation is required 
to test the overall effect of this therapy (Matsumoto and Abe, 2011). In this section, 
the model is used to clarify the existing controversies and evaluate the therapy of 
inhibiting TGF-β in MM patients. 
In the simulation, ‘Factor.TGF-Beta’ is used to describe the degree in which 
TGF-β is suppressed, where (for example) a ‘Factor.TGF-Beta’ value of 0.9 
represents a decrease in TGF-β concentration to 90% (0.9). Thus, Figures 5.35 to 
5.37 show the variations in cell concentrations, bone volume and the ratio of 
OBa:OCa after the intervention of TGF-β therapy from day 301, with
 ‘Factor.TGF-
Beta’ set to 0.7. The inhibition of TGF-β leads to a significant drop (13.3%) in MM 
cell concentration and the bone cells, which indicates that the tumour burden can be 
reduced through the suppression of TGF-β. However, the MM-induced bone 
destruction does not decrease and actually increases after the TGF-β therapy. This 
increasing bone loss can be explained by the decreasing OBa:OCa ratio (24.3% 
decrease compared to the value at day 300) caused by the TGF-β therapy as shown in 
Figure 5.37. Therefore, it is concluded that the inhibition of TGF-β is not an effective 
therapy for MM-induced bone disease, since it cannot reduce the bone destruction, 
although it does reduce MM cell concentration. 
Figures 5.38 to 5.40 show the variations in cell concentrations, bone volume 
and the OBa:OCa ratio with different values of ‘Factor.TGF-Beta’ (0.7, 0.8 and 0.9). 
As a result, the MM concentration decreases to 86.5%, 86.7% and 86.9%, and the 
OBa:OCa ratio decrease to 82.0%, 89.0% and 95.5%, respectively. As demonstrated 
in Figure 5.39, the smallest ‘Factor.TGF-Beta’ leads to the most bone loss. The 
simulation suggests that a larger decrease in TGF-β leads to a greater drop in MM 
concentration but a quicker bone loss. 
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Figure 5.35: The variation of normalized cell concentrations with respect to their 
initial values during different periods: the normal period from day 1 to day 50, the 
invasion of MM cells from day 51 to day 300 and the intervention of TGF-β therapy 
from day 301. 
 
Figure 5.36: The variation of normalized bone volume with respect to its initial value 
during different periods: the normal period from day 1 to day 50, the invasion of MM 
cells from day 51 to day 300 and the intervention of the TGF-β therapy from day 
301. 
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Figure 5.37: The variation of normalized ratio of OBa :OCa with respect to its initial 
value during different periods: the normal period from day 1 to day 50, the invasion 
of MM cells from day 51 to day 300 and the intervention of the TGF-β therapy from 
day 301. 
 
Figure 5.38: The variation of normalized MM concentration with respect to the value 
at day 300 after use of the TGF-β therapy with different values of ‘Factor.TGF-β’. 
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Figure 5.39: The variation of normalized bone volume with respect to its initial value 
after use of the TGF-β therapy with different values of ‘Factor.TGF-β’. 
 
 
Figure 5.40: The variation of normalized ratio of OBa:OCa with respect to the value 
at day 300 after use of the TGF-β therapy with different values of ‘Factor.TGF-β’. 
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5.5 CONCLUSION 
The results presented in this chapter demonstrate that the model can simulate the 
interaction between MM cells and the bone microenvironment, and the contribution 
of that interaction to the progression of the MM cells and the resultant bone 
destruction. The sensitivity study demonstrates how the variations of parameters 
(D_OBu, D_OBp, D_OCu, β_OPG, β_RANKL, β_PTH and β_IL6) influence MM 
concentration and bone volume and identifies those that are most critical. There 
therapies for treatment of MM-induced bone disease are also examined. The model 
simulation indicates that the bisphosphonates and bortezomib treatments are effective 
therapies for MM-induced bone disease by reducing the tumour burden as well as 
bone destruction, however the TGF-β treatment cannot inhibit MM-induced bone 
loss although MM concentration is suppressed. 
The development of MM-induced bone disease involves many biochemical 
factors and mechanisms, although only a minority of these are considered in the 
current literature. This model integrates these partial findings and tries to analyse the 
progression of MM-induced bone disease. It goes much further than the recent model 
of Wang et al. (2011) by including the effects of osteoblast activities. However, the 
effects of soluble factors responsible for inhibiting osteoblast activity are still 
currently not considered. 
The model demonstrates how bone cell concentrations fluctuate after the 
invasion of MM cells, and how these variations result in bone destruction. The 
simulation results agree with published experimental data and explain why the 
lesions resulting from MM-induced bone destruction rarely heal, even after the 
disappearance of MM cells. The model also shows how therapies bisphosphonate 
and bortezomib reduce tumour cells and inhibit (or stop) bone destruction (as 
observed in experimental investigations). However, although TGF-β treatment also 
suppresses MM concentration, it cannot inhibit MM-induced bone loss. The model 
thus serves as a solid foundation for more detailed analyses of the development of 
MM-induced bone disease.  
A general discussion follows in Chapter 6 which highlights the background, 
novelties, assumptions and potential application of the proposed mathematical 
models. 
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6. DISCUSSION 
In this project, two mathematical models have been developed to simulate the 
trabecular bone remodelling process at the cellular level and the pathology of MM-
induced bone disease, respectively. The models and their predictions are discussed in 
detail earlier in this thesis, and their relationships to other published work are 
evaluated. This chapter summarises the main points of this research project and 
demonstrates how it develops the previous work, and contributes to the 
understanding of the mechanobiology of bone (e.g. the bone remodelling process and 
bone related diseases) via computational simulations. 
Bone remodelling has a vital function in enabling bone to adapt to the 
mechanical demands exerted by the biological environment. It involves a large 
number of complex processes and knowledge of this natural phenomenon is still 
incomplete. Mathematical modelling can be used to improve our understanding of 
the bone remodelling process. 
Probably the first mathematical model of bone remodelling was developed by 
Kroll (2000) to simulate the interaction between osteoclasts and osteoblasts in 
response to PTH. The model simulations confirmed the clinical observation that 
intermittent PTH administration increases bone formation, while constant PTH 
administration stimulates bone loss. Rattanakul et al. (2003) developed Kroll’s model 
further by including the effect of oestrogen stimulation on the dynamics of the 
osteoblast and osteoclast populations. The model developed by Komarova et al. 
(2003) was the first attempt to include autocrine and paracrine interactions between 
the osteoclastic and osteoblastic lineages at a single BMU. It was developed further 
by Moroz et al. (2006) to include the role of osteocyte apoptosis on bone remodelling. 
The RANK-RANKL-OPG pathway, along with growth factors, is the underpinning 
control network for regulating bone remodelling and was included in mathematical 
modelling by Lemaire et al. (2004). This model was further refined by Pivonka et al. 
(2008) to investigate the functional implications of the RANKL/OPG expression 
proﬁle. In addition, the same group built another mathematical model to investigate 
the effect of the RANK-RANKL-OPG pathway on the bone remodelling process. 
Buenzli et al. (2011) included both temporal and spatial properties of BMUs in their 
models through a group of the material-balance equations. A different type of model 
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was constructed by Zumsande et al. (2011), who focused on the bifurcation 
properties of mathematical models through a generalised model. 
While these models have become increasingly complex and biologically 
reasonable, they reconstruct the bone remodelling cycle in a qualitative way. 
Therefore, in the first part of this current research we developed a novel predator-
prey based mathematical model to simulate the bone remodelling process 
quantitatively. The motivation to adopt the predator-prey model was based on its key 
characteristic of enabling competitive cyclic growth between the prey and predator 
populations, and restricting the populations from decreasing into negative values. 
These properties are similar to the growth of osteoclasts, which is tightly coupled to 
the growth of osteoblasts during the remodelling process at a BMU (Parfitt, 2000; 
Udagawa et al., 2006).  
Several assumptions exist in the predator-prey based mathematical model: (1) 
the osteoclastic and osteoblastic lineages contain several intermediate stages (e.g. 
precursors and mature cells) which were not distinguished in this model, and were 
represented by two terms ‘osteoclast’ and ‘osteoblast’; (2) the factors activating the 
bone remodelling cycle (such as biological and mechanobiological signals) were not 
included in the model; (3) the resorption and formation rates are determined by the 
resorptive and formative activities of osteoclasts and osteoblasts, as well as their 
populations. However, it was assumed that osteoclasts and osteoblasts both had a 
constant level of activity during one bone remodelling cycle, and the bone resorption 
and formation rates were solely related to their population; and (4) the end of the 
resorption period (and start of the formation period) was defined when the number of 
osteoclasts fell below 0.5. However, the end of the formation period (and the start of 
the quiescent period) was defined as the moment when the formed cavity depth 
reached 99.5% of its maximal value (rather than the time when the osteoblast 
population fell below 0.5). This inconsistency lies in the underlying predator-prey 
equations, in which the preys (osteoclasts) thrive again as soon as the predators 
(osteoblasts) have decreased (and vice versa), and not after a period where neither 
population is present.  
There are four novelties of the proposed model: (1) the adoption of a 
predator-prey model to replicate the sequential dynamic interaction between 
osteoclasts and osteoblasts at a BMU; (2) the bone remodelling cycles were 
reconstructed quantitatively for the first time; (3) a feedback mechanism was used to 
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maintain the balance of bone thickness during a remodelling cycle; and (4) a genetic 
algorithm was used to optimize the values of model parameters corresponding to 
various biochemical conditions, including normal and pathological conditions, based 
on published experimental data. 
The model consisted of three ordinary differential equations, which describe 
the variation of osteoclast and osteoblast populations, and bone volume with time. 
The model reconstructed trabecular bone remodelling cycles for normal and two 
pathological conditions (hypothyroidism and primary hyperparathyroidism). The 
values of model parameters were actually statistical values of a group of 
experimental data, and thus the reconstructed remodelling cycle did not correspond 
to one single bone remodelling cycle, but rather reflected the average of many 
remodelling cycles. A sensitivity study was conducted to show how the variation in 
model parameters influenced the maximum populations of osteoclasts and 
osteoblasts. Also, a stability analysis was performed to determine whether the 
numerical solution to model equations was stable. The model was partly validated 
through the comparison between model predictions of maximum osteoclast and 
osteoblast populations and experimental results. However, further data is still 
required to confirm model predictions regarding maximum populations of osteoclast 
and osteoblast under the two pathological conditions. 
The bone remodelling process actually involves complex cellular interactions 
which the predator-prey model does not consider. However the second mathematical 
model does include those cellular interactions in both normal and a chronic 
pathological condition that of multiple myeloma (MM). MM is the second most 
frequent haematological malignancy and can induce a destructive bone disease 
characterised by bone removal, bone pain and pathological fractures. Ayati et al. 
(2010) built the first model to simulate MM-induced bone disease, however they did 
not consider specific cellular mechanisms. Another model developed by Wang et al. 
(2011) included some of the underlying mechanisms in the development of MM-
induced bone disease, but critically did not consider the MM-induced inhibition of 
osteoblastic activity. In the second half of this thesis, a mathematical model is 
developed to simulate the pathology of MM-induced bone disease based on the 
published clinical observations shown in Figure 5.12. The model is based on the 
work of Pivonka et al. (2008) and was developed in parallel with the work of Wang 
et al. (2011). It includes the underlying mechanisms of osteoblast inhibition and its 
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role in the development of MM-induced bone disease. It consists of five ordinary 
differential equations, describing the temporal variation of bone cells concentrations 
and bone volume. 
Again, there are several limitations in this model: (1) the model did not 
include all the stages in the lineages of osteoclasts, osteoblasts and MM cells. Only 
four stages of osteoblasts, three stages of osteoclasts and three stages of MM cells 
were considered; (2) in addition to the adhesion of bone marrow stromal cell and 
MM cells, soluble factors produced by MM cells also suppress osteoblast 
differentiation. However, these were not included in the model as the underlying 
mechanisms are not fully understood; and (3) it was also assumed that osteoclasts 
and osteoblasts have a constant level of activity during one bone remodelling cycle, 
and the bone resorption and formation rates were only dependent on their 
populations. 
The model mimicked bone cell concentrations and bone volume, and 
investigated how the variations in the levels of OPG, RANKL and PTH influence 
bone cell concentrations and bone volume in the normal bone microenvironment. 
These simulation results are consistent with the findings of earlier work (Lemaire et 
al., 2004; Pivonka et al., 2008). The model was then extended by including the effect 
of MM cells to simulate how bone cell concentrations vary due to the appearance of 
tumour cells. This extended model also simulated the variation of the OBa:OCa ratio 
after the invasion of MM cells, which can be used to explain MM-induced bone 
destruction. Therapies were subsequently simulated (such as bisphosphonates, 
bortezomib and the inhibition of TGF-β) to demonstrate the model’s potential in 
modelling treatments for MM-induced disease.  
Chapter 7 concludes the findings of this study and outlines potential further 
work that is required to develop the proposed models further. 
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7. CONCLUSIONS AND FUTURE WORK 
Mathematical modelling has the potential to predict and help us understand the 
behaviour of complex biological systems. The current application of computational 
simulation in research of biological systems has been demonstrated through a review 
of existing mathematical models of bone remodelling and the detailed discussion of 
two new mathematical models in this project. 
Bone remodelling is a complicated process and has important biological and 
biomechanical functions. A greater understanding of the bone remodelling process 
can help to explain the pathology of bone related diseases, and even propose and 
evaluate therapeutic treatments. MM-induced bone disease is a major cause of 
morbidity and remains incurable for the majority of MM patients. The interaction 
between MM cells and the bone microenvironment is known to form a ‘vicious cycle’ 
which facilitates the development of the disease. A mathematical model was 
developed to simulate the bone remodelling process within trabecular bone at the 
cellular level, while another modelled the interaction between MM cells and the bone 
microenvironment.  
The proposed mathematical model of bone remodelling was used to simulate 
the dynamic interaction between osteoclasts and osteoblasts and their corresponding 
resorption and formation activities at a BMU during the bone remodelling process. 
The model initially reconstructed the variations in osteoclast and osteoblast 
populations and bone volume with time, during normal bone remodelling cycles. The 
predicted cellular activity correlated to primary histomorphometry data, plus the 
pattern of the whole remodelling cycles was predicted. The model was also used to 
investigate the bone remodelling cycle under the pathological conditions of primary 
hyperparathyroidism and hypothyroidism. The model predicted the osteoclast and 
osteoblast populations under these two pathological conditions. However, it was 
difficult to validate these predictions as there is currently no available data.  
A sensitivity study was conducted to show how the variations in model 
parameters influence the maximum populations of osteoclasts and osteoblasts. Based 
on this the connection between model parameters and factors involved with bone 
remodelling is considered with the aim of increasing the physiological representation 
of the simulations. The model was constructed through a group of nonlinear ordinary 
differential equations, with a numerical method employed to solve the model 
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equations. A stability analysis was performed to assess the stability of the numerical 
method. Although future work is required to validate the model, the predicted data 
and remodelling cycles compared well with published experimental data. The 
proposed model has the potential to model a range of pathological conditions and 
investigate associated treatments of those conditions.  
MM is a cancer of the plasma cells in bone marrow and leads to bone pain 
and fracture, anaemia, infections and other complications. Recent experimental 
findings have demonstrated the important role of the interaction between MM cells 
and the bone microenvironment in the development of MM bone disease. In order to 
integrate these experimental observations, a mathematical model is proposed to 
simulate how the interaction between MM cells and the bone microenvironment 
drives the progression of MM bone disease and induces bone destruction. The model 
is first developed without the MM cells to simulate the normal (healthy) bone 
microenvironment. Then model was subsequently extended to include the effect of 
MM cells, to describe the bone microenvironment after the invasion of MM cells. 
Based on these two mathematical models, it demonstrated how tumour cells 
influence the bone microenvironment, and how such changes promote the growth 
and survival of these cells, forming a ‘vicious cycle’ between the bone 
microenvironment and MM cells. 
The model was used to simulate how cell concentrations fluctuate from the 
stable state due to the invasion of MM cells, but return to the stable state after the 
removal of the MM cells. The variation in bone volume with time was also presented 
to demonstrate the MM-induced bone destruction, and the reason for the bone 
destruction was revealed by examining the variation in the ratio of active osteoclasts 
to osteoblasts. The simulation results matched the published data and explained why 
the lesions resulting from MM-induced bone destruction rarely heal, even after the 
disappearance of MM cells. A sensitivity study was also performed to show how the 
variations in eleven model parameters MM concentration and bone volume. The 
model was also used to simulate three therapeutic interventions including 
bisphosphonates, bortezomib and TGF-β for MM-induced bone disease.  
The mathematical modelling in this thesis of the bone remodelling process 
and MM-induced bone disease are not complete and the further work is required. The 
predator-prey based mathematical model has provided encouraging results in 
quantitatively reconstructing bone remodelling cycles for normal and two 
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pathological conditions. The model was validated by the consistency of the model’s 
predictions and the experimental data. In addition, it predicted the populations of 
osteoclasts and osteoblasts under two pathological conditions. Further experimental 
studies are required to validate this work. 
Osteoporosis is a disease caused by a disorder in the bone remodelling 
process, primarily targeting the elderly and postmenopausal women. The proposed 
predator-prey based mathematical model could be applied to simulate the pathology 
of osteoporosis to obtain a greater understanding of the underlying mechanisms of 
this disease, and evaluate potential treatments in the future.  
Another mathematical model successfully simulated the contribution of the 
interaction between multiple myeloma (MM) cells and the bone microenvironment to 
the development of MM cells and the induced bone destruction. The simulation 
results agree with clinical observations well providing some validation of the model. 
However, the current model did not consider the role of soluble factors produced by 
MM cells in the inhibition of osteoblastic activity. This is because the process, which 
involves the Wnt signalling pathway and its underlying mechanisms, is not fully 
understood. Therefore, the model could be improved by including the effect of 
soluble factors on the inhibition of osteoblastic activity in future work. The model’s 
potential in modelling therapies for MM-induced bone disease has been 
demonstrated by simulating there therapies (bisphosphonates, bortezomib and TGF-
β). The model could be used to evaluate and find new therapies for MM-induced 
bone disease in the future. 
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